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On the cover pages, three-dimensional images are presented of a patient with a 
somatostatin receptor-positive tumor. The images were generated using the 
reconstructed transversal slices of the patient study as collected with a three-head 
gamma camera (Prism 3000, Picker), 48 hours after intravenous injection of ["'ln-
DTPA-D-Phe']-octreotide (220 MBq). 
The front cover shows an ante-
rior view of the abdomen with 
the tumor (T) projected between 
the liver (L) and the colon (C). 
On the back cover the same 
tumor (T) is visible from pos-
terior between kidneys (K), 
colon (C), and liver (L). 
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CHAPTER 1 
Introduction to somatostatin receptor scintigraphy 
In this thesis tumor scintigraphy by means of new radiophannaceuticals is 
described, based on the binding of a peptide hormone, sonuaost01in, to its recep-
tors, which are often present in large numbers on various endocrine tumors. 
Consequently, these tumors can be visualized by gamma camera scintigraphy after 
in vivo administration of radiolabeled somatostatin analogues which have similar 
high affinities for the somatostatin receptor. Before discussing this in more detail, 
brief introductions are given about radioactivity, radiophannaceuticals, somato-
statin and somatostatin receptor-positive tumors. 
The fir>'! section of tltis chapter briefly describes the history of radionuclides 
from the time of discovery of radioactivity via the general availability of artificial 
radionuclides to the first tumor-seeking applications of radionuclides. 
In the second section the general biochemical principles of scintigraphic 
imaging are presented by a description of the three different types of current 
radiophannaceuticals, according to their structure and biochentical behaviour, 
while special attention is paid to the developments in the field of tumor scin-
tigraphy. 
More specifically, this chapter will be concluded with a section about sonuao-
staiin and tumors containing receptors for somatostatin. This final section is 
intended as an introduction to the following chapters dealing with the preparation, 
the in vitro validation, the kinetic handling by the isolated perfused rat liver, and 
the in vivo application in rats and humans, of two radiolabeled somatostatin analo-
gues for the scintigraphic imaging of sonuaostarin receptor-containing tumors. 
FROM DISCOVERY OF RADIOACTIVITY TO TUMOR SCINTIGRAPHY' 
At the end of the 19" century Henry Becquerel was continuing his father's 
study on the luminous radiations emitted by the double sulfate of potassium and 
uranium. By accident he discovered that, long after the phosphorescent radiation 
had extinguished, these uranium salts still produced very sharp silhouettes in 
'The data of this introductory section are mainly derived from references 1-3. 
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photographic emulsions. He demonstrated that this radiation had similar properties 
to the X-rays discovered by Roentgen at about the same time, namely passing 
through black paper and even through thin metal foils. Apparently this pheno-
menon was caused by certain properties of the uranium compound itself. This ex-
periment marked the discovery of a new phenomenon, not related to the chemical 
state of the compound, for which Marie Curie (working in Henry Becquerers 
laboratory) introduced the name radioactivity. Marie Curie successively discovered 
other radioactive elements, such as thorium. polonium and radium. The biological 
effect of radiation already had been demonstrated long before the frrst medical ap-
plication of radionuclides (radioactive elements): a reddened area on Becquerers 
abdominal skin due to a sample of radium in his vest pocket during a journey to 
England. The existence of two different kinds of radiation, both emerging from 
radium, was described by Villard in 1900. The first one is deviated by electric 
charge and stopped by less than l em glass (panicle radiation), and the second, 
more penetrating one, is not deviated by electric charge and is weakened only 
slightly by matter. Because the characteristics were similar to the penetrating 
radiation produced by electric discharge tubes which had been demonstrated by 
Roentgen in 1895, Villard at frrst named this also X-radiation. Later, however, this 
electromagnetic radiation, emanating from the atomic nuclei, was called gamma 
radimion. Further investigations of the types of radiation were undertalcen by 
Rutherford, Curie, Bragg and Soddy. Three types of radiation emerging from 
nuclei of radionuclides were established: a-particles (clusters of two neutrons with 
two protons: 'He nuclei), 6-particles (electrons) and y-radiation (electromagnetic 
radiation). 
Application of radioactivity to living matter was introduced by Hevesy in 1923, 
who introduced the "tracer" -concept in· the investigation of lead-metabolism in 
plants using the naturally occurring decay product of radium, "'Pb, and a sensitive 
radiation detection method. One of the first described human in vivo nuclear 
medicine studies, by Blumgart and Yens in 1926, concerns the investigations of the 
velocity of blood flow using Radium-C (or "'Bi, emanating from a radium 
solution) dissolved in saline, as the tracer administered in one arm and a cloud 
chamber (to visualize the path of ionizing particles through a gas) as the detection 
apparatus situated at the other arm. Until 1930, only naturally occurring 
radionuclides were available and detecting systems were insufficient. In the 
thirties, several important events took place which advanced nuclear science. in 
1932 Chadwick suggested that capture of an a-particle by a 'Be nucleus should 
result in an artificial "C-nucleus together with the emission of a neutron. Artificial 
radionuclide production was subsequently presented by Joliot and Marie Curie's 
daughter Irene. They proposed the formation of the radioactive nucleus "N after 
capture of an ~-particle by 10B and emanation of a neutron. 13N decays via emission 
of positrons (i.e., positively charged electrons). Also, they presented two other 
(a,n) nuclear reactions resulting in the formation of "'P and "Si. Similarly, Joliot 
and Curie predicted at the same time the origin of artificial radioactivity on the 
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basis of neutron capture. Only three months later, in May 1934, Fermi presented 
his experiments concerning the production of fourteen different new radionuclides 
by neutron irradiation. Apart from radionuclide generation by charged particles 
originating from radioactive sources, the much more powerful cyclotron, first 
described by Lawrence in 1932, was used for the production of artificial 
radionuclides. The cyclotron is still used extensively nowadays. Livingood and 
Seaberg were the first to describe the cyclotron production of two isotopes of 
iodine ("'! and '"I with physical half-lifes of 8 and 13 days, respectively) by 8 
MeV deuteron bombardment of stable tellurium. However, the radioiodine which 
was firstly used as indicator for thyroid function by Hertz and coworkers, was still 
prepared by neutron irradiation of stable '"! by a radium-beryllium neutron source, 
resulting in '"! with a physical half-life of 25 minutes. Only after the discovery of 
nuclear fission by Halm and Strassmann in 1939, radioactive isotopes became more 
readily available by application of high neutron fluxes in the nuclear reactor. The 
first announcement that radioactive isotopes were available for public distribution 
was published in the June 14, 1946, issue of Science. For quite a few years "'! 
was the most important radionuclide in nuclear medicine. The largest 
breakthrough, however. came with the ready availability of ""Tc, a radionuclide 
with ideal physical characteristics, after the development of the "Mo-""Tc-
generator in 1958 (4), long after the discovery of the "Mo-""Tc system by Segre 
and Seaborg in 1938 (5). Also, in 1958 the scintillation camera was introduced by 
Anger (6). The combination of the general accessibility of ""Tc and the scintil-
lation camera marked a clear improvement for nuclear medicine. Nowadays still 
the majority of nuclear medicine in vivo investigations in The Netherlands (and 
probably also elsewhere) are performed with ""Tc (7). However, the first suc-
cessful investigations in the field of tumor scintigraphy concerned the use of ''"Hg-
neohydrin for brain tumor localization (8), reported in 1962, two years after the 
demonstration of accumulation of this radiopharmaceutical in brain tumor tissue 
after biopsy (9). Also, in 1962, a second radiopharmaceutical, "Co-tetraphenylpor-
phine sulfonate, was presented for the scintillation scanning of neoplasms (10). The 
use of ""Tc in the form of the generator-eluted pertechnetate was firstly reported 
some years later in the scintigraphy of brain tumors (11, 12). 
RADIOPHARMACEUTICALS' 
Before going any further into the matter of scintigraphic imaging of tumors 
containing somatostatin receptors, the general biochemical principles on which 
scintigraphic imaging is based, the various types of radiopharmaceuticals, and 
developments in tumor scintigraphy, will be discussed. 
'Various data are derived from reference 13. 
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Biochemical principles of scintigraphic imaging 
Various processes, such as tumors, abcesses. hyperfunctioning glands, lung 
embolism, and reflux of urine from the bladder to the kidney, can be localized and 
imaged with the gamma camera by means of the biochemical properties of 
radiopharmaceuticals, roughly based on four general principles: (a) changes in 
flow, (b) changes in permeability of the capillary wall, (c) metabolic properties of 
the radiopharmaceutical, and (d) ligand-receptor binding. 
Types of radiopluJrmaceuticals 
Radiopharmaceuticals can be divided into three different categories: (a) 
radionuclides in elementary and ionic state, (b) radionuclides, coupled to solid 
panicles (including blood cells), and (c) radionuclides as part of dissolved com-
pounds. Most radiopharmaceuticals are administered intravenously and use the 
blood circulation to reach their target. A minority of these substances is ad-
ministered via other routes. In the following paragraphs examples of all types of 
radiopharmaceuticals will be discussed briefly, along with their specific 
biochemical behaviour. 
a) Ionic and elementary radionuclides. 
In its ionic and elementary state, a radionuclide acts according to the 
biochemical properties of its non-radioactive analogue. Examples of some 
radiopharmaceuticals, firstly in the form of radioactive ions and secondly as 
radioactive elements, will be given below. 
Radioactive cations as well as anions are widely used for scintigraphic imaging. 
Next to ""'Tc, radioactive iodine (in the form of "'I· and "'!') is probably the 
best well-known radionuclide in nuclear medicine. Anyway, "'I was the first 
radionuclide that achieved widespread use. Radioiodide, administered orally as 
well as intravenously, accumulates in one organ: the thyroid. Thyroid scintigraphy 
is possible not only because of radionuclide trapping by the plasma membrane of 
the thyroid follicle cells (this trapping mechanism can also be imaged with 
""TeO;), but also because of accumulation due to organijicarion by the follicle 
cells of the thyroid, resulting in incorporation into thyroid hormone. Consequently, 
a higher concentration of radioiodine is measured in hyperfunctioning thyroid 
tissue (e.g., in a "hot" thyroid nodule), compared to the surrounding thyroid tis-
sue. ln contrast, a relatively lower uptake within the thyroid is observed in areas, 
where less functioning thyroid hormone-producing cells are situated (e.g., in cases 
of thyroid carcinoma and thyroiditis). 
The radioactive cations of the alkali metals (e.g., "K', "Rb'. and "'Cs') and 
"'Tl' behave in vivo like the stable potassium ion and can be used for scintigraphy 
of the myocardium ( 14). The accumulation is dependent on the regional blood 
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flow. Additionally. these cations accumulate in normal myocardial tissue by means 
of the Na'-K'-ATPase system, i.e., following the metabolic behaviour of potas-
sium. Because of its nuclear properties ''"TI, in the form of thallium chloride, is 
used most often for myocardial scintigraphy. Absence of radioactivity means an 
ischaemic or an infarcted region. "'TI' is also used for scintigraphy of various 
malignancies, such as thyroid carcinoma (15) and lung cancer (16). Like myocar-
dial scintigraphy, tumor imaging with thallium is probably due to increased blood 
supply of tumorous tissue together with an active hyperaccumulation of "'TI via 
the Na+ -K' -pump of the tumor cells. 
67Ga3+ is an example of a non-specific radiopharmaceutical agent used in 
imaging of tumors and inflammatory processes (17). The exact mechanism of "Ga-
accumulation is still unknown (18). but it is probably a combination of a panly 
iron-like metabolism and defects in capillary vessel walls in tumorous and inflam-
matory processes (17). It has been suggested that gallium resembles iron in its 
metabolism, because after intravenous administration in the form of gallium citrate, 
"Ga". like iron, binds to the plasma proteins transferrin and lactoferrin. Although 
the radionuclide will not be incorporated into hemoglobin, transferrin and lactofer-
rin play a clear role in the mechanism that is reponsible for tumor imaging with 
"Ga. For instance, iron saturation of transferrin prevents accumulation of gallium 
in tumors and diminishes liver uptake in favour of a more rapid clearance via the 
kidneys. Accumulation of "Ga in tumors will be favoured by increased blood 
supply and defects in the capillary endothelium in tumorous tissue. High ferritin 
concentrations in tumors (competing with transferrin and lactoferrin) will ac-
cumulate "Ga, allowing the scintigraphic imaging of these processes. Likewise, as 
lactoferrin is a major protein constituent of neutrophilic leukocytes, it is not 
surprising that also abcesses can be visualized using 67Ga. 
At last, radioactive noble gasses such as g1""Kr, 127Xe and 133Xe are used in 
ventilation and perfusion studies of the lungs and the brain, respectively, on the 
basis of their inen biochemical behaviour. There is minimal retention of 
radionuclide in the body because of immediate exhalation. The widest use of these 
radiogasses is made in scintigraphy of the ventilation of the lungs, predominantly 
in combination with the perfusion scintigraphy in the detection of pulmonary em-
bolism (see below). Dissolved in saline, radioactive noble gasses are used 
intravenously in investigations of the regional cerebral blood flow. 
b) Radionuclides, coupled to panicles and aerosols. 
Visualization of organs or processes by means of radioactive particles (including 
blood cells) and aerosols is based on their dimensions or their specific 
physiological properties. 
""Tc-coupled microspheres and macroaggregates are used for the detection of 
obstructed blood vessels. Due to their dimensions (20 - 80 I'm), these radiolabeled 
particles, which are injected intravenously, are trapped in capillaries. In lung 
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perfusion scintigraphy images are made of the capillary bed of the lungs. Absence 
of radioactivity can indicate the presence of lung embolism, especially if that 
particular area is well ventilated. The radiopharmaceutical is also used in 
radiophlebography, showing collateral venous blood flow. when a major vein of 
the leg is obstructed by thrombosis. 
Radioactive particles of smaller dimensions (less than 2 I'm) are the ""Tc-
colloids, such as tin-, sulphur- and albumin-colloids, which are used in liver and 
spleen scintigraphy on the basis of phagocytosis by the reticulo-endothelial cells in 
these organs. A second application of radioactive colloids is lymphoscintigraphy in 
which drainage of lymph vessels with small colloidal particles visualizes the lymph 
nodes and lymph vessels. 
Radiolabeled aerosols are composed of ""Tc solutions. Mostly a solution of 
""Tc-DTPA (diethylenetriaminopentaacetic acid) in saline is nebulized and 
administered via oral inhalation. Ventilation scintigraphy of the lung is maiuly 
combined with lung perfusion scintigraphy in examining the presence of lung 
embolism. The use of a radiolabeled aerosol is an alternative for radiogasses. 
Radiolabeled solid food (e.g., "•Tc-colloid in a pancake) or liquid food (e.g., a 
solution of radiolabeled DTPA) is used to image oesophageal transit and gastric 
emptying. 
Finally, radiolabeled blood cells have to be mentioned. Without going into 
detail, it must be stated that these agents are used as blood pool markers in heart 
function scintigraphy (radiolabeled erythrocytes) and to visualize, for instance, 
gastrointestinal bleeding sites and locations of degradation (by radiolabeled 
erythrocytes), thrombosis (radiolabeled thrombocytes) and abcesses (by 
radiolabeled leucocytes). 
c) Radionuclides in dissolved compounds. 
Radioactive dissolved compounds, in which the radionuclide is a part of the 
molecule, form the largest group of radiopharmaceuticals. Usually these radiophar-
maceuticals are also administered intravenously. 
CompoUJlds with non-specific biochemical properties. 
""Tc, in the fonn of sodium pertecbnetate, is used in perfusion imaging and 
radionuclide angiography as a marker for the blood circulation. In this application. 
specific accumulation in the thyroid (see below) is prevented by a previous 
blocking dose of KClO, or Kl. 
"'!-albumin has been previously used in imaging of brain tumors which have a 
defective blood-brain barrier, and in cisterooscintigraphy after intrathecal ad-
ministration of the radiopharmaceutical. 
Compounds with specific metabolic properties. 
""TeO;, which resembles iodide, is trapped by the follicle cells of the thyroid, 
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enabling thyroid scintigraphy. 
""'Tc-phosphonates visualize bone metabolism scintigraphically due to their 
affinity for hydroxyapatite crystals. 
"'"Tc-mercaptoacetyltriglycine (MAG,) and ""'Tc-DTPA are used for renal 
stndies, based on tubular excretion and glomerular filtration, respectively. 
"'"Tc-dimercaptosuccinic acid (DMSA) is used for scintigraphic imaging of the 
morphology of the kidney, because of its longer renal retention after glomerular 
filtration as compared to ""'Tc-DTPA. 
""'Tc-etifenine (HIDA) and various other iminodiacetic acid derivatives are used 
for scintigraphy of the hepatobiliary function on the basis of uptake of these 
lipophilic compounds by hepatocytes, followed by excretion into the biliary 
system. 
Ortho-"'l-hippuric acid (Hippuran) is excreted via the tubuli and, therefore, 
used for renal stndies. 
6Jl-"'I-iodomethyl-19-norcholest-5-(IO)-en-3Jl-ol (NP-59), as a steroid precur-
sor, accumulates in adrenocortical cells and is, therefore, used in scintigraphy of 
the adrenal cortex. 
"'l-meta-iodobenzylguanidine (MJBG), like the related norepinephrine, ac-
cumulates in the chromaffin granules of adrenergic tissue, present in 
pheocbromocytoma and neuroblastoma (19), enabling scintigraphic imaging of 
these groups of tumors. 
In some radiolabeled gasses, antino acids, sugars and catecholantines such as 
CO,, glutamic acid, glucose and norepinepbrine, the structure and cousequently the 
metabolism is not affected at all by the radionuclide, because of replacement of a 
stable isotope by a radioisotope (e.g, by "C, "N and "0). Such isotopic 
replacements make metabolic studies of these simple compounds by positron emis-
sion tomography (PET) possible, which however has gained limited use for 
economic reasons and is mostly limited to the brain and the heart. 
Compounds charaCterized by specific binding ro tissue cells. 
These compounds are used in the detection of tissue-specific components. 
Radiolabeled monoclonal antibodies and radiolabeled fragments of these 
antibodies are used to visualize various processes. Myocardial infarction and 
rejection after heart transplantation, thrombosis, and ovarian cancer can be 
localized with 111 In-antimyosin (binding to myosin), 111In-antifibrin (binding to 
fibrin clots), and "'ln-OV-TL 3 or"'ln-OC 125 (binding to antigens present in 
ovarium carcinoma tissue), respectively. 
Radiolabeled peptide hormones can be used for specific detection of receptor-
positive tissues including tumors (see below). 
Developments in tumor scintigraphy 
It is surprising that in the past 30 years only two simple cationic materials, "Ga 
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and "'TI have achieved significant and widespread clinical utility in tumor scin-
tigraphy, while still little is known about their accumulation mechanism in tumor 
and normal tissue (18). Five hundred articles, published in The Journal of Nuclear 
Medicine since its first issue in 1960, are related to nearly 100 different radiophar-
maceuticals for tumor-imaging (18). A vast majority of these radiopharmaceuticals, 
including gamma as well as positron emittors, turned out to have merely scientific 
merit; this holds especially for the last kiDd. Out of these developments the ap-
plication of radio1abeled polyclonal (after 1970) and monoclonal (after 1980) 
antibodies seemed to be very promising, not only for imaging, but also for subse-
quent therapeutic purposes (e.g., labeled with a suitable a- or 6-emitting 
radionuclide). However, until now, real success or widespread use of radiolabeled 
antibodies has not yet been achieved, mostly due to low tumor accumulation 
combined with aspecific sequestration and slow clearance from the body. Perhaps 
not the high molecular weight radiolabeled antibodies, but radiolabeled tumor-
specific oligo/polypeptides, with more suitable in vivo properties (e.g., a more 
rapid clearance), will tum out to be more successful tumor-imaging agents. 
ln the following section a new concept will be introduced with respect to the in 
vivo application of radiolabeled small peptides, based on their well-established in 
vitro receptor binding. lt was intended to develop such a radiopharmaceutical 
based on the knowledge of the specific binding of native somatostatin to somato-
statin receptor-positive tissues, including tumors. Therefore, some aspects of the 
native peptide somatostatin and the particular somatostatin receptor -positive tumors 
will be reviewed hereafter. 
SOMATOSTATIN AND SOMATOSTATIN RECEPTOR-POSITIVE 
TUMORS 
This section deals with the physiological and biochemical aspects of somato-
statin, especially with its receptors in normal and tumorous tissues. 
The function of somatostatin. 
Experimental and clinical observations (20) have led to the concept that the 
hypothalamus controls and regulates the secretion of pituitary growth hormone. ln 
1968 Krulich (21) investigated the growth hormone (GH) production by anterior 
pituitaries in the presence of various concentrations of sheep and rat hypothalamic 
extracts. lt appeared that in vitro GH production by rat pituitaries was stimulated 
by these extracts, while in vivo administration of hypothalamic extracts to rats led 
to a decrease of serum GH concentrations. The contrary was the case in sheep. 
These observations led to the discovery of two separate peptide-like substances in 
these hypothalamic extracts, one having a stimulating effect on GH production 
(hence called GH-releasing factor: GRF) and the second one inhibiting GH 
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secretion (GH-release-inhibiting factor: GRIF). In 1973 Brazeau and coworkers 
(22) reponed the isolation and the primary structure of GRIF in the ovine 
hypothalamic gland which was later called somatostatin (23), because of its 
supposed specific function: inhibition of somatotropin (mostly called growth hor-
mone, GH) secretion by the pituitary gland. In vitro GH release from both human 
and rat pituitary cells is inhibited at somatostatin levels above 10"' M. Similarly. 
GH inhibition was demonstrated in vivo in rats (22). Somatostatin was shown to be 
a polypeptide consisting of 14 amino acids (SS-14) including a disulfide bridge: 
H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH 
Nowadays, it is clear that the identical peptide structure is present not only in the 
hypothalamus, but also in various other organs (24) of mammalian species, in-
dicating that inhibition of GH secretion is not its only function. Furthermore, 
somatostatin also exists as a somewhat larger peptide than the already mentioned 
tetradecapeptide: somatostatine-28 (SS-28). The same somatostatin molecule is also 
found as a part of still larger molecules in fish (25). pigeon (26), and even in 
protozoa (27). The tetradecapeptide somatostatin itself has also been identified in 
the porcine hypothalamus (28) and in the pancreas of the pigeon (26), and the 
catfish (29). It was therefore concluded that somatostatin was already present 
before the separate evolution of invertebrates and vertebrates, presumably more 
than 400 million years ago (24). After the laboratory synthesis of the linear 
tetradecapeptide, which was shown to have similar GH-inhibitory properties as the 
native somatostatin (22), Rivier reponed the first synthetic somatostatin with cyclic 
structure, identical to the native tetradecapeptide (30). Thereafter, antisera were 
prepared, which led to the subsequent development of the radioimmunoassay for 
somatostatin (31) and immunohistochemical studies (32). These studies 
demonstrated the presence of somatostatin (and its derivatives) in a large number 
of tissues. High amounts of somatostatin and somatostatin-like peptides were found 
in the gastrointestinal tract, the cerebral cortex, the spinal cord, the brainstem, the 
hypothalamus and the pancreas, with the highest concentrations located in the D-
cells of the pancreatic islets and the central nervous system (33). 
Somatostatin has been shown to have many different biological activities, such 
as being a neurotransmitter (acting within the central nervous system), a neurohor-
mone (inhibiting the release of the pituitary hormones GH and TSH), a classical 
hormone (secreted by the D-cells of the pancreatic islets into the portal vein) or a 
paracrine factor (mediating the influence of the D-cells on the A- and B-cells of 
the pancreatic islets) (33). The action of somatostatin is mainly characterized by its 
inhibitory function, which is not only restricted to the inhibition of the GH 
secretion. Somatostatin also has inhibitory effects on the secretion of hormones by 
the pancreatic islands (insulin. glucagon) and on the exocrine pancreatic function. 
Also, somatostatin inhibits normal gastrin production and consequently gastric acid 
and pepsin production. 
The very rapid action of somatostatin (34, 35) suggests a mechanism of action 
via plasma membrane receptors in contrast to steroids and some actions of thyroid 
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Figure 1 
Somarostarin receptors in a 
human carcinoid tumor 
(reproduced with kind permission 
of Dr. J. -C. Reubi) 
A: Hematoxylin-eosin stained 
section. 
B: Autoradiogram showing total 
binding of ["'1-Tyr]-octreotide. 
C: Autoradiogram slwwing near-
ly no non-specific binding off" 1-
Tyrj-octreotide (in presence of 
1()< M [Tyr']-octreotide). 
The receptors are exclusively 
located on the tumor strands and 
nests. Bar= I mm. 
c 
hormones, which require intracellular translocation. High-affinity binding sites for 
somatostatin have been identified on cultured pituitary tumor cells (36) and on rat 
cortical membranes (37, 38). The binding affinity for somatostatin receptors on 
pituitary tumor cells is high (K, = I x 10'" M·') and a receptor number of 0.11 x 
H!" mol/mg cell protein (14000 binding sites per cell) have been reported (36). 
The affinity for neuronal membranes was also about I x I 0'" M·' and the number 
of binding sites 0.16 x JO·" mol/mg (38). The effects os somatostatin on the 
electrical activity of pancreatic B-cells (39) and on the activity of neuronal cells 
(40, 41) suggest that somatostatin acts at the membrane level. These binding sites 
are clearly seen on autoradiographic images of normal and pathological tissues. 
Autoradiography of normal pituitary tissue illustrates the location of somatostatin 
receptors within the anterior lobe of the gland (42). 
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Somaiostarin receptor-positive rumors. 
The general inhibitory effect of somatostatin on hormone production by various 
glands led to the concept of possible beneficial effects of somatostatin in the 
treatment of diseases. based on gland hyperfunction and on overproduction of 
hormones by endocrine active tumors. However, some difficulties bad to be 
overcome, for the tetradecapeptide somatostatin itself turned out to be unsuitable 
for routine treatment. After intravenous injection somatostatin has a half-life of less 
than 3 mins in man (43, 44) and is rapidly degraded enzymatically (45). Treatment 
with somatostatin has only a very short duration of 30-60 mins (33), when ad-
ministered subcutaneously and no long-term studies with somatostatin have been 
undertaken. Short-term somatostatin treatment bas been investigated in patients 
with diabetes (46), acromegaly (47, 48) and various pancreatic islet cell tumors 
( 49, 50). In recent years successful efforts have been undertaken to prepare 
somatostatin derivatives !bat are more resistant to enzymatic degradation by 
modifying the molecule in various ways with preservation of the specific biological 
characteristics of the original compound. Firstly, the biologically active site of the 
somatostatin molecule was preserved as much as possible while making the 
somatostatin derivative as small as possible. Furthermore, D-aminoacids bave been 
introduced to increase the resistance to enzymatic degradation. Many of these 
somatostatin analogues have been shown to inhibit the secretion of growth hor-
mone, insulin and glucagon even better than somatostatin itself. The 8 amino 
acids-containing somatostatin analogue octreotide (Sandostatin" or SMS 201-995) is 
currently widely used successfully in the treatment of endocrine active tumors such 
as GH-producing pituitary adenomas and gastroenteropancreatic tumors (51, 52). 
Apart from the presence of somatostatin receptors in normal tissues, it is 
obvious that hormone-secreting tumors that are treated succesfully with somato-
statin analogues might contain receptors for somatostatin. Indeed, on most en-
docrine active gastrointestinal tumors large numbers of high-affinity binding sites 
for somatostatin bave been detected (53). In figure I the somatostatin receptors are 
clearly visualized in the autoradiographic image of a human carcinoid tumor, using 
["'1-Tyr']-octreotide as radiolabeled somatostatin analogue. 
Following the in vitro characterization of the somatostatin receptor status of 
tumors, the in vivo administration of radiolabeled somatostatin analogues as new 
radiopharmaceuticals was launched for the purpose of scintigraphic imaging of 
these tumors, which are often difficult to localize. 
In the next chapters the preparation and in vivo behaviour of two different new 
radiopharmaceuticals (both radiolabeled somatostatin analogues) in animals and 
man with somatostatin receptor-positive tumors will be presented. 
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CHAPTER2 
Receptor scintigraphy with a radioiodinated somatostatin analogue: 
Radiolabeling, purification, biologic activity, and 
in vivo application in animals 
Willem H. Bakker, Eric P. Krenning, Wout A. Breeman, Jan W. Koper, 
Peter P. Kooij, Jean-Claude Reubi, Jan G. KJijn, Theo J. Visser, 
Roe! Docter, and Steven W. Lamberts. 
Departments of Nuclear Medicine and Internal Medicine IJI, 
University Hospital Dijkzigt and Erasmus University Medical School, 
Rotterdam, The Netherlands; 
Division of Endocrine Oncology, Dr, Daniel den Hoed Cancer Centre, 
Rotterdam, The Netherlands; 
and Sandoz Research Institute, 
Berne, Switzerland. 
Radioiodinated [Tyr']-octreotide, a somatostatin analogue, is a useful 
ligand for the in vitro detection of somatostatin receptors. In this study, we 
have investigated the possible in vivo application of this radioligand in the 
detection of somatostatin receptor-bearing tumors by scintigraphy. The 
specific somatostatin-like biologic activity of radioiodinated [Tyr']-octreotide 
was confirmed in vitro: (a) radioiodinated [Tyr']-octreotide competes in the 
nanomolar range with specific receptor binding of somatostatin to suspended 
human meningioma membranes and (b) the secretion of growth hormone by 
cnltured rat pituitary cells was similarly inhibited by iodinated [Tyr']-
octreotide and somatostatin. In rats intravenously injected ["'I-Tyr']-
octreotide is rapidly cleared from the circulation mainly by the liver. 
Although this rapid clearance limits the amount of tracer available for 
somatostatin receptor-bearing tumors, the advantage of this rapid clearance is 
that the background level is rapidly reduced in favor of scintigraphic imaging 
of these tumors. Pancreatic tumors in rats were localized by scintigraphy 
after intravenous injection of ['"1-Tyr']-octreotide. 
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Figure 1 
Structural formulae of native somatostatin (a) with the Phe-Trp-Lys-Thr 
sequence which has been proposed to be the active site of the molecule (23, 
24) and octreotide (b). In [Tyrj-octreotide (c) Phe is replaced by Tjr to 
make radioiodination possible with preservation of biologic activity. 
Most endocrine active gastrointestinal tumors are usually slow-growing. They 
are often very small and therefore difficult to localize with conventional techniques 
(1). Hormone secretion by several of these tumors is inhibited by the 
tetradecapeptide somatostatin (Fig. la), which is endogenously produced, e.g., by 
the hypothalamus and pancreas (2). Somatostatin also inhibits the growth of some 
tumors (3). The native hormone, however, is susceptible to rapid enzymatic 
degradation (4); therefore, it is not suitable for long-term therapeutic use. For that 
reason, synthetic derivatives with a similar bioactive structure as somatostatin have 
been developed, which are not only less susceptible to biologic degradation but 
also have a stronger inhibitory effect on hormone release by the relevant tumors. 
The octapeptide octreotide (SMS 201-995 or Sandostatin"; Fig. lb) fulfils these 
criteria (4). After subcutaneous injection, this peptide has a longer biologic half-
life than somatostatin itself and, hence, prolonged inhibitory effects on normal 
growth hormone production (5), hormone release by endocrine pancreatic tumors 
(6) and on tumor growth (6-9). Octreotide is currently used in the treatment of 
gastroenteropancreatic tumors and acromegaly (6, 10). 
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Large numbers of higb affurity binding sites for native somatostatin and 
synthetic octreotide have been detected on most endocrine active tumors (11). This 
opens the possibility for the scintigraphic localization of such tumors using a 
radiolabeled somatostatin derivative. Since octreotide cannot be radiolabeled easily 
with a gamma-emitting radionuclide, a synthetic analogue ([Tyr']-octreotide) has 
been developed in which phenylalanine has been replaced by tyrosine, allowing 
radioiodination of the molecule (Fig. I c). This compound has been used 
successfully as "'I-radioligand for in vitro somatostatin receptor studies (12). Since 
its application for human scintigraphy needs methodologic changes (use of "'I with 
different properties instead of "'I and omitting toxic substances during 
purification), we report here the radiolabeling, the subsequent purification 
procedure and the confirmation of the specific biologic activity of radiolabeled 
[Tyr']-octreotide. The distribution and metabolism of the radiolabeled somatostatin 
derivative have been studied following its intravenous athninistration to rats by 
gamma camera scintigraphy and measurements of radioactivity in isolated organs. 
Radioiodinated [Tyr']-octreotide was shown to be an attractive new 
radiopharmaceutical for the in vivo detection of somatostatin receptors using a rat 
tumor modeL 
MATERIALS AND METHODS 
Radioplulrmaceuticals 
Octreotide and [Tyr']-octreotide were obtained from Sandoz (Basel, 
Switzerland). Radioiodination of [Tyr']-octreotide was performed on the basis of 
the "'!-iodination technique described by Reubi (12). Toxic substances were 
omitted during the purification steps in connection with the proposed i.v. 
administration. Two iodine isotopes ("'I and '"I) from different manufacturers 
were used. Radioactivity concentrations (and specific activities) amounted to 1.85 
GBq "'IImi (0.62 TBq "'Iimg) and 3.7 GBq "'IImi (3.7 TBq "'Iimg). To the 
solution of radioiodide (in 40 1'1 0.01 M NaOH) in the manufacturer's vial were 
added successively 20 1'1 0.05 M phosphate (pH 7.5) and 1.4 l'g [Tyr']-octreotide 
in 20 1'1 0.05 M acetic acid. The solution was vortexed. The iodination was started 
by adding L 6 l'g chloramine-T in (20 I' I 0. 05 M phosphate), representing only a 
5-fold excess over peptide in order to prevent oxidation of the disnlfide bridge of 
the [Tyr']-octreotide. The mixture was then vortexed for I min. The iodination 
was stopped by the addition of 0 .I mi I 0 % human serum albumin (Merieux, 
Lyon, France). After vortexing for 30 sec, 1.85 mi 5 mM ammonium acetate was 
added. Purification was performed by using a SEP-P AK C., reversed-phase 
exttaction cartridge (Waters Associates, Milford, MA), which was prewashed with 
5 ml 70 % ethanol and subsequently activated with 5 mi 2-propanoL After 
application of the sample, the cartridge was washed successively with 5 mi distilled 
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water and 5 ml 0.5 M acetic acid. Radioiodinated [Tyr']-octreotide was eluted with 
5 ml 96 % ethanol. The solvent was evaporated at 40 'C under a gentle stream of 
nitrogen. The dry residue was dissolved io 2 - 10 ml 154 mM NaCl and 0.05 M 
acetic acid (pH 3). After passing through a low proteio-bioding 0.22-micron 
Millex-GV filter (Millipore, Milford, MA) the solution was ready for i.v. athninis-
tration. The labeling procedure was scaled up at least 30-fold when larger amounts 
of radiolabeled peptide were necessary for (human) sciotigraphic purposes. ln those 
cases, 10-fold higher peptide- and chloramine-T concentrations were used io order 
to keep the reaction volume below 1 ml. For labeliog with "'I and 1231, 1.5 and 30-
fold excess of peptide over iodide were used, respectively. 
Quality control 
The radioactivities io the fractions eluted from SEP-P AK C, were measured in 
a dose calibrator (VDC-202, Veenstra, Joure, The Netherlands) under similar 
geometric conditions (5 ml liqnid). Also, the SEP-PAK c, cartridge itself was 
measured after the elutions, takiog ioto account the different geometric conditions. 
The ammonium acetate, water, and acetic acid fractions eluted from SEP-PAK 
C, were examined for low molecular weight ( < 1.5 kD) iodine (i.e., free iodide 
and peptide-bound radioiodine) and high molecular weight ( > 1.5 kD) protem-
bound iodine (i.e., radioiodinated human serum albumio) using Sephadex G-25 gel 
filtration chromatography (PD-10 column, Pharmacia, Sweden) with 154 mM 
NaCl as the eluent. The low molecular weight PD-10 fractions were analyzed by 
reversed-phase, high-performance liquid chromatography (HPLC), described 
hereafter. 
The acetic acid and ethanol fractions eluted from SEP-P AK C., were analyzed 
by HPLC with a Waters 600 E multisolvent delivery system connected to a p.-
Bondapak-C, reversed-phase column (300 x 3.9 mm, particle size 10 p.m). Elution 
was carried out at a flow of l · ml/mio with a linear gradient of 40 % to 80 % 
methanol in 154 mM NaCI in 20 mio and the latter composition was maiotaioed 
for another 5 mio. Eluted radioactivity was monitored on-lioe using a Nal probe 
connected to a Canberra siogle-channel analyzer with a recorder. Collected 
fractions were measured by routine sciotillation countiog. 
The receptor-bioding affinity of the radioiodinated [Tyr']-octreotide was 
measured using suspensions of human meningioma membranes, which are reported 
to contaio somatostatio receptors ( 13). A sinrilar procedure as described previously 
(12) was used. Meningioma membranes (280 p.g proteio) were iocubated in a total 
volume of 100 1'1 (triplicate tubes) at 20'C for I hr with five different 
concentrations of ['"I-Tyr']-octreotide between 0.2 and 8 nM io the absence or 
presence of 10 p.M somatostatio. The iocubation contaioed 10 mM HEPES buffer 
(pH 7.6), 0.5 % BSA, 5 mM MgCI,, and bacitracin (20 p.g/ml). The incubation 
was stopped by the addition of I ml ice-cold HEPES buffer followed by 
centrifugation (2 min at 14,000 rpm in an Eppendorf microcentrifuge). The 
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membrane pellet was washed twice with 1 ml ice-cold HEPES buffer and the final 
pellet was counted in a LKB-1282-Compugamma system. Specific receptor bindiog 
was calculated to be the difference between bindiog in the absence and in the 
presence of 10 I'M somatostatio. The data were analysed usiog the method of 
Scatchard (14), giving the dissociation constant (KJ and the number of bindiog 
sites (B..J for the meningioma preparation. 
The biologic activity of HPLC-purified mono-iodinated ['"1-Tyr']-octreotide 
(i.e., free from unlabeled [Tyr']-octreotide) was assessed by measuring its potency 
to inhibit the secretion of rat growth hormone (rGH) by cultured rat pituitary cells 
as described previously (15). lodioe-125 was used instead of"'! because we were 
only able to establish the exact specific radioactivity of the ['"1-Tyr']-octreotide 
(see Discussion). 
Animals and tumors 
A transplantable rat pancreatic tumor model (CA 20948) with somatostatio 
receptors, as demonstrated with in vitro assays ( 16), was used. lnlribition of the 
growth of this tumor by 40 % - 70 % compared to controls under chronic 
treatment with the somatostatin analogue octreotide during 6 wk had been 
demonstrated previously (17, 18). Eight male Lewis rats were inoculated with a 
suspension of pancreatic tumor cells as described before ( 17). Two weeks after 
tumor transplantation 95 % of the rats showed a detectable tumor mass. When the 
tumors had reached a solid palpable mass, the animals were used for the 
experiments. Nine male Lewis rats without tumor were used as controls. (18.5 - 37 
MBq (I - 3 !<g) ['"I-Tyr']-octreotide in 0.5 - 0.8 ml 154 mM NaC1 and 0.05 M 
acetic acid were injected intravenously in tumor-bearing and control rats. The 
thyroids of the animals were not blocked. The radiopharmacon was injected in the 
dorsal vein of the penis. Two out of eight tumor-bearing rats received 1 mg 
octreotide subcutaneously 30 min before injection of I"' I-Tyr']-octreotide in order 
to saturate somatostatio receptors on the tumors. 
Data acquisition and analysis 
Images were acqnired with a large field of view gamma camera 
(Counterbalance 37 ZLC, Siemens Gammasonics) equipped with a 190-keV 
parallel-hole collimator. The animals were in a supine position on the collimator in 
such a way that overprojection of the tumor and the intestioes was avoided. The 
analyzer was set to 159 keV with a 20% window. Data were stored in a dedicated 
computer (Gamma-!1, Nuclear Diagnostics). In all animals (9 controls, 6 tumor-
bearing animals without and 2 with octreotide pretreatment), acquisition took place 
for 40 intervals of 3 sec and !8 intervals of 60 sec (matrix 64 x 64) during the 
first 20 min of the study. After 30 min, static images were made containing 500K 
counts for a good quality image. Of four control animals and two tumor-bearing 
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animals, additional static images (500K counts) were made 3 and 5 hr after 
injection; 24 hr after injection of the radiopharmacon another static image was 
made during 15 min. Static images were acquired in a 128 x 128 matrix and on X-
ray film. In order to investigate the organ distribution of radioactivity, animals 
were killed 30 ntin (5 control and 2 tumor-bearing animals) and 24 hr (4 control 
and 2 tumor-bearing animals) after injection of the radiopharmacon and the 
radioactivity in the various tissues was measured with a GeLi-detector equipped 
with a multicbannel analyzer (Series 40, Canberra). Tissues were not isolated from 
octreotide-pretreated animals. 
One urine sample, collected from a tumor-bearing animal 30 min after 
injection, was used to investigate the radiochentical composition by HPLC (after 
1:10 dilution in 40 % methanol in 154 roM NaCI). Urine samples obtained 24 hr 
after injection from 2 tumor-bearing animals were analyzed on a SEP-PAK C, 
cartridge. 
RESULTS 
Radiol.abeling. 
In Figure 2, a typical elution pattern is presented of the purification of "'I-
[Tyr']-octreotide over a SEP-P AK C, reversed-phase extraction cartridge. The 
radioactivity eluted with the ammonium acetate and water fractions appeared to be 
free radioiodide. The acetic acid fraction contained some peptide-bound 
radioiodine. The ethanol fraction contained 40 % - 60 % of the applied 
radioactivity when "'I was used for the labeling and 70 % - 80 % when "'I was 
used. Usually the specific activity of the SEP-PAK C,-purified ['"l-Tyr']-
octreotide reached a value of 30 - 37 MBq/l'g peptide. Occasionally. labeling 
yields of less than 5 % were observed after labeling with '"! (see Dicussion). With 
high labeling yields the SEP-P AK C, separations resulted in > 99 % peptide-
bound radioiodine. HPLC analysis of the material in the ethanol fraction is shown 
in Figure 3a-b. After labeling with "'!, two major peaks (at 19 and 21 min) were 
seen (Fig. 3a), of which the frrst one represents the mono-iodinated peptide (12) 
and the second probably the di-iodinated compound (see Discussion). With "'I, 
usnally over 99 % of the labeled product consisted of mono-iodinated [Tyr']-
octreotide (Fig. 3b), whereas in cases of low labeling yields, mentioned above, 
radioactivity was clearly present as di-iodinated peptide as well (up to 70 % of 
total peptide-bound activity). For all further experiments, at least 99 % 
radiochentically pure mono-iodinated [Tyr']-octreotide was used. 
lt was not possible to detect the low peptide mass of radioiodinated [Tyr']-
octreotide along with the radioactivity in the elution profiles presented in Figure 3 
(using either '"I or "'I). Furthermore, "cold" mono-iodinated ["'I-Tyr']-octreotide 
and di-iodinated ["'I-Tyr']-octreotide were not available. However, a clear 
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Figure 2 
SEP-PAK C, elution pattern after radioiodination of {Tyrj-octreotide. 
separation between mono-radioiodinated (retention time 19 min) and unlabeled 
[Tyr']-octreotide (retention time 15 min) by HPLC was demonstrated. 
In an attempt to increase the labeling efficiency with '"!, a range of higber 
chloramine-T concentrations was tested. These radio labeling procedures led not 
only to a substantial lowering of the labeling efficiency but also to a lower specific 
biologic somatostatin response measured as inhibition of the growth hormone 
secretion in rat pituitary cell cultutes (data not shown). This is probably due to 
oxidative damage of ITyr']-octreotide at higb chloramine-T concentrations. 
Receptor binding and specific biologic activity. 
In Figure 4, the binding characteristics of radiolabeled [Tyr']-octreotide to 
human meningioma membranes are illustrated. Scatchard analysis of the data (inset 
Fig. 4) showed a dissociation constant K. of 1.50 nM (r = 0.96) and a receptor 
concentration (B~) of 98 fmol/mg of membrane protein, values similar to those 
reported for 1"'1-Tyr"]-somatostatin (13). 
Radiolabeled ITyr']-octreotide showed the same biologic activity as octreotide, 
and somatostatin. In Table l the secretion of rat growth hormone (rGH) by 
cultuted rat pituitary cells is shown as a function of added ITyr']-octreotide, 
HPLC-purified mono-iodinated 1'"1-Tyr']-octreotide and somatostatin. The 
inhibition of rGH secretion by all three peptides was very similar. The presence of 
the radionuclide '"I in the peptide did not distutb the results of the rGH 
radioimmunoassay. 
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Figure 3 
HPLC elution poaems after labeling [Tyr'[-octreotide with "'I (A) and [Tyr'f-
octreotide with "'I (B). 
Animal studies. 
Dynamic scintigraphy of control rats after i. v. administration of ["'!-Tyr']-
octreotide showed a fast disappearance of the radioactivity from the blood 
circulation. Measurements with the gamma camera above the heart region showed 
that the time required to reach 50 % of the higbest radioactivity in the blood 
circulation was less than 2 min. Thirty minutes after injection static images showed 
clear appearance of radioactivity in the liver and intestines. The left kidney was 
seen as well as excreted activity in the bladder. The rigbt kidney was not visible 
because of overprojection of the intestines. The accumulation of the radiolabeled 
[Tyr']-octreotide in the liver was immediately followed by hepatobiliary excretion. 
Thirty minutes after injection no further radioactivity accumulation was seen 
elsewhere. Two hours after injection the thyroid was visible. The main 
radioactivity at that time was situated in the intestines, while activity in the bladder 
was also seen. Five and 24 br after injection the radioactivity in the thyroid was 
further increased. Althougb after 24 br the higbest activity was found in the 
thyroid, a similar amount was spread diffusely over the intestines, but little 
radioactivity was seen in other tissues at that time. 
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Figure 4 
Saturation curve of radiolabeled [Tyr' ]-octreoride binding to human 
meningioma membranes: ( ") total binding in absence of 10 p.M somatostatin, 
( -'-) non-specific binding in presence of 10 p.M somatostatin and (•) specific 
binding. Points are average of triplicates. Inset: Scatchard plot. 
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Table 1 
Biologic activiry of (HPLC-purijied) ["' 1-Tylj-octreotide•. 
Peptide Concentration Rat growth 
hormone 
(nM) (ng/ml ± s.d.) (%) 
['"!-Tyr']-octreotide 0 296 ± 11 100 
0.05 299 ± 6 101 
0.1 220 ± 7 74 
0.5 188 ± 21 64 
1.0 184 ± 22 62 
[Tyr']-octreotide 0 303 ± 11 100 
0.05 282 ± 11 93 
0.1 285 ± 13 94 
0.5 204 ± 13 67 
1.0 172 ± 19 57 
Somatostatin 0 344 ± 18 100 
0.05 290 ± 27 84 
0.1 267 ± 24 77 
0.5 185 ± 18 54 
1.0 158 ± 8 46 
• Secretion of rar growth hormone from cultured raJ pituitary cells (n = 4); 
by radiolabeled [Tyl]-octreotide. [Tyl]-octreotide and somarostatin. 
The tissue radioactivity distributions in control rats, 30 min and 24 hr after i.v. 
injection of ["'1-Tyr']-octreotide, were analyzed by radioactivity measurements of 
the various organs with a GeLi-detector. Thirty minutes after injection most of the 
administered radionuclide was located in the intestines, the liver, and the kidneys, 
while the highest radioactivity concentrations (% dose/ g tissue) were found in the 
intestines, the adrenals, the kidneys and the liver (Table 2). However, even much 
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Table 2 
Tissue distribution in five rars 30 min after intravenous 
administration of ("1-Tyr'!-ocrreotide 
% dose (mean ± s.d.) % dose/g (mean ± s.d.) 
Intestines 50± 10 2.7 ± 0.5 
Liver 12 ± 2 1.3 ± 0.2 
Kidneys 3.5 ± 0.5 1.5 ± 0.2 
Lungs 0.44 ± 0.12 0.37 ± 0.07 
Spleen 0.10 ± 0.07 0.20 ± 0.12 
Heart 0.10 ± 0.02 O.ll ± 0.01 
Adrenals 0.06 ± 0.01 1.6 ± 0.3 
Par otis 0.06 ± 0.03 0.11 ± 0.04 
Thymus 0.048 ± 0.008 0.!1 ± 0.02 
Thyroid 0.004 ± 0.006 0.15 ± 0.06 
Rest 26 ± 5 0.13 ± 0.02 
Blood 0.24 ± 0.05 
Urine 16 ± 13 
higher concentrations of radioactivity were found in the collected urine specimens 
30 min after injection. Twenty-four hours after injection the highest activities were 
measured in the thyroid and the intestines, with the thyroid having the highest 
concentration of radioactivity (Table 3). Urine samples were not collected 24 hr 
after injection. 
In tumor-bearing rats. accumulation of the radioiodinated [Tyr']-octreotide at 
tumor sites could be demonstrated with the gamma camera. The scintigrams 
demonStrate a clear visualization of tumors at 30 min, 3 and 5 h after injection. 
However, 24 hr after injection the previously accumulated radioactivity at the 
tumor sites had disappeared, which was confrrmed by counting the isolated tumors 
30 min and 24 hr after injection (data not shown). 
Figure 5 shows a posterior view of a rat with somatostatin receptor-positive 
tumors to the left (320 mm') and to the right (144 mm') 30 min after injection, 
whereas at the same time point in a rat pretreated with I mg octreotide 
subcutaneously 30 min before injection of ["'1-Tyr']-octreotide an even larger 
tumor at the left (640 mm') was only visible as vascular tissue radioactivity (Fig. 
6). 
A significant increase in radioactivity was demonStrated above nine tumors in six 
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Intestines 
Liver 
Kidneys 
Lungs 
Spleen 
Heart 
Adrenals 
Parotis 
Thymus 
Thyroid 
Rest 
Blood 
Table 3 
Tissue distribution in four rats 24 hr after intravenous 
administration of!"' I-Tyr' ]-octreotide 
% dose (mean ± s.d.) % dose/g (mean ± s.d.) 
9 ±10 0.6 ± 0.7 
0.31 ± 0.03 0.027 ± 0.005 
0.26 ± 0.04 0.10 ± 0.01 
0.040 ± 0.011 0.033 ± 0.006 
0.011 ± 0.010 0.028 ± 0.021 
0.007 ± 0.002 0.009 ± 0.002 
0.0028 ± 0.0007 0.07 ± 0.02 
0.0045 ± 0.0020 0.009 ± 0.004 
0.006 ± 0.003 0.016 ± 0.007 
7±2 180 ± 50 
3.0 ± 0.6 0.016 ± 0.004 
0.020 ± 0.006 
animals immediately after i.v. injection. Because of different sizes of tumors (and 
normal tissues) in various animals normalization of data was necessary. The 
measured radioactivity during the first minute after injection was taken as a 
reference. Figure 7 shows the radioactivity as a function of time measured above 
rune tumors in six ammals, expressed as percentage of the 1-min value. In Figure 
7 is also shown that the above tumors in two rats (of which one is depicted in Fig. 
6), which were pretreated subcutaneously with I mg octreotide 30 min before 
injection of the radiopharmacon, a decrease of radioactivity with time was 
measured similar to control tissues in eight animals retlecting the decreasing 
vascular tissue radioactivity. 
Compared to the upta.\:e in the liver the initial increase of radioactivity above the 
tumors was clearly higher in six tumors, equal in two tumors. and less in one 
tumor. 
The tissue radioactivity distribution in tumor-bearing rats was similar to that in 
control rats both 30 min and 24 hr after ["'1-Tyr']-octreotide injection (data not 
shown). 
The biodistribution of the radiopharmacon in octreotide-pretreated animals 
showed a similar pattern as in the animals not pretreated with octreotide (including 
the controls), according to gamma camera measurements. 
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Figure 5 
Scintigraphy of a rat with one 
somatostatin receptor-positive 
tumor at the left (suiface: 320 mni) 
and one at the right (144 mrri). 20 
min after i. v. m;ection of 
radiolabeled {Tyr'J-octreotide. 
Apan from tumors (T) and bladder 
(B) activity is seen in hean. liver. 
intestines (including right kidney). 
and the left kidney. 
T 
e 
Figure 6 
Scintigraplry of a rat pretreated 
with I mg octreotide with one 
somatostatin receptor-posuLve 
tumor at the left (suiface: 640 mm') 
20 min after i. v. injection of 
radiolalJeled {Tyr'J-octreotide. (See 
also Fig. 5 legend) 
A 30-min urine sample was obtained from one tumor-bearing animal. HPLC-
analysis of that sample showed, that !'"1-Tyr']-octreotide was excreted in 
unchanged form. Extraction of urine samples obtained 24 hr after injection from 
two tumor-bearing animals with a SEP-PAK C,. cartridge showed that more than 
95 % of the radioactivity was free radioiodide. 
DISCUSSION 
[Tyr']-octreotide is a stable analogue of somatostatin that can be easily 
radioiodinated (12). In this study, the postulate is tested that radioiodinated [Tyr']-
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Figure 7 
Radioactivity as a 
function of time, 
expressed as percentage 
(± s,d_) of the 1-min 
value, measured above 
nine tumors in six rats 
(•). nvo tumors in nvo 
rats. which were 
pretreated with I mg 
octreotide ( .. ) and 
control tissues in eight 
animals (")-
radioactivity (% of t=1 min value) 
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minutes after injection 
octreotide, which has been used successfully in detecting somatostatin receptors in 
isolated tissues (12, 19, 20), is also suitable for in vivo imaging of tumors 
containing somatostatin receptors with "'I as a radiolabel. For this, we investigated 
the radiolabeling of [Tyr']-octreotide ("'I compared with "'I), the purification of 
the radiolabeled product, its specific biologic characteristics, in vivo metabolism, 
and application for imaging somatostatin receptor-positive tumors in the rat. 
With "'l, always consistent labeling yields of 40 % - 60 % are obtained at a 
peptide : iodide ratio of 3 : 2. Because of the very higb specific activity of "'I a 
large excess of [Tyr']-octreotide over total iodide can be used while keeping the 
absolute amount of peptide low (peptide : iodide = 100 : 3). In general, very high 
labeling yields (70 % - 80 %) with high specific activities are obtained using "'!. 
Occasionally, however, very low radiolabeling yields (below 5 %) are observed 
with "'!. These difficulties are never seen when completely carrier-free "'l 
(Amersharn, England) is used. In the case of "'I, other iodine isotopes (e.g., '"I 
and stable "'I) are contaminating the "'!-preparation (maximal seven other iodine 
atoms versus one "'l atom at the time of labeling) as a consequence of the 
radionuclide production method. The occasionally observed labeling yields below 5 
% are caused by production problems by which the product specifications ( > 3.7 
TBq "'limg iodine) are not met (see also below). The best and constant results are 
finally obtained with "'! obtained from Medgenix (Fieurus, Belgium). 
The high peptide-to-iodide ratio (100 : 3) favors not only a high labeling yield 
but also the formation of mono-iodinated over di-iodinated [Tyr' ]-octreotide. 
Radioactivity in the first HPLC-eluted peptide peak representing the mono-
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iodinated "'!-compound usually was more than 99 % of the total peptide 
radioactivity. This is in contrast to the '"!-labeling (with a much lower peptide : 
iodide ratio of 3 : 2), where the second HPLC-eluted eli-iodinated product always 
represents at least 30 % of the total peptide-bound radioactivity, and HPLC is 
necessary to isolate the mono-iodinated peptide. A sintilar separation of 
radioiodinated [Tyr']-octreotide in two components has been reported previously 
(12) using '"! as radiolabel and a different HPLC system. The occasionally low 
labeling yields with "'! are always associated with formation of relatively much di-
iodinated [Tyr']-octreotide (up to 70 % of all peptide bound radioactivity) because 
of the unexpectedly high amount of stable "'I in the radionuclide preparation, 
which was afterwards confirmed by the manufacturer. Clearly a large excess of 
[Tyr']-octreotide compared to total iodide guarantees a high labeling yield and the 
formation of mainly mono-iodinated ['"!-Tyr']-octreotide, of which high binding to 
somatostatin receptors was reported (12). Thus, it appears that the SEP-PAK c, 
separation technique is adequate to prepare high activities (e.g., more than 2 GBq) 
of mono-iodinated ['"!-Tyr']-octreotide. 
The specific radioactivity of the "'!-labeled peptide isolated on SEP-P AK C, is 
proven to be high enough to demonstrate specific binding to human meningioma 
membranes. This suggests that additional HPLC purification is not necessary for 
the large amounts of radioactivity required for routine i. v. adntinistration. 
To demonstrate the specific biologic activity of the radiolabeled compound, the 
latter has been isolated by HPLC; it inhibits growth hormone release to a similar 
extent as [Tyr']-octreotide and somatostatin. This indicates that the radiolabeling 
procedure is not deleterious to the biologic activity of the peptide. In this case, 
mono-iodinated ['"!-Tyr']-octreotide has been isolated, of which the specific 
radioactivity can be exactly calculated. This is not possible with '"! because of the 
contamination with variable and unknown amounts if other iodine isotopes (see 
above). 
In vivo disposal of circulating radioiodinated [Tyr']-octreotide in both control 
and tnmor-bearing rats occurs predominantly by rapid hepatic clearance and biliary 
excretion as demonstrated with the scintigraphic stndies and analyses of 
radioactivity in isolated tissues. This finding is in accordance with studies with 
octreotide itself (21) and another somatostatin analogue in the rat model (22). 
A second route of clearance via the kidneys is demonstrated at 30 min on the 
scintigrams (left kidney and bladder) and organ distributions (Table 2). Note the 
very high radioactivity concentration in the urine samples collected at that time. 
The identification of urinary radioactivity in the form of unchanged radioiodinated 
[Tyr']-octreotide in a 30-min sample demonstrates that the compound is cleared 
intact by the kidneys. Of the low radioactivity in the 24-hr samples at least 95 % is 
in the form of free radioiodide. The appearance of radioiodide in the urine is 
explained by complete hydrolysis of the labeled peptide followed by deiodination 
of iodotyrosine. A relatively high amount (7 % - II %) of injected radioiodine is 
trapped in the thyroid after 24 hr, since the thyroids of the animals were not 
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blocked. 
The relatively high adrenal radioactivity concentration found 30 min after 
injection in control and tumor-bearing animals is in accordance with reported 
autoradiographic experiments (20), demonstrating the existence of somatostatin 
receptors in the rat adrenal. 
The observed. rapid decrease in circulating radioactivity of the 
radiopharmaceutical may benefit the sensitivity of the scintigraplric detection 
technique, especially as the receptor-bound radioactivity is stable once binding has 
taken place. This will result in a higher tumor/background ratio. For in vivo 
experiments, radioiodinated [Tyr']-octreotide is injected intravenously in rats with 
transplantable rat pancreatic tumors (CA 20948), which are known to contain 
somatostatin receptors in vitro ( 16 - 18). The increasing radioactivity measured 
above the tumor sites immediately after injection contrasts with the decreasing 
blood-pool radioactivity, which excludes imaging of the tumors solely on the basis 
of blood-pool radioactivity. This increase is usually more pronounced than that 
above the liver, which is an indication of a very rapid binding process. Obviously, 
the total maximum radioactivity above the liver is higher due to its greater size. 
The specificity of the binding of I'" I-Tyr']-octreotide to the tumors is most 
firmly established by the observation that pretreatment of the tumor-bearing rats 
with a high dose (1 mg) of octreotide (without changing the biodistribution of the 
radiopharmacon as observed with the gammacamera) results in a complete 
inhibition of the binding of label to the tumors. Consequently, immediately after 
injection decreasing radioactivity is measured over the blocked tumors, reflecting 
the radioactivity in the vascular pool, in contrast to the increasing radioactivity 
measured over the unblocked tumors (Fig. 7). 
CONCLUSION 
The radioiodination of [Tyr']-octreotide and the described purification procedure 
do not alter the specific somatostatin characteristics of the original compound, 
which means that tltis radiopharmaceutical is suitable for scintigraphic imaging of 
somatostatin receptors in vivo. 
The fast disappearance from plasma of radioiodinated [Tyr']-octreotide after 
i. v. administration rapidly reduces the background level in the circulation, 
enhancing the possibility of scintigraphic imaging of somatostatin receptor-bearing 
tumors. 
Because of the successful scintigraphic demonstration of somatostatin receptor-
bearing tumors in the rat model using radioiodinated [Tyr']-octreotide, application 
of this new radiopharmaceutical in humans is promising since it is known that 
various human tumors possess large numbers of high-affmity somatostatin 
receptors, as demonstrated with I"'I-Tyr']-octreotide in vitro (II, 13). 
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CHAPTER3 
In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism 
and binding to somatostatin receptor-positive tumors in man 
Willem H. Bakker, Eric P. Krenning, Wout A. P. Breeman, Peter P.M. Kooij, 
Jean-Claude Reubi, Jan W. Koper, Marion de Jong, Johannes S. Lameri.s, 
Tbeo J. Visser, Steven W. Lamberts. 
Departments of Nuclear Medicine, Internal Medicine Ill and Radiology, 
University Hospital Dijkzigt and Erasmus University Medical School, 
Rotterdam, The Nether lands and 
Sandoz Research Institute, Berne, Switzerland. 
Somatostatin analogues, labeled with gamma-emitting radionuclides, are 
of potential value in the localization of somatostatin receptor-positive tumors 
with gamma camera imaging. We investigated the application in man of a 
radioiodinated analogue of somatostatin, ['"1-Tyr']-octreotide, which has 
similar biologic characteristics as the native peptide. 
The radiopharmaceutical is cleared rapidly from the circulation (up to 85 
% of the dose after 10 minutes) mainly by the liver. Liver radioactivity is 
rapidly excreted into the biliary system. Until 3 hr after injection, radioac-
tivity in the circulation is mainly in the form of ['"1-Tyr']-octreotide. 
Thereafter. plasma samples contain increasing proportions of free iodide. 
Similarly, during the first hours after injection, radioactivity in the urine 
exists mainly in the form of the unchanged peptide. Thereafter, a progressive 
increase in radioiodide excretion is observed, indicating degradation of the 
radiopharmaceutical in vivo. Fecal excretion of radioactivity amounts to only 
a few percent of the dose. 
The calculated median effective dose equivalent is comparable with values 
for applications of other "'1-radiopharmaceuticals (0.021 mSv/MBq). 
['"1-Tyr']-octreotide can be used for the visualization of a variety of 
somatostatin receptor-positive cancers. One patient with an endocrine 
pancreatic tumor and a meningioma is presented. 
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Somatostatin is a peptide hormone which exerts a wide variety of actions 
throughout the body. It plays an inhibitoty role in the normal regulation of several 
organ systems, including the central nervous system, the hypothalamus, the 
pituitary gland, the gastrointestinal tract and the endocrine and exocrine pancreas 
(1, 2). Large numbers of binding sites with a high affinity for somatostatin have 
been detected with in vitro techniques in many tumors arising from these organ 
systems; these include pituitary tumors (3), brain tumors like meningiomas and 
low-grade astrocytomas (4, 5), and hormone-producing tumors in the gastro-
intestinal tract including the pancreas (6, 7). It has previously been shown in 
animal studies that it is possible to detect somatostatin receptors in vivo after ad-
ministration of ["'l-Tyr']-octreotide to somatostatin receptor-positive tumor-bearing 
rats (8). 
It has also been shown in a preliminary study that the in vivo application of the 
same radiopharmaceutical in man results in scintigraphic imaging of somatostatin 
receptor-positive tumors (9). lo this study we present data on the metabolism of 
intravenously athninistered ['"I-Tyr']-octreotide in man and estimates of the 
radiation dose. Also scintigraphy is shown of a patient with two different somatos-
tatin receptor-positive tumors. 
MATERIALS AND METHODS 
Radiopharmaceuticals 
Radioiodination of [Tyr']-octreotide was performed with the chloramine-T 
method as described previously (8). Specific activities ranged from 18.5 to 37 
MBq/l'g (0.5 - 1 mCi/l'g) of ['"1-Tyr']-octreotide. Images were obtained after 
intravenous injection of 370 - 555 MBq (10 - 15 mCi; 15 - 25 !'g) "'!-labeled 
somatostatin analogue. To prevent accumulation of radioiodine in the thyroid, 
patients were given daily 3 x 50 mg potassium iodide and 4 x 250 mg potassium 
perchlorate for 3 days, starting 1 day before injection of ["'I-Tyr']-octreotide. 
imaging 
Planar and SPECT images were obtained with a large field of view gamma 
camera (Counterbalance 3700 and ROTA-II, Siemens) equipped with a 190 keV 
parallel-hole collimator. The analyzer was set to 159 keV with a 20 % window. 
Data were stored in a dedicated computer (Gamma-11, Nuclear Diagnostics, 
Hiigersten, Sweden). During the first 30 minutes of the study, computer images 
(matrix 64 x 64) were acquired in 40 intervals of 3 sec each and 28 intervals of I 
min each. Analogue images were made at regular intervals during the first 30 min. 
Anterior and posterior whole-body scintigraphy were performed 30 min after 
injection. Images (both analogue and digital, matrix 128 x 128) were also obtained 
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at approximately 4 and 24 hr after injection. In a few cases, scintigraphy was also 
performed after 2 and 48 hr. SPECT was always performed for localization of 
primary tumors in the head/neck region as well as in case of overprojection of 
tumor with normal tissue (e.g., liver and kidneys). SPECT reconstruction images 
were made at 60 angles for 360'. Acquisition time per angle was always 30 sec. 
The original data were prefiltered with a Wiener filter. The filtered data were 
reconstructed with a Ramp filter. The reconstruction program (SPETS version 
6.01) was obtained from Nuclear Diagnostics. 
Measurements of radioactiviry in blood, urine and feces. 
The radioactivity in blood, urine, and feces was measured with a LKB-1282-
Compugamma system or a GeLi-detector equipped with a multichannel analyzer 
(Series 40, Canberra). Blood samples were collected directly before the injection 
and after 2, 5, 10, 20, 40, 60, 90 min and 2, 3, 5, 8 and 20 hr. Urine was 
collected in 5-hr intervals until 50 hours after injection. If feasible, feces were 
collected until 48 hours after injection. 
The chemical status of the radionuclide in blood and urine was analyzed as 
function of time by using the SEP-PAK c,., HPLC and gel filtration techniques 
described previously (8). The nature of peptide-bound radioactivity in blood and 
urine was tested by investigation of specific binding to human meningioma 
membranes as described previously (4). 
Patients 
Kinetic studies with ["'!-Tyr']-octreotide by means of gamma camera scin-
tigraphy were performed in 13 patients with several types of tumors, including 
endocrine pancreatic tumors, metastatic carcinoids, and meningiomas. Additionally 
plasma, urine, and feces samples were obtained from seven, eight and seven 
patients, respectively. 
Dosimetry 
For the estimation of the radiation dose the M!RDOSE version 2 program (10) 
and ICRP publication 53 (11) were used. The dose estimates were calculated on 
the basis of the following. The uptakes in the most important source organs, the 
gallbladder, the liver, the urinary bladder, and the total body, were determined as 
a function of time. Radioactivity in liver and the gallbladder was calculated using 
the geometric mean of anterior and posterior counts. Patient overall thickness, for 
attenuation correction, was determined from a lateral view and was assumed to be 
constant over the abdomen. An anatomic liver phantom contained in a waterbath 
was used to calculate the effects of the object geometry (12). The water thickness 
was varied from 15 to 20 centimeters, a typical patient range. 
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Calibrated amounts of radioactivity were placed in the liver phantom and in a 
standard bottle. The standard bottle was placed on top of the colliw.ator and counts 
were determined from one view. From calculated counts in the liver phantom and 
measured counts in the standard bottle a geometry factor was determined as a 
function of the water thickness. Because of the observed small variations in the 
geometry factor, as a function of water thickness, a constant was used to calculate 
the absolute uptake of the radionuclide in the liver (13). The gallbladder was 
regarded to have the same geometry as the standard bottle. A geometry factor for 
the intestines could not be determined but was taken to be the same as for the 
liver. ln order to quantitate the percentage uptake in the various organs a standard 
bottle containing an aliquot of the injected dose was measured just before each 
patient study. Background correction for the liver was performed on the basis of an 
area just outside the liver region. Background correction for the gallbladder was 
performed on the basis of a region within the liver next to the gallbladder. 
For dosimetry the biological half-life of the liver activity was calculated by 
analysis of the computer images 4 and 24 hours after injection. The biologic half-
life in the gallbladder could not be measured, but was estimated to be 2.5 hr based 
upon experimental circumstances and literature (11). No predominant accumulation 
of radioactivity was seen in organs other than liver and gallbladder during patient 
studies. With further exception of the urinary bladder contents and the total body 
other organs therefore were disregarded as source organs. Since urine data were 
not available for all patients, it was assumed for dose calculations (including cal-
culations of the urinary bladder content) that the activity in the urine for these 
patients was equal to the mean activity in the urine for the eight patients with 
correct urine collection. Total body radioactivity was assumed to be 100 % minus 
that in liver, gallbladder, urinary bladder and collected urine together. Further-
more, dosimetry calculations were performed on an individual basis. 
RESULTS 
ln seven consecutive patients injected with ["'l-Tyf']-octreotide, the average 
plasma radioactivity decreased rapidly after injection. Assuming a plasma volume 
of 3 liters, the radioactivity in the circulation was calculated to decrease within 10 
minutes to less than 15 % (s.d. 5 %) of the dose. ln two patients the chemical 
status of the radionuclide in the plasma was investigated as a function of time. 
During the first hours, plasma radioactivity was mostly peptide-bound. After 3 hr. 
the peptide-bound fraction of total radioiodide was still about 70 %. In Figure 1, 
the time course of total and peptide-bound radioactivity are presented during the 
flrst 5 hr after injection of ['"1-Tyf']-octreotide. 
The urinary excretion of radioactivity in eight patients was measured by 
collecting samples at 5-ilr intervals. Figure 1 (inset) shows that about 45 % of the 
administered dose was excreted in the urine within 30 hr after injection. The 
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Figure 1 
Total plasma radioactivity (e) after administralion of f"'I-Tyr'}-octreotide in 
seven patients. Peptide-bound (•) radioactivity was calculated on the basis of 
data from two paJients. Data are expressed as percentage (mean ± s.d.) of 
the dose. (Inset) Cumulative total "'!-excretion (") in the urine after 
intravenous injection of f"'I- Tyr]-octreotide in eight patients. Cumulative 
peptide-bound radioactivity (•) was calculated on the basis of data obtained 
from four padents. Data are expressed as percentage (mean ± s.d.) of the 
dose. 
chemical status of the radionuclide in the urine was investigated as a function of 
time. Figure I (inset) also shows that in four of the patients mainly peptide-bound 
activity was excreted during the first 10 hr after injection. Thereafter, a progres-
sive increase in radioiodide excretion was observed. 
!n four patients with a normal intestinal function, feces collected until 48 hr 
after injection of 1"'1-Tyr']-octreotide, contained less than 2 % of the administered 
radioactivity. However, in another 3 patients with abnormal intestinal function 
(e.g., due to previous intestinal surgery), 20 % - 45 % of the adntinistered 
radioactivity was excreted in the feces within 48 hr after injection. This difference 
in fecal excretion was in accordance with scintigraphy, showing more radioactivity 
in the colon of the patients with abnormal intestinal function compared with 
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Figure 2 
(A) Anterior abdominal image of somatostarin receptor-positive gastrinoma. 
taken 28 hours after injection of f"'I-Tyrt-octreoride in a parienr after 
gasrrecromy and intestinal surgery. (B) CT scan of the abdomen with a slice 
ar the level of the hot spot in Figure 2A showing an enlarged lymphe node 
containing a gastrinoma merasrasis (see arrow). 
patients with normal intestinal function. Figure 2A is an example of a patient with 
a disturbed intestinal function (after total gastrectomy and partial removal of the 
duodenum), which clearly shows the presence of radioactivity in the colon. 
The SEP-PAK C, and HPLC-purified radiolabeled-peptide component in 
plasma and urine showed the same biologic activity as the radiopharmaceutical 
itself as indicated by its specific binding to human meningioma membranes (data 
not shown). 
After the intravenous administration of ["'!-Tyi"]-octreotide scintigraphy 
demonstrated that radioactivity was rapidly cleared from the circulation, as 
measured by a decreasing blood-pool activity over the cardiac region. Gamma 
camera images showed that at the same time the radiopharmaceutical accumulates 
rapidly in the liver. immediately followed by appearance in the biliary system and 
eventually in the small intestines, confrrming the data of our animal experiments 
(8). 
The calculated uptakes in liver and gallbladder. which varied strongly between 
patients, reached their highest values between 0.5 and 1.5 hours after injection of 
1"'1-Tyi"]-octreotide. After an initial rapid passage through the liver the median 
radioactivity in the liver decreased to 28 % of the dose (range l3 % - 41 %) 4 hr 
after injection, and 6 % of the dose (range 2 % - 17 %) after 24 hr. Radioactivity 
in the gallbladder could already be observed after 5 min. After 4 hr. the ac-
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Table I 
Dose estii'TU11es after ii71Tavenous administration of f"I-Tyr]-octreotide in 
man on the basis of gamma camera measurements (n = 13) and 
measurements of urinary excretion (n = 8). 
Target organ median absorbed dose range 
(mGy/MBq) (mGy/MBq) 
Gallbladder wall 0.119 0.043 - 0.222 
Liver 0.048 0.024 - 0.081 
Urinary bladder wall 0.041 0.040 - 0.045 
Median effective dose equivalent range 
(mSv/MBq) (mSv/MBq) 
0.021 0.018- 0.031 
cumulation in the gallbladder was 18 % of the dose (range 3 % - 35 %). Radioac-
tivity in the gallbladder had disappeared after 24 br. After 4 br less than 2 % of 
the dose was measured in the intestines. In patients without tumors in the intestinal 
region and in patients who did not undergo intestinal surgery, some activity was 
measured in this area (median 6 %, range 2 % - 9 %) after 24 br. Because of the 
short physical half-life of "'I and the low intestinal residence time, the intestines 
were disregarded as source organ in dosimetry. The calculated uptake in the total 
body in individual patients did not show a significant decrease from 4 to 24 br 
after injection. For this reason, in the dose calculations the effective half-life for 
the total body was the same as the physical half-life of "'!. Patients were inves-
tigated under maximum thyroid-blocking conditions to prevent accumulation of the 
radionuclide in the thyroid. Therefore, the circulating free radioiodide, released 
from the radiolabeled analogue, was largely cleared by the kidneys. Indeed, only 
very low thyroidal accumulation was seen. Consequently, the radiation dose to the 
thyroid was negligible and was not considered in the calculations. The kidneys and 
the intestines were sometimes seen on the gamma camera images but treated as 
negligible source organs because of the short residence time of the radionuclide in 
these organs. The results of the dosimetry are shown in Table I. 
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Case history 
As an example, the detection of two different somatostatin receptor-positive 
tumors in one patient is presented. The patient a 40 year old woman, underwent a 
total gastrectomy, subtotal pancreatectomy, and partial removal of the duodenum 
because of a large gastrin-secreting tumor in the cauda and corpus of the pancreas 
as well as in the wall of the duodenum at age 34. In the last 4 yr, serum gastrin 
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Figure 3 
(A) Anterior scintigraphy of a lymph node metastasis of the gastrinoma (on 
the left side of the mediastinum) and a meningioma 24 hr after injection of 
("1-Tyrf-octreotide. (B) Right lateral scintigraphy of the lymph node metas-
tasis and the meningioma. (C) CT-scan of a lymph node metastasis of the 
gastrinoma in the mediastinum (see arrow). (D) CT-scan of the somatostatin 
receptor-positive meningioma (see arrow). 
levels increased steadily to levels 20 times above the upper limit of normal. This 
suggested the recurrence of gastrin-secreting tumor tissue, but its location could 
not be established immediately. In addition, this patient had a meningioma located 
parasellarly on the right side, which was removed at age 36. This tumor recurred, 
causing loss of vision of the right eye. 
The presence of a somatostatin receptor-positive tumor (diameter 5 em), which 
was subsequently shown to be a single gastrinoma-containing lymph node, was 
seen 3 min after injection of ['"!-Tyr']-octreotide (not shown here) and was still 
clearly visible after 28 hr. Figure 2A shows the gastrinoma together with colon 
radioactivity and decreased liver activity on an anterior abdominal image 28 hr 
after injection of ["'1-Tyr']-octreotide. Figure 2B shows this gastrinoma on the CT 
scan. At abdominal surgery, no other gastrinoma metastases were found in the 
abdomen or in the liver. 
Figures 3A-B (24 hr after administration of ['"1-Tyr']-octreotide) indicate the 
existence of another lymph node metastasis of the gastrinoma on the left side of the 
mediastinum, while the somatostatin receptor-positive meningioma is also clearly 
visualized. Figures 3C-D present CT-images of the lymph node metastasis and the 
meningioma, respectively. 
DISCUSSION 
[Tyr']-octreotide, labeled with '"!, which is successfully applied to in vitro 
somatostatin receptor studies, is not suitable for in vivo imaging because of the 
low-energy gamma emissions of'"!. Although the radiation emitted by "'I is more 
favourable for scintigraphy, the disadvantage that this isotope shares with '"! is its 
low specific activity (14), which necessitates purification of the radioiodination 
products by HPLC and lowers the yield of monoiodinated [Tyr']-octreotide 
especially when the usual, low amounts of peptide are labeled. However, with the 
availability of cyclotron-produced "'I (half-life 13.2 hours, gamma energy !59 
keY), efficient radiolabeling of [Tyr']-octreotide is possible (8), enabling excellent 
imaging, including SPECT. Because of its short half-life it is possible to ad-
minister high doses (maximal 555 MBq "'I was used). while the dose equivalent to 
the patient can be kept within regular limits of common nuclear medicine studies. 
The metabolism of intravenously administered radio-iodinated [Tyr']-octreotide 
in man is primarily characterized by a rapid clearance by the liver, immediately 
followed by biliary excretion into the small intestine. On the basis of preliminary 
rat liver perfusion experiments (Bakker WH et al, unpublished data), it is 
presumed that ["'l-Tyr']-octreotide is excreted intact through the bile in man. The 
degradation of ['"!-Tyr']-octreotide in the intestines is uncertain, but presumably 
the compound is hydrolyzed and its degradation products are enterally absorbed 
like those of octreotide (15). Thereafter, deiodination happens in tissues after 
which free radioiodide is ultimately cleared via the kidneys. This is supported by 
the observations in our patients that nearly all excreted radioactivity is present in 
the urine and normally only a very small amount is found in the feces, despite 
considerable biliary excretion. Exceptions are patients with previous intestinal 
operations leading to a short bowel syndrome as in the case presented in Fig. 2A. 
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Figure 4 
Hypothetical rrwdel of the metabolism of !"'1-Tyr'J-octreotide. (Closed 
arrows) "'I-Tyr-3-octreotide and (open arrows) degradation products of f"'I-
Tyr'J-octreotide including free iodide. 
Analysis of the chemical status of plasma radioactivity in the samples of the 
first 3 hr after injection mainly shows peptide-bound radioiodine in the form of the 
original ["'1-Tyr']-octreotide. Analysis of radioactivity in the urine as a function of 
time shows predominantly intact I "'l-Tyr']-octreotide during the first I 0 hr after 
injection. In the subsequent samples, more and more free radioiodide is found. 
This free iodide is excreted over a long time course. These observations clearly 
indicate an effective deiodination of the injected compound andlor its degradation 
products in vivo. On the basis of these data a metabolic model is presented in 
Fignre 4. 
In order to visualize a tumor by receptor binding of ["'!-Tyr']-octreotide, the 
specific activity expressed in counts per unit of area must exceed the local back-
ground radiation. For instance, in the hepatic region tumor receptor accumulation 
is more difficult to visualize during the period of normal hepatic uptake of the 
radioligand. The rapidly decreasing background activity (also in the liver area due 
to biliary excretion) facilitates the detection and localization of somatostatin 
receptor-positive tumors, which is further improved by the use of SPECT. 
We previously reported successful imaging with this procedure of various 
somatostatin receptor-positive tumors, including endocrine pancreatic tumors, 
carcinoids, meningiomas, small cell cancers of the lung, neuroblastomas, 
paragangliomas, pheochromocytomas, astrocytomas, and some hormone-producing 
pituitary tumors (9, 16-19). 
The advantage of this technique compared with currently available diagoostic 
radiological procedures is evident. ['"1-Tyr']-octreotide scintigraphy is a con-
venient, painless, and harmless technique without side effects and with an accep-
table effective dose equivalent, comparable with values for other "'!-labeled 
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radiopharmaceuticals (II). Apart from the detection of previously often unknown 
metastases or multiple-tumor localizations with whole-body scintigraphy, the 
visualization of somatostatin receptor-positive tumors may predict the possible 
success of octreotide radiotherapy. Although "'! is an attractive radionuclide for 
this purpose, its low specific activity would necessitate the administration of very 
high amounts (milligrams) of [Tyr']-octreotide required for binding of therapeutic 
amounts of "'!. However, somatostatin analogues radiolabeled with an ultra pure 
short-lived alpha or beta emitter are potential, new therapeutic radiophar-
maceuticals in the treatment of somatostatin receptor -positive cancer. 
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CHAPTER4 
1''' In-DTP A-D-Phe']-octreotide, a potential radiopharmaceutical 
for imaging of somatostatin receptor-positive tumors: 
Synthesis, radiolabeling and in vitro validation 
W.H. Bakker. R. Albert, C. Bruns, W.A.P. Breeman, 
L.J. Hofland, P. Marbach, J. Pless, D. Pralet, B. Stolz, J.W. Koper, 
S.W.J. Lamberts. T.J. Visser, and E.P. Krenning. 
Departments of Nuclear Medicine and Internal Medicine Ill, 
University Hospital Dijkzigt and Erasmus University, Rotterdam, The Netherlands, 
Department of Endocrinology, Sandoz Pharma AG, Basel, Switzerland. 
Summary 
Somatostatin receptor-positive human tumors can be detected using 
radioiodinated analogues of somatostatin, both in vitro and in vivo. ["'1-
Tyr']-octreotide has been successfully used in the visnalization of somatos-
tatin receptor-positive tumors by gamma camera scintigraphy, but this 
radiopharmaceutical has some major drawbacks, which can be overcome with 
other radionuclides such as "'ln. As starting material for a potentially 
convenient radiopharmaceutical, a diethylenetriaminopentaacetic acid (DTPA) 
conjugated derivative of octreotide (SMS 201-995) was prepared. This 
peptide, [DTPA-D-Phe']-octreotide (SDZ 215-811) binds more than 95 % of 
added "'In in an easy. single-step labeling procedure without necessity of 
further purification. The specific somatostatin-like biologic effect of these 
analogues was proven by the inhibition of growth hormone secretion by 
cultured rat pituitary cells in a dose-dependent fashion by octreotide, [DTPA-
D-Phe']-octreotide and non-radioactive !"'ln-DTPA-D-Phe']-octreotide. The 
binding of f"'In-DTPA-D-Phe']-octreotide to rat brain cortex membranes 
proved to be displaced similarly by natural somatostatin as well as by 
octreotide, suggesting specific binding of ["'ln-DTPA-D-Phe']-octreotide to 
somatostatin receptors. The binding of the indium-labeled compound showed 
a somewhat lower affinity when compared with the iodinated [Tyr']-octreo-
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tide, but indium-labeled [DTPA-D-Phe']-octreotide still binds with nanomolar 
affinity. In conjunction with in vivo studies, these results suggest that ["'ln-
DTPA-D-Phe']-octreotide is a promising radiopharmaceutical for scin-
tigraphic imaging of somatostatin receptor-positive tumors. 
Many endocrine tumors are small and difficult to localize with the usual 
radiological techniques (I, 2). Most endocrine pancreatic tumors and carcinoids 
contain receptors for the native peptide somatostatin (3). It has been previously 
shown that a "'!-labeled somatostatin analogue with similar biologic activity as 
native somatostatin specifically binds to receptors on cell membranes of these 
tnmors (3). Subsequently, we showed with the use of the same somatostatin 
analogue, labeled with "'! (["'1-Tyr']-octreotide or "'1-SDZ 204-090), that 
somatostatin receptor -positive tumors can be visualized in vivo by means of gamma 
camera scintigraphy both in animals (4) and man (5). 
['"1-Tyr']-octreotide, however, has the following major drawbacks (4). (a) The 
cyclotron-produced radionuclide '"I, with the very high-quality specifications 
required, is not readily available world-wide. (b) The radiolabeling and consecutive 
purification steps are time-consuming and make the application of this label 
unsuitable for routine investigations. (c) Althougb favourable in terms of the 
radiation dose to the patient, the physical half-life of the radionuclide is so short 
that scintigraphy later than 24 hours after administration of the radiopharmaceutical 
is difficult. (d) After intravenous injection ["'1-Tyr']-octreotide is cleared very 
rapidly from the blood with a consequent relatively low effective residence time 
that limits its accumulation in tumor tissue, althougb this has the advantage of a 
very low interfering background radioactivity already shortly after injection. (e) 
The potential accumulation of radioactivity in endocrine tumors in or around the 
liver, bile ducts, gallbladder and gastro-intestiual tract is difficult to interpret 
because of the extensive hepatic clearance of ['"1-Tyr']-octreotide followed by 
rapid biliary excretion in the intestinal tract. 
In recent years many radiopharmaceuticals, mostly larger proteins (e.g. albumin 
and antibodies) have been conjugated successfully with the strong metal-chelating 
group diethylenetriaminopentaacetic acid (DTPA) with the purpose of labeling the 
molecule in a simple, one-step procedure with '"In (6). In contrast to "'!, this 
isotope is readily available and has attractive physical characteristics (balf-life, 
gamma energy). To cope with at least some of the drawbacks of ['"!-Tyr']-
octreotide mentioned above, introduction of DTPA in a somatostatin derivative was 
proposed. Conjugation of proteins with DTPA-dianhydride as described by 
Hnatowich (6) occurs especially at e-NH, groups of lysine residues. However, this 
method did not seem appropriate in the case of somatostatin derivatives, because of 
the location of the lysine residue within the bioactive site of the molecule. A 
synthetic method was used, therefore, in which the lysine residue in the active site 
of octreotide was protected before reaction with DTPA-dianhydride and de-
protected afterwards. In this way ouly the a-NH, group was coupled with DTPA. 
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In the present manuscript we describe the synthesis of [DTPA-D-Phe']-
octreotide, the preparation and the quality control of the radiopharmaceutical, as 
well as the biologic activity and binding characteristics of the '"In-coupled 
compound. 
MATERIALS AND METHODS 
Synthesis of /DTPA-D-Phe'j-octreotide (Fig. 1) 
The N"-diethylenetriaminepentaacetic acid (DTPA, Fluka) derivative of 
octreotide (Sandostatin") was synthesized usiog the protected [ e-t-butyloxy-car-
bonyi-Lys']-octreotide as starting material which was available by the reaction of 
octreotide (7) with di+butyl-dicarbonate [(Boc),O, Fluka] io dimethylformamide 
(unpublished results). DTPA was coupled to the selectively protected octreotide in 
form of its dianbydride ( 6). The starting material was dissolved io dioxane/water 
(Ill) and after addition of 20 equivalents sodiumhydrogencarbonate 1.1 equivalents 
of the DTPA-dianbydride were added. After 5 min dioxane was removed under 
diminished pressure and the remaining aqueous solution was lyophilized. 
Purification of the product was achieved by silicagel chromatography (Silica Gel 
60, Merck) with chloroform/methanol/acetic acid,,. (7/3/1) io order to separate 
the wanted [DTPA-D-Phe'-e-Boc-Lys']-octreotide from the contaminating double 
substituted DTPA-derivative and unreacted starting material. Deprotection with 
trifluoracetic acid and subsequent sequential purification on Silica Gel 60, Duolite• 
ES-861 (Diaprosim) and a weak basic anionic exchanger AG4-X4 (BioRad) yielded 
homogeneous [DTPA-D-Phe']-octreotide as lyophilisate. The purity was checked 
by reverse phase HPLC 1 mobile phase: solvent A = H,O/CH,CN/H,P0,(85% )I 
TMAH (tetramethylammonium-hydroxide, 10 % io water, Merck), 90/10/0.2/4 
(pH 2.9) and solvent B, 30/70/0.4/4 (pH 4.0); gradient 5 - 95 % B io 20 min; 
column temperature: 45'C; flow rate: 1.5 ml/min; wavelength 205 nm] and on 
Silica Gel 60 HPTLC plates (Merck). Structure and amino acid composition were 
proven by means of nuclear magnetic resonance, fast atom bombardment mass 
spectrometry and by amino acid analysis. 
Preparation and purification of !'"In-DTPA-D-Phe']-octreotide 
In order to label [DTPA-D-Phe']-octreotide efficiently with "'In, a 40- to 70-
fold molar excess of peptide over radionuclide was used. [DTPA-D-Phe']-
octreotide was labeled with '"In by reaction ( 10 min at room temperature) of 2 l'g 
peptide io 20 1'1 0.1 M acetic acid with 37 MBq '"In io 20 1'1 0.04 M HCI 
("INS.IP", Amersham, England), preparation A, or by reaction of 60 l'g 
peptide io 300 1'1 0.01 M acetic acid with 1000 - 1500 MBq "ultrapure" "'InC!, io 
2 mi 0.05 M HCl (Malliockrodt, The Netherlands), preparation B. The resulting 
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H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr( ol) 
l (Boc),O 
H-D-Phe-Cys-Phe-D-Trp-Lys(Boc )-Thr-Cys-Thr( ol) 
l DTPA-dianhydride 
DTP A-D-Phe-Cys-Phe-D-Trp-Lys(Boc )-Thr-Cys-Thr( ol) 
l TFA 
HOOC-CH, H,C-COOH CH,-COOH 
\ I I 
N-(CH,),-N-(CH,),-N 
I \ 
HOOC -CH, CH,CO-D-Phe-Cys-Phe-D-Trp-Lys-Thr -Cys-Thr( ol) 
Figure I 
Reaction scheme for the synthesis of {DTPA-D-Phe' t-oetreotide 
specific radioactivity (radioactivity/mass labeled and unlabeled IDTPA-D-Phe']-
octreotide) amounted from 17 to 25 MBq '"ln/l'g peptide. Nonradioactive l"'ln-
DTPA-D-Phe']-octreotide was prepared by mixing [DTPA-D-Phe'l-octreotide (104 
M) with a large excess of '"InC!, (0.2 M; Aldrich) in 0.01 M acetic acid. 
The efficiency of the labeling was tested using Instant Thin Layer 
Chromatography (ITLC-SG, Gelman, Ann Arbor, Ml) with 0.1 M Na-citrate (pH 
5) as solvent. Under these conditions indium citrate and indium chloride migrate 
along with the solvent front, whereas peptide-bound "'ln stays near the origin. 
Further quality control was performed by reversed-phase HPLC using a I'Bo-
ndapak-C, column (300 x 3.9 mm, particle size !0 I'm; Waters, Milford. MA) 
with a linear gradient of 40 % to 80 % methanol in 0.05 M acetate (pH 5.5) in 20 
min. The final solvent composition was maintained another 5 min. 
Radioligand binding studies 
The binding assay for ["'ln-DTPA-D-Phe']-octreotide was carried out using rat 
brain cortex membranes according to Reubi et al (8). Briefly. cerebral cortex was 
dissected on ice and homogenized in 10 mM HEPES buffer, pH 7.6, centrifuged 
and washed two times with ten volumes of the same buffer. Cortex membranes 
corresponding to 50 l'g protein/tube were incubated for 30 min at room 
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temperature with approximately 2 x 10' cpm of ["'In-DTPA-D-Phe']-octreotide and 
increasing concentrations of somatostatin analognes in a final volume of 300 JLL 
Incubation was stopped by rapid filtration through Whatman GF/C filters. Specific 
radioligand binding was defined as total binding ntinus binding in the presence of 
0.1 JLM octreotide (non-specific binding). Binding curves were calculated from 3 
experiments (triplicate deterntinations) using the computer fitting program of De 
Lean (9). 
To compare the affinities of (mono)-iodinated [Tyr']-octreotide with indium-
labeled [DTPA-D-Phe']-octreotide the same displacement studies as described 
above have been performed using ["'I-Tyr']-octreotide as radioligand and ["'1-
Tyr']-octreotide and ['"ln-DTPA-D-Phe']-octreotide as competing peptides. 
Biologic activity of {DTPA-D-Phe' j-octreotide 
To test its specific biologic activity, [DTPA-D-Phe']-octreotide was compared 
with octreotide with regard to its growth hormone (GH) release-inhibitory effect on 
cultured rat pituitary cells. The preparation of dispersed female rat anterior 
pituitary cells and cell culture conditions have been described previously (10). 
Briefly, the pituitary cells were cultured at a density of I 0' cells per well per m1 in 
48-well plates (Costar, Cambridge, MA). On day 4 the culture medium was 
changed and after another medium change on day 7 of culture, 4 hr incubations 
without or with drugs were performed in quadruplicate. The culture medium 
consisted of minimal essential medium, supplemented with non-essential antino 
acids, sodium pyruvate (I mM), penicillin (10' U/1), streptomycin (100 mg/1), 
fungizone (0.5 mg/1), L-glutarnine (2 mmol/1), sodium bicarbonate (2.2 g/1) and 10 
% fetal calf serum. Rat GH concentrations in the culture media were deterntined 
by a double-antibody RJA as described previously (II). 
RESULTS 
Synthesis 
[DTPA-D-Phe']-octreotide was synthesized according to the protocol given 
above by a two step synthesis. The DTPA conjugation products consisted for more 
than 60 % of the protected [DTPA-D-Phe']-octreotide and for about 30 % of the 
also formed double substituted analogne (two peptide molecules linked to the 
DTPA-group). The protected [DTPA-D-Phe']-octreotide was well separated from 
this bis-derivative as well as from unreacted starting material by silicagel 
chromatography. The pure end product (overall yield 10 %) had a purity higher 
than 95 % which was detertuined by reversed phase HPLC [retention time 8.9 ntin 
(octreotide: 8.1 ntin)] and with silica gel HPTLC plates [R, 0.3 (octreotide 0.8)]. 
Antino acid analysis yielded a peptide content of 95 % and an amino acid com-
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poSil!on in the correct ratio and in addition a molecular weigbt of !395 was 
detected by fast atom bombardment mass spectroscopy. 
Preparation and quality control of the radiopharmaceutical 
A 40- to 70-fold molar excess of peptide over '"In was used to assure efficient 
labeling of [DTPA-D-Phe']-octreotide in the presence of (variable) amounts of 
other trace metals in the radionuclide solution. ITLC and HPLC analyses of the 
product revealed that the labeling efficiency was more than 95 %. A typical HPLC 
elution proflle is presented in Fig. 2. With lTLC nearly all activity remained near 
the origin while with HPLC it eluted predominantly as a single peak with a 
retention time of 19.5 min. Within !.5 hr after labeling less than 5 % of the 
activity was found to be bound to other compounds. Some ntinor peaks eluting 
before ["'ln-DTPA-D-Phe']-octreotide (between 17 and 19 min) increased with 
time of storage up to 24 or more hours. Formation of these contaminants was 
observed to be inhibited by either dilution or addition of a quencher, such as 
ascorbic acid or even [DTPA-D-Phe']-octreotide itself (data not shown). Other-
wise, if used within 1 hr after radiolabeling, further purification on HPLC did not 
improve the binding properties of the tracer. No purification was, therefore, 
performed after the labeling procedure except that aliquots were checked by HPLC 
for quality control. 
Receptor biruii.ng studies 
To characterize the binding properties of the indium-labeled somatostatin 
analogue, the pharmacological profile of somatostatin binding sites labeled by 
["'ln-DTPA-D-Phe']-octreotide was deterntined. Therefore, the inhibitory effects 
of various somatostatin analogues were tested in competition experiments using rat 
brain cortex membranes as a source of somatostatin receptors as described above. 
Representative competition experiments with the various analogues are shown in 
Fig. 3. The rank order of potency of different somatostatin analogues corresponded 
to that obtained with other well characterized ligands, such as ['"1-Tyr']-octreotide 
(12). The analogues [Lys(ol)']-octreotide (SDZ 203-304) and [Orn']-octreotide 
(SDZ 204--354), which are relatively ineffective in inhibiting growth hormone 
release, also exhibited weak affinities for the [ln-DTPA-D-Phe']-octreotide 
recognition site. In contrast, somatostatin and octreotide showed the expected high 
affinities with lC50 values in the sub-nanomolar range. while l'"ln-DTPA-D-Phe']-
octreotide and unlabeled [DTPA-D-Phe']-octreotide showed intermediate affinities 
with JC,;s in the nanomolar range. Under these conditions total binding was 2-5 
% of total radioactivity and non-specific binding was less than 1 0 % of total 
binding. Stable '"In" alone did not inhibit receptor binding (data not shown). 
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Figure 2 
HPLC elution profiles I, 4 and 24 hr after labeling of [DTPA-D-Phe']-
octreotide with Ill ln. 
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Figure 3 
Binding of ['"In-DTPA-D-Phe'j-oareotide to rar brain conex membranes in 
the presence of increasing concentrations of somatostarin-14 (•). oareotide 
(•). ['"In-DTPA-D-Phe']-oareotide (+ }, [DTPA-D-Phe'J-oareotide (• }, 
[Om'f-octreotide (e) and [Lys(ol}'f-octreotide (0). expressed as percentage 
of binding in the absence of competing compounds (n = 3, maximal SEM 
< 5 %). 
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Figure 4 
Binding of ["'1-Tyr'/-octreotide ro raJ brain cortex membranes in the presence 
of increasing concentrations of f"'I-Tyr]-octreotide (•) and ["'In-DTPA-D-
Phe1]-octreotide (0}, expressed as percentage of binding in the absence of 
competing compounds (n = 3, maximal SEM < 5 %). 
In Figure 4 the difference in affinity of the "'In-labeled [DTPA-D-Phe']-
octreotide and "'!-labeled [Tyr']-octreotide for the somatostatin receptors in rat 
brain cortex membranes is shown with pK;-values of 8.4 ± 0.2 and 9.9 ± 0.3 
(mean ± SEM, n=3), respectively, indicating a somewhat lower affinity for the 
"'In-labeled compound. Total binding was 15 % to 20 % of total radioactivity and 
non-specific binding was less than 10 % of total binding. 
Biologic activity of [DTPA-D-Phe j-octreotide 
Figure 5 shows results from a representative experiment on the effects of 
unlabeled [DTPA-D-Phe']-octreotide and octreotide on GH release by female rat 
anterior pituitary cells. Both peptides inhibited GH release in a dose-dependent 
manner, with octreotide being about 10 times more potent than {DTPA-D-Phe']-
octreotide. Similar results were obtained with unlabeled and '"In-labeled [DTPA-
D-Phe'j-octreotide (data not shown). Stable '"ln'• alone did not inhibit GH release 
(data not shown). 
54 
125 
0 
€< '- (y 
" ~~ ' 0 100 u ' 
- '~ 0 75 "" 
'" 
- -B 
~ 50 
"' 
'" 
'" '- 25 
:0:: 
Cl 
I 
0 
0.0001 0.001 0.01 0 1 10 100 1000 
peptide (nmol/l} 
Figure 5 
Effects of unlabeled octreotide (•) and {DTPA-D-Pfu!]-octreotide (0) on the 
secretion of raJ growth hormone by cultured raJ pituitary cells (maximal SEM 
< 10%). 
DISCUSSION 
The radiolabeling of [DTPA-D-Phe'j-octreotide with '"In is an easy single-step 
procedure with high yields ( > 95 %) which does not require special equipment. 
However. ultrapure 111lnCl3 is required for an efficient labeling, since con-
taminating metals, which might be present in some preparations in unknown 
quantities, compete with "'ln. The use of the highest possible specific activity is 
therefore recommended. It is not surprising that the disulfide-containing peptide, if 
radiolabeled to high specific radioactivity, is susceptible to radiation damage. This 
results in the generation of compounds with shorter retention times on HPLC, 
which may represent degradation products of [111ln-DTPA-D-Phe']-octreotide. 
Effective prevention of radiolytic deterioration by dilution or by addition of 
scavengers allow the use of [111ln-DTPA-D-Phe']-octreotide up to several hours 
after labeling without furtber purification. Because of the fact, that somatostatin 
binding sites are very well characterized in rat brain cortex membranes (13), this 
system was used for binding studies. The results of the binding studies demonstrate 
that [111 ln-DTPA-D-Phe']-octreotide is a high affutity, selective radioligand for 
somatostatin receptors, although its affinity is less than that of ['"1-Tyr']-
octreotide. Complexing of [DTPA-D-Phe']-octreotide with indium increased the 
affinity for the somatostatin receptor compared with the unlabeled compound. Rat 
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growth hormone inhibition experiments showed a similar biologic effect with 
unlabeled [DTPA-D-Phe']-octreotide and "'In-labeled [DTPA-D-Phe']-octreotide, 
although it was less than with octreotide. However, in the accompanying paper it 
will be shown, that this new radiopharmaceutical has a completely different, but 
more suitable metabolic and pharmacokinetic behaviour. Its renal clearance without 
degradation in vivo contrasts to the hepato-biliary clearance of ["'!-Tyi']-octreotide 
and subsequent degradation in vivo (4, 14, 15). Because of the longer physical 
half-life of "'In (2.8 days) and consequent easy availability ["'ln-DTPA-D-Phe']-
octreotide can be used everywhere. This also contrasts with the previously used 
"'!, which has a half-life of 13.2 hr. An additional advantage of the longer 
physical half-life of "'In is that gamma camera imaging will be improved later than 
24 hr after injection. In the presence of an appropriate quencher ['"In-DTPA-D-
Phe']-octreotide is very well suited for preparation in a "kit" procedure and may be 
used several hours after the labeling procedure. ["'ln-DTPA-D-Phe']-octreotide, 
therefore, is a promising radiopharmaceutical for routine in vivo imaging of 
somatostatin receptor-positive tumors in animals and man. 
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Summary 
Radioiodinated somatostatin analogues are useful ligands for the in vitro 
and in vivo detection of somatostatin receptors. ["'ln-DTPA-D-Phe']-
octreotide, a somatostatin analogue labeled with a different radionuclide, also 
binds specifically to somatostatin receptors in vitro. In this study we 
investigated its in vivo application in the visualization of somatostatin 
receptor-positive tumors in rats. The distribution of the radiopharmaceutical 
was investigated after intravenous injection in normal rats and in rats bearing 
the somatostatin receptor-positive rat pancreatic carcinoma CA 20948. After 
IDJection the radiopharmaceutical was rapidly cleared (50 % decrease in 
maximal blood radioactivity in 4 min), predominantly by the kidneys. 
Excreted radioactivity was mainly in the form of the intact 
radiopharmaceutical. Ex vivo autoradiographic studies showed that specific 
accumulation of radioactivity occurred in somatostatin receptor-contammg 
tissue (anterior pituitary gland). However. in contrast to the adrenals and 
pituitary, the tracer accumulation in the kidneys was not mediated by 
somatostatin receptors. Increasing radioactivity over the somatostatin 
59 
receptor-positive tumors was measured rapidly after injection and the tumors 
were clearly visualized by gamma camera scintigraphy. In rats pretreated 
with I mg octreotide accumulation of ["'ln-DTPA-D-Phe']-octreotide in the 
tumors was prevented. Because of its relatively long effective half-life, ["'ln-
DTPA-D-Phe']-octreotide is a radionuclide-coupled somatostatin analogue 
which can be used to visualize somatostatin receptor-bearing tumors 
efficiently after 24 br, when interfering background radioactivity is 
minimized by renal clearance. This is an advantage over the previously used 
["'I-Tyr']-octreotide which has a shorter effective half-life and shows high 
abdominal interference due to its hepato-biliary clearance. Therefore, ["' ln-
DTPA-D-Phe']-octreotide seems a better alternative for scintigraphic imaging 
of somatostatin receptor-bearing tumors. 
Radioiodinated analogues have been used extensively in the detection of 
somatostatin receptors in vitro (1). Recently one of these analogues, ['"1-Tyr']-
octreotide, intravenously administered, was shown to visualize somatostatin 
receptor-positive tumors in vivo by means of gamma camera scintigraphy (2, 3, 4). 
However, because of a number of drawbacks of tltis radioiodinated compound, 
such as its short effective half-life in the blood circulation and high background 
radiation in the abdominal region, a search was made for an alternative 
somatostatin analogue, which could be labeled with a different radionuclide, '"ln. 
Predominant advantages of '"In over "'l (half-life 13.2 br) are its ready availability 
as well as its attractive physical properties, such as 173 ke V and 246 ke V gamma 
radiation, appropriate for scintigraphy, and half-life of 2.8 d, enabling scintigraphy 
at longer intervals after injection. Therefore, the somatostatin analogue [DTPA-D-
Phe']-octreotide has been synthesized and the specific binding properties of tltis 
peptide, labeled with "'In, to somatostatin receptors have been demonstrated (5). 
MA TERlALS AND METHODS 
Somaiostatin analogues 
Somatostatin analogues [DTPA-D-Phe']-octreotide (SDZ 215-811), [Tyr']-
octreotide (SDZ 204-090) and octreotide (SMS 201-995) were obtained from 
Sandoz (Basle, Switzerland). Radiolabeling of [Tyr']-octreotide and [DTPA-D-
Phe']-octreotide with respectively "'I and "'In and consecutive quality control were 
performed as described before (3, 5). The radiochemical purity of the radiolabeled 
somatostatin analogues ['"1-Tyr']-octreotide and ['"ln-DTPA-D-Phe']-octreotide 
was greater than 95 %. 
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Animals and tumors 
Nine male Lewis rats were inoculated in both upper left- and right hindlegs 
with the transplantable rat pancreatic tumor CA 20948, which was previously 
shown to possess somatostatio receptors (6). The growth of this tumor is inhibited 
by octreotide treatment (7). All conditions were as described before (3). Twelve 
control animals were studied in parallel. The tumor-bearing animals were divided 
into two groups: (a) 4 animals without pretreatment and (b) 5 animals which were 
pretreated subcutaneously with I mg octreotide, 30 min before injection of the 
radiopharmaceutical. All tumor-bearing animals and 10 control animals, used for 
gamma camera scintigraphy and tissue radioactivity measurements, received 18.5 
MBq (0.5 - I p.g) f"'ln-DTPA-D-Phe']-octreotide in 0.5 - 0.8 ml 154 mM NaC! 
intravenously via the dorsal vein of the penis. Two control animals used for ex 
vivo autoradiography received 74 MBq (1 p.g) ["'ln-DTPA-D-Phe']-octreotide. For 
injection and scintigraphy the animals were anaesthetized with ether. 
Data acquisition and analysis 
The gamma camera and computer system were as described before (3). A 
medium-energy parallel-hole collimator was used. The analyzer was set to both 
"'In peaks: 173 keV and 246 keV, window 20 %. Dynamic acqnisition took place 
in I min intervals during the first 30 min after injection of ["'ln-DTPA-D-Phe']-
octreotide. For the disappearance of radioactivity from the blood the percentage of 
the injected dose measured over the heart area was calculated. The renal excretion 
during the first 30 min after injection, measured over the kidneys together with the 
bladder, was also calculated as percentage of the injected dose. Over less well-
defmed regions such as tumor, head and lower right hindleg fixed areas were 
chosen in which the time course of radioactivity was expressed relative to that 
measured during th~ first min immediately after injection. Static images were 
obtained 30 min, 4 hr and 24 hr after injection. On the basis of the static digital 
images of the animals and proper standards, estimates were made of whole body, 
kidney and tumor retentions. The 24-hr results of the gamma camera measurements 
were compared with determinations of radioactivity in isolated tissues using a 
semi-conductor (GeLi) detector connected to a multichannel analyzer (Series 40, 
Canberra). The distance to the detector was 20 em. The uptake of the radionuclide 
was calculated as a percentage of the dose and as a percentage of the dose/ gram 
tissue. Urine samples of four different control rats were obtained 30 min, 2 hr and 
24 hr after injection of ["'ln-DTPA-D-Phe']-octreotide for analysis by high 
performance liquid chromatography (HPLC) as previously described (5). For this 
purpose urine samples were diluted l :10 in HPLC solvent, i.e. 40 % methanol in 
0. 05 M acetate buffer, pH 5.5, and applied to the C,. column. 
Two control animals were perfused with 100 ml 2.5 % glutaraldehyde solution 
2 hr, respectively 24 hr after injection of the radiopharmaceutical. Kidneys and 
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pituitaries were isolated and cut with a cryostate (Leitz, Wetzlar, Germany) or a 
freezing microtome (Jung, Heidelberg, Germany) into 10 - 15 fLm thick sections. 
The sections were then apposed to ['H]-LKB ultrofi.lm as described previously (8). 
Kidneys of control rats were tested for the presence of somatostatin receptors by 
means of in vitro receptor autoradiography using ['"1-Tyr']-octreotide as ligand (I). 
The statistical significance of differences was determined with Student's t -test or 
by analysis of variance. Differences were considered significant if p < 0.05. All 
data are reported as mean ± SD. 
RESULTS 
['"ln-DTPA-D-Phe']-octreotide is rapidly cleared from the blood as is indicated 
by the decreasing radioactivity above the heart area (Fig. 1). During the fifth min 
after injection radioactivity over the heart had decreased to 50 % of that during the 
first min. Dynamic gamma camera observations show that the radionuclide is 
cleared almost exclusively via the kidneys. Already 4 min after injection 
radioactivity appears in the bladder. Also in Fig. I the renal activity together with 
the excretion of the radionuclide in the bladder, is presented as a function of time. 
In control rats about 50 % of the injected dose had already been cleared within 30 
min via the kidneys, whereas in tumor-bearing rats this clearance was significantly 
slower (p < 0.05). 
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Figure 1 
Disappearance of !'"In-DTPA-D-Phe'f-ocrreotide from the blood (left) 
expressed as mean ± SD percentage of the administered dose measured over 
the hean area and renal clearance (right) expressed as mean ± SD 
percentage of the administered dose measured over the ld.dneys and the 
bladder together in 4 control rats ( 0 ) and 9 tumOr-bearing rats ( "' ). 
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Figure 2 
Radioactivity as jimction of 
time. expressed as mean ± SD 
percentage of the 1-min value. 
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Pretreatment with l mg octreotide did not influence blood clearance or renal 
clearance (data not shown). During the first 30 min after injection radioactivity 
measured above the head and lower right hindleg (without tumor) of all 
investigated animals showed decreasing blood pool radioactivity (data not shown). 
Increasing radioactivity was observed over the tumors of the animals immediately 
after injection, whereas this was not the case in the octreotide-pretreated group (p 
< 0.001, Fig. 2). Figure 3 presents static analogue images, 30 min and 24 hr 
after injection, of one untreated and one octreotide-pretreated animal. It is evident 
that the clear visualization of this transplantable pancreatic carc-inoma (notably after 
24 hr) was prevented by pretreatment with the high dose of unlabeled somatostatin 
analogue. 
From digital static images obtained 24 hr after injection, whole body retention 
of radioactivity appeared to be about 10 % (Table !), which was mainly localized 
in the kidneys (7 % ). This quantity closely parallels measurements in isolated 
kidneys using the semi-conductor detector (Table !). Radioactivity measured over 
the kidneys remained constant between 4 and 24 hr after injection. The presence of 
tumors did not significantly influence 24-hr kidney accumulation of radioactivity. 
Table I also gives the results of the measurements of radioactivity in the tumors 
with the gamma camera and the semi-conductor detector. In the tumors of the 
untreated animals significantly higher percentages of the injected dose were found 
in comparison with the tumors of the octreotide-pretreated group. 
Results of rddioactivity measurements in a number of tissues (of animals which 
were not pretreated with octreotide), isolated 24 hr after injection, are reported in 
Table II. The highest tissue radioactivity concentrations were found in the kidneys 
and the adrenals. There was no significant difference between radioactivity 
concentrations in most tissues of control and octreotide-pretreated animals. 
However, after pretreatment with octreotide the radioactivity concentrations were 
much lower in the adrenals and in the tumors. 
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30 min 24 hours 
a b a b 
Figure 3 
Staric images, 30 min and 24 hr after injection, of one untreated (a) and one 
octreotide-pretreated animal (b), showing accumulation in the kidneys (K) 
and/or urinary bladder (B). Accumulation of radioactivity in tumors (T) in 
both hindlegs is noted in a, not in b. 
Ex vivo autoradiography of the pituitary glands of control rats, obtained 2 and 
24 hr after in vivo administration of ["'ln-DTPA-D-Phe']-octreotide demonstrated 
accumulation of radioactivity in the anterior lobe but not in the posterior lobe (Fig. 
4), confirming previous studies using in vitro or ex vivo autoradiography (9, 10). 
Interestingly, ex vivo autoradiography of kidney tissue of the same animals clearly 
showed the presence of radioactivity in the proximal tubules but not in the 
glomeruli (Fig. 5). However, with in vitro autoradiography using ['"1-Tyr']-
octreotide as ligand, no specific somatostatin receptors were detected in the kidney 
(data not shown). 
HPLC of a 30-min and a 2-hr urine sample of two different control rats showed 
that the excreted radioactivity was in the form of the intact ["'ln-DTPA-D-Phe']-
octreotide. Of two late urine samples obtained from control rats 24 hr after 
injection of the radiopharmaceutical (when most radioactivity already had been 
excreted, see Table l) more than 90 % of the radioactivity was not peptide-bound 
and eluted in the void volume, probably representing '"ln-DTPA. 
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A 
Figure 4 
Ex vivo au.toradiography 24 hr after injection, showing the somarostatin 
receptors in the rat pituitary gland: A) hemaroxylin-eosin stained section 
showing anterior (A) and posterior (P) pituitary gland. B) autoradiogram 
showing binding in the anterior pituitary but not in the posterior lobe. 
Bar= I mm. 
Figure 5 
Ex vivo autoradiography showing accumulation of['" In-DTPA-D-Phe' j-oc-
treotide by the proximal tubules of the rat kidney (same animal and proce-
dure as Fig. 4). A) Hemaroxylin-eosin stained section. B) Autoradiogram 
showing dense labeling of the proximal tubules with sparing of the glomeruli. 
As discussed in the text the labeling does not represent receptor-bound li-
gand. Bar=[ mm. 
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TABLE! 
Method n % dose at 4 hr % dose at 24 hr 
Whole body 
Control animals A 2 15 ± 3 10 ± 1 
Tumor-bearing animals A 4 21 ± 2 13 ± 2 
Kidnevs 
Control animals A 2 9 ± 1 7 ± 1 
B 6 6 ± 2 
Tumor-bearing animals A 4 8 ± 1 7 ± 1 
B 4 8 ± 1 
Tu!oor 
Not pretreateda A 8 1.6 ! 0.5 o.s ± 0.3 
B 8 0.9 ± 0.4 
Pretreated with A 10 0.6 ± 0.3c o.2s ± o.zsc 
octreotideb B 10 o.25 ± o.os' 
Mean ± SD retention in the whole body, kidneys and tumor after the intravenous 
administration of [111rn-DTPA-D-Phe1]-octreotide to control and tumor,.bearing rats 
expressed as percentage of the dose, based on A) digital gamma camera images, and B) 
semi-conductor measurements of isolated tissues. a) Tumor mass (mean ± SD) 12 ± 5 gram; 
b) tumor mass 11 ± 4 gram. 0) Significantly different (p < 0.001) from untreated rats). 
DISCUSSION 
After injection of f'"ln-DTPA-D-Phe']-octreotide the radionuclide disappears 
rapidly from the circulation. Blood clearance (measured over the hean) during the 
first 30 ntin was not noticeably influenced by octreotide-pretreatrnent nor by the 
presence of tumors. Gamma camera images indicate that radioactivity is mainly 
cleared by the kidneys and excreted with the urine into the bladder (Fig. 3). Total 
66 
TABLE II 
Tissue Control animals Tumor-bearing animals 
+ octreotide 
n=4 n=4 n=S 
%dose % dosejgram % dosejgraJD. % dosejgram 
kidneys 6 ± 2 2.2 ± 0.6 2.5 ± 0.4 2.4 ± 0.7 
liver 0.48 ± 0.05 0.041 ± 0.012 0.038 ± 0.003 0.039 ± 0.011 
heart 0.011 ± 0.002 0.012 ± 0.002 0.012 ± 0.004 0.011 ± 0.001 
intestinesa 2.1 ± 0.4 0.13 ± 0.03 0.09 ± 0.02 0.09 ± 0.06 
spleen 0.032 ± 0.010 0.06 ± 0.02 0.05 ± 0.03 0.06 ± 0.02 
adrenals 0.08 ± 0.02 2.0 ± 0.4 2.2 ± 0.6 o.l9 ± o.o4b 
lungs 0.023 ± 0.004 0.019 ± 0.003 0.015 ± 0.003 0.015 ± 0.003 
thy> us < 0.01 
thyroid < 0.01 
pituitary < 0.01 
rest 1.1 ± 0.3 0.0049 ± 0.0010 0.005 ± 0.002 0.003 ± 0.001 
blood 0.008 ± 0.001 0.030 ± 0.016 0.018 ± 0.007 
urine 0.14 ± 0.04 0.18 ± 0.13 0.34 ± 0.58 
tumors 0.09 ± 0.04 o.o25 ± o.oosb 
Hean ± SD tissue distribution in rats 24 hr after intravenous administration of [111rn-
DTPA-D-Phe1]-octreotide, based on semi-conductor measurements of isolated tissues. 
a) including pancreas b) p < 0.001 vs untreated rats 
renal excretion during the first 30 min after injection appeared to be lower in 
tumor-bearing rats than in control animals (Fig. 1). while the whole body retention 
at 24 br after injection showed no significant difference (Table I). This suggests a 
decreased kidney function in tumor-bearing rats. The predominantly renal 
clearance of ["'ln-DTPA-D-Phe']-octreotide contraSts with the (more rapid) hepato-
biliary clearance of ["'1-Tyr']-octreotide as shown previously (3). With ["'ln-
DTPA-D-Phe']-octreotide 4 min are required to reduce blood radioactivity to 50 
%. while 1'"1-Tyr']-octreotide was cleared already by 50 % within 2 min. If it is 
presumed that this clearance already starts during the first min after injection. the 
difference in clearance rate between these radiopharmaceuticals might be even 
greater. Furthermore. in contrast to the "'!-labeled somatostatin analogne, ['"In-
DTPA-D-Phe']-octreotide is hardly metabolized and thus excreted intact. 
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Additionally, high radioactivity background levels interfering with scintigraphic 
detection in the abdominal region are not seen using !'"ln-DTPA-D-Phe']-
octreotide. Although initial renal clearance (during the first 30 min, Fig. I) is 
higher in control animals, whole body retention of radioactivity after 24 hr is not 
significantly different between control and tumor-bearing rats, demonstrating that 
the presence of tumors does not noticeably influence the cumulative excretion. 
Renal retention after 24 hr was also not influenced by octreotide-pretreatment, 
suggesting that tltis process is not mediated via specific somatostatin receptors. 
Although the proximal tubules of the kidney showed accumulation of '"In as 
demonstrated by ex vivo autoradiography of kidneys from untreated control rats 
which were injected with l'"ln-DTPA-D-Phe']-octreotide 2 and 24 hr before 
sacrifice, no somatostatin receptors were detected with in vitro autoradiography of 
the kidney with the somatostatin analogue ['"1-Tyr']-octreotide. We hypothesize 
therefore, that accumulation of ['"ln-DTPA-D-Phe']-octreotide in the kidney 
occurs by fixation in the proximal tubules during reabsorption after glomerular 
filtration or during tubular excretion via the proximal tubules. 
During the first 30 min studied, decreasing radioactivity was measured over the 
heads and lower hindlegs of all animals, reflecting the disappearance of 
radionuclide from the blood pooL However, over the tumors of the untreated 
animals radioactivity increased significantly, while the tumors of the octreotide-
pretreated animals only showed decreasing blood pool activity. It shoulo be 
realized that the increasing radioactivity over the tumors in the untreated animals is 
the sum of increasing receptor binding and decreasing blood pool radioactivity. 
The latter component masks the increase in specific tumor accumulation. 
Therefore, specific tumor accumulation increases even more sharply than depicted 
in Fig. 2. Measurements after 4 and 24 hr demonstrated siguificantly higher 
accumulation of 111 In in tumors of untreated animals than in the octreotide-
pretreated rats, suggesting binding to the somatostatin receptors of these tumors 
(Table I). These findings are confirmed by gamma camera scintigraphy after 24 
hr (Fig. 3). 
Furthermore, specific accumulation of l'"ln-DTPA-D-Phe']-octreotide is shown 
in somatostatin receptor-positive tissues, such as the adrenals (8) and the anterior 
lobe of the pituitary gland (9), by counting of isolated organs and/or 
autoradiography, confirming the specificity of l'"ln-DTPA-D-Phe' J-octreotide as a 
radioligand for somatostatin receptors. Their high numbers in the brain (9) 
however are not visualized, probably because the radioligand does not cross the 
blood-brain barrier. 
CONCLUSION 
['"ln-DTPA-D-Phe']-octreotide which bas been shown to bind to somatostatin 
receptors in vitro, accumulates in vivo specifically in somatostatin receptor-positive 
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normal tissues such as the adrenal and anterior p1tmtary gland. Similarly. 
somatostatin receptor-pos1nve tumors accumulate the radiopharmaceutical 
specifically and can be visualized by gamma camera scintigraphy. 
Compared with the previously used somatostatin analogue ["'1-Tyr']-octreotide, 
the combination of the longer residence of ["'ln-DTPA-D-Phe']-octreotide in the 
circulation. its longer physical half-life (2.8 d versus of 13 hr) and the absence of 
hepato-biliary metabolism (with consequent interfering radioactivity in this region) 
makes this compound very suitable for imaging of somatostatin receptor-positive 
tumors in rats. Tumor/background ratios were highest 24 hr after administration 
when interfering blood pool radiation was minimal. These properties suggest that 
["'ln-DTPA-D-Phe']-octreotide is also a very useful radiopharmaceutical for 
scintigraphic imaging of somatostatin receptor-positive tumors in man. 
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CHAPTER6 
Somatostatin receptor scintigraphy with I"'In-DTPA-D-Phe']-octreotide in 
man: metabolism, dosimetry and comparison with !"'I-Tyr']-octreotide 
E.P. Krenning. W.H. Bakker, P.P.M. Kooij, W.A.P. Breeman, H.Y. Oei, 
M. de Jong. J.C. Reubi, T.J. Visser, C. Bruns, D.J. Kwekkeboom, 
A.E.M. Reijs, P.M. van Hagen, J.W. Koper, and S.W.J. Lamberts. 
Departments of Nuclear Medicine and Internal Medicine Ill, University Hospital 
Dijkzigt, Rotterdam, The Netherlands; Sandoz Research Institute, Berne and 
Department of Endocrinology. Sandoz Pharma AG. Basel, Switzerland. 
Scintigraphy with ['"I-Tyr']-octreotide has several major drawbacks as regards 
its metabolic behaviour, its cumbersome preparation and the short physical half-life 
of the radionuclide. The use of another radiolabeled analogue of somatostatin, 
l'"ln-DTPA-D-Phe']-octreotide, has consequently been proposed. [DTPA-D-Phe']-
octreotide can be radiolabeled with '"In in an easy single-step procedure. I"'In-
DTPA-D-Phe']-octreotide is cleared predominantly via the kidneys. Fecal excretion 
of radioactivity amounts to only a few percent of the administered radioactivity. 
With regard to the radiation dose of normal tissues, the most important organs are 
the kidneys. the spleen, the urinary bladder, the liver and the remainder of the 
body. The calculated effective dose equivalent is 0. 08 mSv /MBq. Optimal ["'In-
DTPA-D-Phe']-octreotide scintigraphic imaging of various somatostatin receptor-
positive tumors was obtained 24 hr after injection. In the six patients studied, 
tumor localization with 1"'1-Tyr']-octreotide and with l"'ln-DTPA-D-Phe']-
octreotide were found to be sintilar. However, the normal pituitary is more 
frequently visualized with the latter radiopharmaceutical. In conclusion, l"'ln-
DTPA-D-Phe']-octreotide appears to be a sensitive somatostatin receptor-positive 
tissue-seeking radiopharmaceutical with some remarkable advantages: easy 
preparation, general availability, appropriate ha!Hife and absence of major 
interference in the upper abdontinal region, because of its renal clearance. 
Therefore l"'ln-DTPA-D-Phe']-octreotide is very suitable for use inSPECT of the 
abdomen, which is especially of importance in the localization of small endocrine 
gastroenteropancreatic tumors. 
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Recently we introduced the somatostatin analogue ITyr']-octreotide labeled with 
"'I for the localization of primary and metastatic somatostatin receptor-rich tumors, 
such as carcinoids, islet cell tumors of the pancreas, paragangliomas and small cell 
carcinomas of the lungs (1-4). Our experience points to several drawbacks of 1"'1-
Tyr']-octreotide in its use for in vivo scintigraphy. First, the labeling of [Tyr']-
octreotide with "'I is cumbersome and requires special skills. Second, Na"'l of 
high specific activity (5,6) is expensive and hardly available world-wide. Third, 
the moment of the labeling and scanning procedures is dependent on the logistics 
of the production and delivery of Na"'L Finally, substantial accumulation of 
radioactivity is seen in the intestines, since a major part of 1"'1-Tyr']-octreotide is 
rapidly cleared via the liver and biliary system. This makes the interpretation of 
planar and single photon emission computed tomographic (SPECT) images of the 
upper abdomen difficult. 
Part of these problems can be solved by replacing "'I with '"In, which also 
improves scintigraphy 24 to 48 hr after application by virtue of its longer half-life. 
Binding of "'In to the somatostatin analogue octreotide has been carried out by 
complexing with a diethylenetriaminepentaacetic acid (DTPA) group coupled to the 
aNH,-group of the N-terminal D-Phe residue (7). In rats, it appeared that l"'ln-
DTPA-D-Phe']-octreotide I) is excreted via the kidneys, 2) shows only minor 
accumulation in the liver, and 3) bas an initial plasma half-life in the order of 
minutes (8). 
ln tltls study ·we report data concerning the metabolism of intravenously 
administered l"'ln-DTPA-D-Phe']-octreotide in man, as well as estimates of its 
radiation dose in principal organs and the effective dose equivalent. Also, scin-
tigraphic images of various somatostatin receptor-positive tumors have been 
compared using both 1'"1-Tyr']-octreotide and l"'ln-DTPA-D-Phe']-octreotide as 
radiopharmaceuticals in the same patients. 
MATERIALS AND METHODS 
Radi.opharmaceulicals 
The somatostatin derivatives IDTPA-D-Phe']-octreotide (SDZ 215-811) and 
ITyr']-octreotide (SDZ 204-090) were prepared by Sandoz (Basel. Switzerland). 
"'InC!, ("ultra-pure") and Na"'l were obtained from Mallinckrodt Diaguostlca 
(Petten, The Netherlands) and Medgenix (Fleurus, Belgium), respectively. "'InC!, 
contained "'"In to a limited extent (0.5 kBq ""ln/MBq "'In at calibration time). 
Radiolabeling of [DTPA-D-Phe']-octreotide with "'In and of ]Tyr']-octreotide 
with '"! and quality control of the products were performed as described before (5-
8). Depending on the interval between injection and scintigraphy. and whether 
SPECT was required, the administered radioactivity of I"'ln-DTPA-D-Phe']-
octreotide and of 1'"!-Tyr']-octreotide ranged from 185 to 259 MBq and from 370 
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to 555 MBq, respectively, given as an intravenous bolus. The dose of the somato-
statin analogues administered varied from 7 to 20 p.g per injection. 
Imaging 
Planar and SPECT images were obtained with a large field of view gamma 
camera (Counterbalance 3700 and ROTA II, Siemens, Hoffman Estates, lll), 
equipped with a medium-energy parallel-hole collimator. The pulse height analyzer 
windows were centered over both "'In photon peaks (172 keY and 245 keY) with a 
window width of 20 %. Data from both windows were added to the acquisition 
frames. The camerd was connected to a dedicated PDP 11/73 computer (Digital 
Equipment Corp., Maynard, Ma.) using the Gamma 11 and SPETS V 6.1 software 
(Nuclear Diagnostics, Stockholm, Sweden). The acquisition parameters were for 
planar images 1) 128 x 128 word matrix, 2) images of head/neck: 300,000 preset 
counts (or max. 15 min) at 24 hr and 15 min preset time ( ~200,000 counts) at 48 
hr after injection, 3) images of the rest of the body: 500,000 counts (or max. 15 
min), and for SPECT 1) 60 projections, 2) 64 x 64 word matrix, 3) 60 second 
acquisition time per projection. SPECT analysis was performed with a Wiener 
filter on original data. The filtered data were reconstructed with a Ramp filter. If 
indicated, SPECT ''tudies were performed 4 hr (head and neck) or 24 hr 
(remainder of the body) after injection of the radiopharmaceutical. Planar studies 
were carried out both after 24 hr and 48 hr (vide supra) and in a few cases also 
after 0.5 hr and 4 hr with the same protocol as for the 24 hr studies. Total body 
scintigraphy (scintigraphy of extremities only if indicated) of every patient was 
performed at least once, in general 24 hr after injection. 
Measurement of"'Jn radioactivity in blood, urine and feces 
Radioactivity in blood, urine and feces was measured with an LKB-1282-
Compugamma system or a GeLi-detector equipped with a multi-channel analyser 
(Series 40, Canberra). 
Blood samples were collected directly before the injection and 2, 5, 10, 20 and 40 
min and I, 4, 20 and 48 hr after injection. Urine was collected from the time of 
injection in two 3-hr intervals and thereafter in intervals of 6 hr until 48 hr after 
injection. If feasible, feces was collected until 72 hr after injection. 
The chemical status of the radionuclide in blood and urine was analysed as a 
function of time by using the SEP-PAK C,., HPLC and gel filtration techniques as 
described previously (5). 
The nature of peptide-bound radioactivity in blood and urine was tested by 
investigation of specilic binding to somatostatin receptors on rat brain conex cell 
membranes as described previously (9). 
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Patients 
The data described in this paper were derived from patients which had been 
referred for a variety of potentially somatostatin receptor-positive tumors. All 
patients gave informed consent to participate in the study, which had been ap-
proved by the ethics committee of our hospital. Kinetic studies with [1"ln-DTPA-
D-Phe1]-octreotide by means of gamma camera scintigraphy were performed in 26 
patients. Additionally, plasma, urine and feces samples were obtained from 9, 10 
and 4 patients, respectively. In another six patients we were able to perform 
somatostatin-analogue scintigraphy with ["'1-Tyr']-octreotide as well as with ['"ln-
DTPA-D-Phe']-octreotide with a maximum interval of three months. 
Dosimetry 
For the estimation of the radiation dose the MlRDOSE version 2 program (I 0) 
and lCRP publication 53 (11) were used. The uptakes in the most important source 
organs, the kidoeys, the spleen, the liver, the urinary bladder and the remainder of 
the body, were determined as a function of time. Radioactivity in the kidoeys, 
liver and spleen was calculated as described before (6). Radioactivity in the urinary 
bladder was calculated using the measured radioactivity excreted in the urine and 
assuming a bladder voiding interval of 3.5 hr (II). Radioactivity in the remainder 
of the body (expressed as percentage of the administered radioactivity) as a 
function of time was determined as 100 % minus the % uptake in kidoeys, liver, 
spleen, urinary bladder and excreted radioactivity in urine and feces. 
In 8 patients the uptake in the kidoeys, spleen and liver was measured with the 
gamma camera 0.5, 4, 24 and 48 hr after injection of ["'ln-DTPA-D-Phe']-
octreotide. The results obtained in two patients could not be used because of an 
extensive overlap of the right kidoey and the liver. In the 6 remaining patients the 
excreted radioactivity in the urine (until 48 hr after ['"ln-DTPA-D-Phe']-octreotide 
injection) was measured as well. In 4 patients the fecal excretion was also deter-
mined until 72 hr after injection. The calculation of the radiation dose in the G! 
tract was performed using the mean radioactivity detected in the feces of these 4 
patients. The dose estimates of the various organs and the effective dose equivalent 
were calculated for each of the 6 patients individually. 
In order to perform dosimetry when only gamma camera measurements were 
available 24 and 48 hr after [111 ln-DTPA-D-Phe1]-octreotide injection, a model was 
developed. In this model the residence times for the kidoeys, spleen and liver were 
calculated for each individual patient on the basis of the organ uptakes after 24 and 
48 hr. For the urinary bladder contents and the remainder of the body 
measurements, mean residence times were used. Using this model it was possible 
to calculate the dose estimates and the effective dose equivalent in another 18 
patients. Apart from the organs mentioned above, radioat.'tivity was seen in most 
patients in the thyroid gland and the pituitary as well. 
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RESULTS 
Metabolism 
The average plasma radioactivity decreased rapidly after injection of ["'ln-
DTPA-D-Phe']-octreotide in 9 patients. Assuming a plasma volume of 3 I, the 
mean radioactivity in the blood circulation was calculated to decrease within 10 
min to 33 ± 7 % (s.d.) of the injected amount. In 5 patients the chemical status of 
the radionuclide in the plasma was investigated as a function of time. In Figure I 
the time courses of total and peptide-bound radioactivity in plasma of these 5 
patients are presented until 20 hr after injection of ["'ln-DTPA-D-Phe']-octreotide. 
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Figure 1 
Total pl.osma (•} and peptide-bound (0) radioactivity after administration of 
f"'In-DTPA-D-Phe'/-octreotide in 5 patients. Results are compared with total 
pl.osma (A) radioactivity after administraiion of ["'1-Tyr'j-octreotide in 7 
patients taken from ref 6. Data are expressed as mean ± s.d. percentage of 
the admistered radioactivity. Note the logarithmic scale of values in the 
ordinate of the inset. 
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Figure 2 
Cumulative total (•) and peptide-bound (0} min urinary excretion (n=5) 
and mean urinary bladder radioactivity voiding (----) (n=5} after intravenous 
injection of fmln-DTPA-D-Phe1]-octreotide. Data are expressed as mean ± 
s.d. percentage of the administered radioactivity. 
During the first 4 hr plasma radioactivity was mainly peptide-bound in the form of 
the intact ["'ln-DTPA-D-Phe']-octreotide as demonstrated by HPLC. Only the last 
two points of the observation period showed proportionally increasing amounts of 
non-peptide-bound radioactivity, eluting in the void volume. 
Urinary excretion of radioactivity was measured in 10 patients. In 5 of these 
patients the chemical status of the radionuclide in the urine was also investigated. 
Figure 2 shows in this group of 5 patients the rapid excretion of the administered 
radioactivity via the urine from about 25 % after 3 hr, 50 % after 6 hr, 85 % after 
24 hr to over 90 % after 48 hr. Figure 2 also shows that in the 5 patients studied, 
excreted radioactivity was mainly peptide-bound. SEP-PAK and HPLC analyses of 
urine and plasma samples as functions of time after injection demonstrdted that 
peptide-bound radioactivity predominantly consisted of ["'ln-DTPA-D-Phe']-
octreotide during the first hours after injection. Twenty-four hr after i!ljection, in 
addition to ["'ln-D-Phe']-octreotide and peptide-bound degradation products, a 
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Figure 3 
Typical HPLC-elution profile of human urine, collected 24 hr after i, v. 
injection of f"'In-DTPA-D-Phe'J-octreoride. At a retention volume of about 4 
ml not peptide-bound "'In, such as "'In-DTPA is eluted, at 12-18 ml "'In-
containing degrutlation products, and at about 19 ml the original 
radioligand. 
major part of urinary radioactivity eluted from the HPLC in the void volume 
(Figure 3). 
Feces, collected until 72 hr after injection of ["'In-DTPA-D-Phe']-octreotide from 
4 patients with a normal intestinal function, contained less than 2 % of the 
administered radioactivity. 
The SEP-PAK C,. and HPLC-purified radiolabeled peptide component in plasma 
and urine showed the same biological activity as the radiopharmaceutical itself, as 
indicated by its specific binding to somatostatin receptors on rat brain cortex cell 
membranes (data not shown). 
Dosimetry 
The uptake of radioactivity in the liver, spleen and kidneys was measured with 
the gamma camera in 6 patients. If the thyroid gland or the pituitary, or both, 
were clearly distinguishable from the surrounding tissue, the uptake in these organs 
was measured as well. Other organs (e.g. the intestines) showed low accumulations 
of radioactivity and were, therefore, disregarded in the gamma camera measure-
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Table I 
Radioactivity in selected organs and refi'ILlinder of the body (mean ± s.d.) as a junction of 
time after intravenous administrarion of ( 111n-DTPA-D-Phe1]-ocrreotide in mo.n on the basis 
of gamma camera measurements and calculations respectively (see text) expressed as 
percentage of the administered radioactivity. 
Time (hr) %Uptake 
n Liver Spleen Kidneys Remainder of 
the body1 
0.5 6 2.8 ± 1.2 2.0 ± 0.9 6.8 ± 1.3 84.2 ± 7.7 
4 6 1.9 ± 0.4 2.4 ± 0.9 7.2 ± 1.8 46.7 ± 17.9 
24 6 2.2 ± 0.6 2.6 ± 1.1 6.3 ± 2.1 8.7 ± 9.7 
48 6 1.8 ± 0.4 !.8 ± 0.6 5.0 ± 2.0 7.2 ± 8.8 
24 18 3.0 ± 1.3 2.9 ± 1.6 4.8 ± 1.7 
48 18 2.5 ± 1.0 2.1 ± 1.2 3.5 ± 1.3 
1The radioactivity in the remainder of the body is the administered radioactivity (100 %) 
minus the % radioactivity in liver. spleen_. kidneys, urinary bladder. urine and feces. 
ments. The time courses of radioactivity in the liver, >-pleen and kidneys showed 
close similarities between individual patients (data not shown). The results of the 
uptake measurements are given in Table l. Five thyroid glands and two pituitaries 
in the group of 6 patients could be completely distinguished from the surrounding 
background (vide infra). The radioactivity in the thyroid gland (maximal 0.03 %) 
and the pituitary (maximal 0.003 %) varied strongly between individual patients. 
Frequently these organs were only visible on the 24 br images. Therefore the 
residence time was calculated assuming that the effective half-life equals the 
physical half-life. The absorbed doses for the thyroid gland and the pituitary 
(12, 13), corresponding to the maximum uptake measured in the group of 6 
patients, are given in Table 2. Radioactivity excTeted in the urine was used for the 
calculation of the residence time of the urinary bladder contents and showed for all 
patients the same course as the mean depicted in Figure 2. For all patients the 
radioactivity in the feces was taken to be the mean of the radioactivity measured in 
the 4 patients (0.5 % and 1.7 % after 24 and 48 br, respectively). Even assuming 
that these maximum values occurred in the same patient, the contribution of the 
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thyroid gland, the pituitary and the feces to the effective dose equivalent was less 
than 5 % and could therefore be neglected. The dose estimates of the various 
organs and the effective dose equivalent were calculated for these 6 patients (data 
not shown). 
The contribution to the absorbed dose caused by the "'"ln contamination was 
calculated on the basis of the information obtained from the manufacturer and was 
found to be less than 0.5 % of the dose from "'ln. In practice the radionuclide was 
administered before calibration time, thus even lowering the contribution of the 
114mln to the radiation dose. 
On the basis of the data obtained in the 6 patients, it appears that more than 
70 % of the effective dose equivalent results from the radioactivity accumulated in 
the kidneys, spleen and liver. The uptake of radioactivity in these organs showed 
much greater individual variation in the 6 patients than the radioactivity excreted in 
the urine and the calculated uptake in the remainder of the body. Therefore, in the 
model employed, the uptake of radioactivity in the liver, kidneys and spleen is 
based on individual gamma camera measurements. Table I shows that in the group 
of 6 patients radioactivity in the spleen increases slightly from 0.5 to 24 hr and 
decreases afterwards in all patients. In the liver the radioactivity decreases rapidly 
during the first hour, thereafter an increase is measured until 24 hr, followed by a 
decrease. For the calculation of the residence time in the model, the radioactivity 
in the liver and the spleen was assumed to remain constant from 0 to 24 hr and to 
decrease after 24 hr mono-exponentially with time. Radioactivity in the kidneys 
shows a steady decrease (Table 1) starting shortly after the injection of the 
radiopharmaceutical. For this reason the calculation of the kidney residence time 
was based on a monoexponential curve. The initial uptake in the kidneys was 
calculated by extrapolating the uptakes at 24 and 48 hr to t=O. The periodic 
accumulation and discharge of radioactivity in the urinary bladder was calculated 
from the mean collected urinary radioactivity in 10 patients. There is no significant 
difference in the cumulative urinary radioactivity between these I 0 and the 5 
patients presented in Figure 2. The radioactivity in the remainder of the body was 
calculated by subtraction of the mean uptakes in the kidneys (n = 6), spleen (n = 
6), liver (n = 6), urinary bladder contents (n = 10) and mean excreted radioac-
tivity in urine (n = 10) and feces (n = 4) from the administered amount. The 
residence time in the remainder of the body could be determined by fitting a 
monoexponential curve to the radioactivity course after injection. The 6 patients 
were recalculated using the model described. There were statistically no sig-
nificant differences in the dose estimates of the various organs and in the effective 
dose equivalent in comparison to the direct estimates for each individual (data not 
shown). Therefore, application of the model appeared to be valid. 
In I 8 patients the uptake in the kidneys, spleen and liver was measured after 24 
and 48 hr. The results are given in Table I. These data did not differ significantly 
from the values obtained at the same time points in the 6 patients. Consequently, 
the model was applied to the additional 18 patients. The final dosimetric results for 
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the complete group of 24 patients are shown in Table 2. 
Table 2 
Dose estimates after imravenous administration of / 11 1/n-DTP A-D-PJu! j-ocrreotide in man on 
the basis of gamma camera measurements (n = 24), measurements of urinary excretion (n 
= 10) and measurements of fecal excretion (n = 4). The input to the Small Intestines is 
taken to be the same as the fecal excretion during 72 hr (n=4}, viz 1.7 %. For the thyroid 
gland and the pituitary ( n =6) the radiation dose corresponds to the maximum organ uptake 
measured in these patients. 
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Target organ Absorbed dose 
(mGy/MBq) 
Kidneys 0.45MD 
Liver Q.Q7MD 
Spleen 0.32MD 
Gonads 0.Q19MD 
RI:Xi Marrow 0.020Ml) 
Urinary bladder wall 0.18MN 
GI tract 
Small Intest. wall Q.03MN.§ 
Ull wall 0.04MN.§ 
LLI wall Q.06MN.§ 
Thyroid gland Q_Q4MX 
Pituitary O.llMX 
Median effective dose equivalent 
MD=median 
MN=mean 
(mSv/MBq) 
0.08 
MX=calculated for the maximum uptake 
* ICRP 30 Gl model used 
1 not applicable due to the model 
Range 
(mGy/MBq) 
0.19- 0.80 
0.04- 0.15 
0.10- 0.66 
0.0!5- 0.026 
0.016- 0.026 
n.a.1 
n.a.1 
n.a. 1 
n.a.1 
Range 
(mSv/MBq) 
0.05- 0.12 
!'" 1-Tyr j-octreotide and !'" ln-DTPA-D-Phe' j-octreotide scintigraphy: 
comparison in localization of tumor tissue 
A comparison between scintigraphy with ["'1-Tyr']-octreotide and scintigraphy 
with ["'ln-DTPA-D-Phe']-octreotide. performed with an interval of less than 3 
months in the same patients. is given in Table 3. In 4 out of 6 patients (patients 1-
3, and 6) the results of the subsequent scintigrams were identical. In patient 2. 
["'1-Tyr']-octreotide scintigraphy showed accumulation of radioactivity in the 
region of the gallbladder. which is not unusual for this radiopharmaceuticaL consi-
Figure 4 
f'"!n-DTPA-D-Phe'j-octreotide 24 hr SPECT image of a patient (no 3) with a 
solitary insulinoma in the tail of the pancreas. which is shown medial and 
anterior to the spleen and left kidney. The line on the reference image (left 
sided panel) indicates the position of the transversal slice (right sided panel). 
K = kidney, S = spleen. T = tumor and L = liver. 
dering its extensive biliary clearance. However, the same was observed with 1111 In-
DTPA-D-Phe']-octreotide. which is unusual. since this radiopharmaceutical is 
largely excreted by the kidneys. SPECT with ["'ln-DTPA-D-Phe']-octreotide 
demonstrated a tumor located ventral to the gallbladder. In patient 3. SPECT 
images after ['"ln-DTPA-D-Phe']-octreotide injection revealed the locali7""tion of 
the insulinoma. medial and anterior to the spleen and left kidney respectively 
(Figure 4). However, this localization had not been recognized on planar images 
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Patient Sex 
I F 
2 M 
3 F 
4 F 
5 I' 
6 F 
Table 3 
Patiellt data and results of somatostatin receptor scintigraphy, using the analogues 
f"'I- Tyr'J-octreotide and!'" In-DTPA-D-Phe' f-octreotide. 
Abnomml sites of radioactive accumulation 
Age Tumor type Interval 
bcl\wen snms 1231-octre111ide 1111 n-octreotide 
66 Small cell lung 5 weeks Right lung, lower lobe Right lung, lower lobe 
cancer 
65 Gastrinuma 7 weeks Gallbladder region Gallbladder region (see text) 
59 Insulinoma I week None (SPECT not done) None (SPECT positive, Fig. 4) 
50 Carcinoid 10 weeks Left supraclavicular Left + right supmclavicular lymph 
lymph node, liver node, abdomen, chest, liver 
64 Carcinoid 5 weeks 3 raudal abdominal sites, 3 caudal abdominal sites, liver 
I cranial abdominal site (gallbladder removed; see text) 
28 Pheochromocytoma 4 weeks Lowt;Jr left abdomen Lower left abdomen 
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with both radiopharmaceuticals. In patient 4, presumed carcinoid deposits were 
more numerous using l"'ln-DTPA-D-Phe']-octreotide scintigraphy. Tumor 
progression in the relatively long interval between the two scintigrams cannot be 
excluded, however. In patient 5, the liver showed an irregular uptake pattern of 
['"ln-DTPA-D-Phe']-octreotide, whereas a homogeneous distribution was seen with 
["'1-Tyr']-octreotide scintigraphy. The cranial abdominal site of radionuclide 
accumulation observed with ['"1-Tyr']-octreotide was not seen on the subsequent 
["'ln-DTPA-D-Phe']-octreotide scintigram. This site very likely represented 
abnormal uptake in the gallbladder and the hepatoduodenal ligament, which had 
been surgically removed between the two scintigrams and were proven to be 
massively infiltrated by a carcinoid tumor. 
Apart from the marked differences in hepatic and renal clearances (Figure 5), 
tissue accumulation of both radiopharmaceuticals was similar except for the 
pituitary, which was nearly always visible with l"'ln-DTPA-D-Phe']-octreotide in 
contrast to 1"'1-Tyr']-octreotide scintigraphy. However, discrimination between 
accumulation of l"'ln-DTPA-D-Phe']-octreotide in the pituitary and in the surroun-
ding tissues is often impossible, especially caudally. Consequently, only the 
contour of the cranial part of the pituitary can be distiguished since in the region of 
the brain the (background) radioactivity is relatively very low because of the 
blood-brain barrier. With both radiopharmaceuticals radioactivity was always 
observed in the thyroid gland, liver, spleen and kidneys, the urinary bladder, and 
in the intestinal tract, although in the last organ l"'ln-DTPA-D-Phe']-octreotide 
was much less visible. 
DISCUSSION 
In spite of a lower affinity of l"'ln-DTPA-D-Phe']-octreotide for the rat brain 
somatostatin receptor compared to that of ["'1-Tyr']-octreotide (7), the indium-
labeled compound visualized somatostatin receptor-positive animal tumors more 
efficiently in vivo, probably due to its different metabolic behaviour (8). These 
metabolic properties turned out to be similar in man; our study shows that after 
intravenous administration l'"ln-DTPA-D-Phe']-octreotide is rapidly cleared from 
the circulation via the kidneys. However, its initial disappearance from the 
circulation is considerably slower compared to that of ["'!-Tyr']-octreotide 
(Figure 1)(6). This slower initial clearance, combined with the longer physical 
half-life of '"In (t'h = 2.8 days for "'In versus 13.2 lrr for '"I) results in a longer 
residence time of the radiopharmaceutical in the tissues. The presence of a lower 
radioactivity in the remainder of the body 24 hr after injection of l"'ln-DTPA-D-
Phe']-octreotide leads to a lower background radioactivity (Figure 1)(6). The 
higher background radioactivity with 1"'1-Tyr']-octreotide is due to its much higher 
circulating levels of degradation products than is the case with l'"ln-DTPA-D-
Phe']-octreotide. Therefore, ["'In-DTPA-D-Phe']-octreotide is a more suitable 
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Figure 5 
Sequential anterior abdominal views of f"'I-Tylj-octreotide scintigraphy 
(upper panel) showing the rapid hepato-biliary clearance, and posterior 
abdominal views of f"'ln-DTPA-D-Phe'f-octreotide scintigraphy (lower panel) 
showing the rapid renal clearance. Note the rapidly decreasing bloodpool 
radioactivity over the hean with both radiopharmaceuticals. The 20 min 
image of the latter scintigrams also shows a low grade accumulation of 
radioactivity in the lower pan of the venebral column, due to a chondrosar-
coma. 
radioligand to localize somatostatin receptor-rich tissues (vide infra). Furthermore, 
using ["'ln-DTPA-D-Phe']-octreotide, interpretation of scintigrams of the ab-
dominal region is less affected by intestinal background radioactivity. This 
contrasts remarkably with ["'1-Tyr']-octreotide scintigraphy, because the hepato-
biliaty clearance of this compound results in a high hepatic and intestinal ac-
cumulation of radioactivity, which is hardly overcome with laxatives. 
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Analysis of the chemical stams of plasma radioactivity during the first 4 hr 
after injection shows mainly peptide-bound "'In in the form of the original ["'In-
DTPA-D-Phe']-octreotide. Similarly, analysis of radioactivity in the urine shows 
predominantly intact ['"ln-DTPA-D-Phe']-octreotide during the first hours after 
injection. Furthermore. peptide-bound radioactivity in plasma and urine has 
somatostatin receptor-binding properties as demonstrated by specific binding to rat 
brain cortex cell membranes. Degradation of ["'ln-DTPA-D-Phe']-octreotide was 
observed only in plasma and urine samples obtained more than 4 hr after 
intravenous injection of the radiopharmaceutical, when circulating radioactivity 
amounted to less than l 0 % of the administered radioactivity. Ultimately, 
degradation to "'In labeled products such as '"ln-DTPA is suggested by the 
appearance of the peak in the void volume of HPLC analysis. 
Accumulation of radioactivity after intravenous administration of ["'ln-DTPA-
D-Phe']-octreotide in man is observed in the pimitary and thyroid gland, the 
spleen, liver, kidneys and the urinary bladder. Imaging of the gallbladder is 
occasionally seen, whereas the presence of intestinal radioactivity (mainly in the 
colon at 24 hr) depends on the simultaneous use of laxatives. The relatively low 
clearance of the radioligand via the hepato-biliary system favors its use in SPECT 
of the abdomen, which is strongly indicated in the localization of small endocrine 
pancreatic tumors. At present the mechanism of the thyroid gland imaging is still 
unclear. With radio labeled somatostatin analogue autoradiography we could not 
fmd somatostatin receptors in normal thyroid gland and differentiated thyroid 
carcinoma (papillary cancer) tissue slices (14, 15). However, a high percentage of 
malignant parafollicular thyroid rumors are somatostatin receptor-positive by both 
autoradiography and scintigraphy (14, 15). It is remarkable that in the two cases 
with Graves' hyperthyroidism investigated so far, accumulation of radioactivity in 
the thyroid gland was increased (unpublished). The presence of lymphocytes 
(which can be somatostatin receptor-positive, 16) in the thyroid gland could 
explain this observation. Autoradiography of normal spleen tissue revealed the 
presence of somatostatin receptors (unpublished); however, the exact cell-type 
bearing the somatostatin receptor has not been identified yet. Patients on octreotide 
treatment show a diminished accumulation of radioligand in the spleen un-
published), compatible with occupancy of spleen somatostatin receptors by the 
unlabeled octreotide. 
The rapid appearance of intact ["'ln-DTPA-D-Phe']-octreotide in the urine 
indicates an effective renal clearance of this radiopharmaceutical. By contrast, ["'l-
Tyr']-octreotide is rapidly cleared by the liver and little of it is excreted intact into 
the urine. The different metabolism of I"'In-DTPA-D-Phe']-octreotide compared 
with ["'1-Tyr']-octreotide indicates that the modification of octreotide with the '"ln-
DTPA group inhibits hepatic clearance and/or facilitates renal clearance. Rat liver 
perfusion studies have indeed shown that ["'ln-DTPA-D-Phe']-octreotide is cleared 
much more slowly by the liver than ["'1-Tyr']-octreotide (unpublished). It is 
unknown whether the effect of the "'In-DTPA group on the metabolic routing of 
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peptides is a general phenomenon. The relatively long residence time of ["'ln-
DTPA-D-Phe']-octreotide in the kidneys suggests that following glomerular 
filtration part of the label is reabsorbed in the tubules (8). 
Remarkable is the higber sensitivity of ['"ln-DTPA-D-Phe']-octreotide com-
pared to ["'1-Tyr']-octreotide in localizing the pituitary, since in vitro studies have 
shown a higber affinity of the radioiodinated ligand for somatostatin receptors in 
rat brain (7). However, its actual affinity for somatostatin receptors on the 
pituitary is at present unknown. 
For several somatostatin receptor-positive tumors, ["'ln-DTPA-D-Phe']-
octreotide shares with ['"1-Tyr']-octreotide the advantage of providing a more 
sensitive imaging technique compared with currently available diagnostic 
procedures, e.g. CT, ultrasound and MRL Furthermore, the future availability of 
both [DTPA-D-Phe']-octreotide and pure "'lnCl,_ will make an easy single-step 
labeling procedure possible and, hence, scintigraphy of somatostatin receptor-
positive tumors generally available. The effective dose equivalent, although higher 
than that of ["'l-Tyr']-octreotide, is comparable with values for other "'In-labeled 
radiopharmaceuticals (II) and is acceptable in view of the clinical indications. 
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CHAPTER 7 
Kinetic handling of I"'I-Tyr'j-octreotide and ["'In-DTPA-D-Phe'J-octreotide 
by the isolated perfused rat liver 
Marion de Jong, Willem H. Bakker, Wout A.P. Breeman, Marcel van der Pluijm, 
Peter P.M. Kooij, Theo J. Visser, Roelof Docter, and Eric P. Krenning. 
Departments of Nuclear Medicine and Internal Medicine !!1, 
University Hospital Dijkzigr and Erasmus University Medical School. 
Rotterdam, The Netherlands. 
Abstract 
Certain radiolabeled bioactive peptides show receptor-mediated binding to 
tumors, making them suitable for scintigraphic imaging of these tumors. The 
liver is an important organ for the clearance of many of these peptides. 
Therefore, we compared the hepatobiliary handling of 1'"1-Tyr']-octreotide 
and l"'In-DTPA-D-Phe']-octreotide, which are >uccessfully used in imaging 
of somatostatin receptor-positive tumors in vivo. This investigation was done 
in isolated recirculating perfused rat livers to gain insight into the uptake and 
intracellular processing of these somatostatin analogues. During 60 min fol-
lowing administration of the radiolabeled peptides, medium and biliary 
radioactivity was analyzed at regular intervals. Radioiodinated [Tyr']-octreo-
tide appeared to be rapidly cleared by the liver and to be excreted intact into 
the bile. After 60 min 60 % of the administered dose was excreted into the 
bile. In contrast, l"'ln-DTPA-D-Phe']-octreotide, was not cleared by the 
liver: radioactivity levels remained about constant in the circulating medium 
and little radioactivity was found in the bile (2 % of the dose after 60 min). 
These findings show that whereas 1"'1-Tyr']-octreotide is rapidly cleared by 
the liver and excreted intact into the bile, I"'In-DTPA-D-Phe']-octreotide is 
not handled by the liver. The results obtained here are in excellent agreement 
with in vivo findings in rats and humans. From this study, it can be 
concluded that the isolated rat liver perfusion is a rapid method to investigate 
the hepatic handling of radiopharmaceuticals. As the liver, besides the 
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kidneys, is an important organ in the removal of many bioactive peptides 
from the body, such investigations may also have a predictable value for the 
in vivo metabolism. 
Tumor receptor-binding radiopharmaceuticals are among the interesting recent 
developments in nuclear medicine, as these substances can be used for in vivo scin-
tigraphic imaging of such tumors. An example is somatostatin (Fig, lA), which 
binds to its receptors on tumors of neuro--endocrine origin (I). 
This native peptide, however, is susceptible to very rapid enzymatic degradation 
(2), and therefore not very useful for in vivo application. For that reason, more 
stable synthetic somatostatin analognes have been developed. The octapeptide 
octreotide (SMS 201-995 or Sandostatin", Fig. !B) fulfils this criterium (3). Large 
numbers of higb affutity binding sites for native somatostatin and synthetic 
octreotide have been detected on most endocrine-active tumors ( 4). Since 
octreotide cannot be radiolabeled easily with a garmna-emitting radionuclide, a 
synthetic analogne ([Tyr']-octreotide) has been developed in which a phenylalanine 
has been replaced by tyrosine, allowing radioiodination of the molecule (Fig. lC). 
This compound, radiolabeled with "'I or "'l, has been used successfully for in 
vitro somatostatin receptor studies (4-7) and tumor scintigraphy in animals (6,8) as 
well as in man (1,9,10). Another radioactive analogne of somatostatin is ["'In-
DTPA-D-Phe']-octreotide (Fig. !D), which is also used for in vivo scintigraphy. 
Furthermore, it lacks some drawbacks of ["'1-Tyr']-octreotide (7.8; see also 
Discussion). 
The liver is an important organ in the degradation of many circulating peptides. 
However, as far as we know, the uptake and intracellular handling of the 
octreotide analognes has not been previously investigated in an isolated rat liver 
perfusion system and our understanding of the pharmacokinetic behaviour of these 
compounds is only limited. Therefore, we compared the liver handling and 
excretion into the bile of ["'l-Tyr']-octreotide and ["'ln-DTPA-D-Phe']-octreotide 
by means of the isolated recirculating perfused rat liver. 
MATERIALS AND METHODS 
Materials 
Na"'l (IMS.30) was obtained from Amersham International, UK. '"InC!, (DRN 
490 I) was obtained from Mallinckrodt Medical BY, Petten, The Netherlands. 
[Tyr']-octreotide and [DTPA-D-Phe']-octreotide were obtained from Sandoz 
Pharma AG, Basle, Switzerland. "'!-Human serum albumin (HSA) was purchased 
from Sorin Biomedica, Italy. Bovine serum albumin (BSA; Boseral) was a product 
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A. Somatostatin 
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Tbr-Ser-Cys 
B. Ocrreotide 
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Tbr( ol) 
C. ['"1-Tyr'j-octreotide 
D-Phe-Cys-Tyr-D-Trp-L ys-Thr-Cys-Tbr( ol) 
I 
"'I 
D. ["'In-DTPA-D-Phi! j-ocrreotide 
'''ln-DTPA-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Tbr(ol) 
Figure 1 
Somatostatin and analogues with the supposed bioactive site primed in italics. 
of Organon Teknika (Oss, The Netherlands). All other reagents were of the highest 
purity commercially available. 
Radiolabeling 
Radioiodination of [Tyr']-octreotide with "'I was performed with the 
chloramine-T method as described previously (6). Labeling of ['"ln-DTPA-D-
Phe']-octreotide with '"In was carried out as described (7). 
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Isolated peifused rm liver 
Livers of male Wistar rats, 200-250 g body weigbt, were isolated and perfused 
in a recirculating system at 37 Cas described previously (II), using 150 ml Krebs-
Ringer buffer supplemented witb 10 mM glucose and 1 % BSA. The pH of tbe 
medium was maintained at 7.43 by gassing witb carbogen (95 % CO, and 5 % 0,, 
400 ml/min). The function of tbe liver was monitored by its outer appearance. 
measurement of hydrostatic pressure necessary to maintain a medium flow of 40 
ml/min, bile flow, and pH of tbe medium. Livers were preperfused for 30 min. 
The experiment was started by addition of 370 kBq of tracer (10 ·' mol) to tbe 
medium. Subsequently, 0.5 ml medium samples were taken at I, 2, 3, 4, 5, 6, 7, 
8, 9, 10, 15, 20, 25, 30, 40, 50 and 60 min. For tbe determination of a correct 
curve fitting more samples were taken in tbe first minutes of some experiments. 
Bile samples were collected during I 0 min intervals. The samples were stored at 
- 20 C until analysis. 
Analysis of medium and bile samples 
The chemical status of tbe radionuclide in medium and bile samples was 
analysed as a function of time using SEP-PAK C, chromatography. Medium and 
bile samples were applied to SEP-PAK C, columns, which had been activated witb 
5 ml 2-propanol. Elution of tbe different fractions was performed witb 5 ml 
distilled water and 5 ml 0.5 M acetic acid to remove free "'!·, and 5 ml 96 % 
etbanol to elute peptide-hound radioactivity. Fractions were collected and counted 
for radioactivity. Radiochemical composition of tbe different samples was com-
firmed by HPLC-analysis witb a Waters 600 E multisolvent delivery system con-
nected to a 1'-Bondapak-C, reversed-phase column (300 x 3.9 mm, particle size 10 
I'm). Before HPLC, bile samples were diluted 1:10 witb 40 % metbanol in 154 
mM NaCI. Elution was carried out at a flow of I ml/min witb a linear gradient of 
40 % to 80 % metbanol in !54 mM NaCI in 20 min. The latter composition was 
maintained for anotber 5 min. Collected fractions were measured by routine 
scintillation counting. 
Calculations 
Curve-fitting of tbe two-exponential medium tracer disappearance curve was 
done as described previously (II). All data are reported as mean ± SD (n ;;, 4). 
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RESULTS 
['"'I-Tyr]-octreotide 
Fig. 2A and 2B show typical time courses in medium and bile of total radioac-
tivity. peptide-bound radioactivity and liberated '"'!·, after administration of ["'I-
Tyr']-octreotide to the medium. Results are expressed as percentage of the ad-
ministered dose. After administration of the tracer. radioactivity shows a very 
rapid disappearance from the medium. followed by a rapid excretion into the bile. 
In Table lA. it is shown that of the administered radioactivity 27 % peptide-bound 
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Table IA 
Original peptides and break-down products expressed as peptide-bound radioac-
tivity (PBR) and non-peptide-bound radioactivity (NPBR), e.g., "'r and "'In-
DTPA, in medium and bile after 60 min ofpelfosion with ["'1-Tyr}-octreotide or 
f"in-DTPA-D-Pht!]-octreotide. Results are given as mean (SD) % dose (n ;;, 
4). 
PBR NPBR PBR NPBR 
(medium) (medium) (bile) (bile) 
['"!-Tyr']-octreotide 26.9 (1.9) 1.2 (0.0) 60.4 (3. 7) LO (0.1) 
['"ln-DTPA-D-Phe' ]- 94.9 (0.8) 0.9 (0.1) 2.2 (0.2) 0.2 (0.0) 
octreotide 
Table IB 
Half-lifes of the fast and slow components of medium disappearance of"' 1-HSA, 
f"I-Tyr]-octreotide and ['"In-DTPA-D-Pht!J-octreotide. Results are given in 
mean (SD) minutes (n ;;, 4). 
fast component slow component 
"'I-HSA 0.29 (0.02) <X> 
['"!-Tyr']-octreotide 0.28 (0.04) 36.2 (3.9) 
[ ''' ln-DTPA-D-Phe']-octreotide 0.25 (0.08) <X> 
radioactivity is left in the medium after 60 min, while about I % consists of free 
iodide. Concerning the bile, free iodide accounts tor only I % of the administered 
radioactivity; most radioactivity (60 % dose) is excreted in peptide-bound form. 
HPLC-analysis revealed that the peptide-bound radioactivity in the bile is intact 
["'1-Tyr']-octreotide (Fig. 3). In all experiments the disappearance of tracer ['"I-
Tyr']-octreotide could be fitted to the sum of two exponentials. In Fig. 4, this two-
exponential medium disappearance curve is shown and the half-lifes of the fast and 
slow component were calculated. 
The distribution time through the system was estimated by perfusion of livers 
with "'1-HSA, a substance that is not taken up into the liver. The half-life of the 
fast component of medium "'1-HSA disappearance was 0.3 min, whereas that of 
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the slow component was very long as almost no radioactivity disappeared from the 
medium. In the case of ['"!-Tyr']-octreotide the half-life of the fast component is 
0.3 min (representing distribution through the perfusion system) and of the slow 
component 36 min (representing uptake and metabolism, Table !B). 
400 30 
300 
20 
E E 
0. 200 0. 
" " 
"" "" 10 
100 
0 '.\ 0 
0 10 20 30 40 50 60 70 80 
fractions 
Figure 3 
Typical examples of HPLC elution patterns (expressed in kcpm per 0.3 ml 
fraction) of ['"1-Tyr]-ocrreotide, as added to the medium (solid line, lift 
ordinate). and of protein-bound fraction excreted into the bile (dashed line, 
right ordinate). 
I'"In-DTPA-D-Phe']-octreotide 
Figs. 5A and 5B show typical time courses in medium and bile, respectively, of 
total radioactivity, peptide-bound radioactivity and non-peptide bound breakdown 
products after administration of ["'ln-DTPA-D-Phe']-octreotide to the medium. In 
Table lA, it is shown that after 60 min, 95 % of the administered radioactivity 
still consists of peptide-bound tracer in the medium, which is identical to intact 
["'ln-DTPA-D-Phe']-octreotide as demonstrated by HPLC (not shown). Concer-
ning the bile, only a small portion (2 %) of the administered radioactivity is 
excreted. Furthermore, it was calculated that the half-lifes of the fast and slow 
component of the biphasic medium disappearance (which is described as the sum 
of two exponentials) are 0.3 min (distribution) and unmeasurably long, respectively 
(Table IB). 
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Figure 4 
Typical example of the curve fitting of a f"I-Tyrj-octreotide disappearance 
curve by a two-exponential model. Plot of % dose per ml against time, with 
the least squares regression line on the final straight pan of the curve (slow 
component). Inset: plot of the fast component, with the least squares regres-
sion line. 
DISCUSSION 
Radiolabeled octreotide analogues bind to the somatostatin receptors on neuro-
endocrine tumor cells, and are therefore suitable for scintigraphic imaging of these 
tumors. Although these radiopharmaceuticals have been investigated in vitro 
(binding studies and autoradiography of somatostatin receptor-positive tissues; 
Refs. 4-7) and in vivo (tumor scintigraphy; Refs. 1,6,8-10), little is known about 
the metabolism of these radioligands, especially in the liver. This is in contrast to 
the knowledge of the hepatic metabolism of the native peptides somatostatin-14 and 
somatostatin-28. They are degraded through the action of hepatic aminopeptidases 
and endopeptidases as studied in the perfused rat liver (12,13). 
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The perfused rat liver is very suitable to investigate several parameters of liver 
metabolism. such as the disappearance from the medium, appearance of 
degradation products and biliary excretion. Therefore, in this study we compared 
the liver handling of ['"1-Tyr']-octreotide and f"'ln-DTPA-D-Phe']-octreotide in 
this system. 
f"'I-Tyr']-octreotide is rapidly taken up into the liver, immediately followed by 
intact excretion into the bile (Fig. 4). As the half-life of the fast component of the 
medium disappearance is the same as that of "'1-HSA, a substance that is not 
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transported into the hepatocytes but passively diStributes into the liver interstitium, 
it is shown that this component is predominantly determined by diStribution of the 
tracer through the system and the extracellular liver compartment, The half-life of 
the second component is mainly determined by handling in the liver. We recently 
reported transport and metabolism of thyroid hormone in the perfused rat liver; in 
that case an uptake and a metrJJolism component could be distinguished clearly in 
the biphasic medium disappearance curve after the diStribution phase ( 11). In the 
case of ['"!-Tyr']-octreotide, uptake is immediately followed by excretion into the 
bile and therefore not seen as a distinct component. Chrontatography of medium 
and bile showed that hardly any free radioactive iodide is found in medium and 
bile, while the majority of the administered dose is already excreted intact into the 
bile within 60 min. Only little of the administered radioactivity accumulates in the 
liver. 
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Figure 6 
Radioactivity, expressed as mean ± SD percentage of the 3-min value, 
measured above regions of interest in humans, i.e. liver tissue without major 
bile ducts (after f"'I-Tyr']-octreotide [•, n=5] and ['"In-DTPA-D-Phe']-
ocrreotide {0. n=J]) and gallbladder (after {"'1-Tyr']-octreotide {A, n=5]). 
After injection of ["'In-DTPA-D-Phe' ]-octreotide no bile-related radioactivity 
was measured neither in major bile-ducts nor in the gallbladder. 
An internalized peptide can reach bile by two pathways: (a) a lysosomal, or 
indirect pathway; and (b) a non-lysosomal, or direct pathway (14). In general, 
molecules processed by the first pathway are not excreted intact into the bile. 
Compounds that utilize the second pathway are generally excreted into bile as 
intact molecules and appear in bile sooner than those excreted by the lysosomal 
pathway. Our results show that ["'!-Tyr']-octreotide is translocated across the 
hepatocytes into the bile by the direct pathway, thereby bypassing the lysosomes, 
because the radiopharmaceutical is excreted intact into the bile and because there 
exists no lag time before excretion into the bile takes place. These findings are in 
accordance with the fact that ['"1-Tyr']-octreotide is very stable against (hepatic) 
enzymatic degradation, in contrast to the native peptides somatostatin-14 and 
somatostatin-28 (12, 13), probably due to the introduction of a D-amino acid at the 
N-terminal and an amino-alcohol substituent at the C-terminal end of the peptide 
chain (3). 
Recently, it has been reported for several types of cyclosomatostatins that 
uptake into isolated rat hepatocytes is a carrier-mediated process which is related to 
the multispecific bile acid transporter (15). Further transcellular bile-acid transport 
to the bile after uptake into the cells has been elucidated by electron microscope 
autoradiography, showing that these substances are excreted rapidly into the bile in 
a chemically unchanged form (for review, Ref. 16). We did not investigate 
possible carrier-mediated transport properties of our somatostatin analogues, but 
intact excretion into the bile after a rapid transcellular transport is in accordance 
with our findings in the perfused rat liver. 
The results of our study in the perfused rat liver are in agreement with rat and 
human in vivo investigations with ["'1-Tyr']-octreotide, which show that disposal 
occurs predominantly by rapid uptake into the liver and excretion via the bile into 
the intestines (6,9). In Fig. 6 metabolism in the human liver is shown. Data are 
derived from studies. described in Ref. 9. !"'1-Tyr']-octreotide is rapidly cleared 
from the circulation by the liver, immediately followed by hepatobiliary excretion; 
radioactivity in a non-major bile duct-containing part of the liver does not increase 
above 150 % of the 3 min-value, but a sharp increase of radioactivity is seen 
above the gallbladder during the fust 20 min after administration. 
["'ln-DTPA-D-Phe']-octreotide is not taken up by the isolated perfused rat 
liver, as almost no tracer disappears from the medium. The half-life of the fast 
component is again determined by distribution through the system, whereas the 
half-life of the slow component is very long, indicating a very slow handling in the 
liver. Furthermore, hardly any radioactivity is found in the liver, and excretion 
into the bile is negligible. This may be due to the addition of the relatively large 
and very hydrophylic DTPA-group to the octapeptide-molecule, favouring renal 
excretion of the latter, like the radiolabeled chelate itself (for instance ""'Tc-
DTPA), which is excreted exclusively by glomerular filtration (17). These findings 
are in excellent accordance with in vivo studies (8,10). In Fig. 6 metabolism in the 
human liver is shown using data derived from studies described in Ref. 10. After 
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administration of ["'ln-DTPA-D-Phe']-octreotide the radioactivity, measured above 
the liver does not increase, but rather decreases, which can be explained by the 
fact that this radiopharmaceutical is not cleared by the liver but by the kidneys 
(8, 10). Scintigraphically no radioactivity could be measured above the gallbladder. 
["'ln-DTPA-D-Phe']-octreotide is the preferred analogue for in vivo scin-
tigraphy, as it has several advantages compared to f"'l-Tyr']-octreotide: general 
availability, simple one-step method of radiolabeling, longer physiological half-life 
in plasma, and a more suitable metabolism. In order to visualize a tumor by 
receptor binding in vivo, the specific activity expressed in counts per unit of area 
must exceed the local background radiation. As - in contrast to radioiodinated 
[Tyr']-octreotide - ["'ln-DTPA-D-Phe']-octreotide is not cleared via the liver and 
causes no accumulation of radioactivity in biliary and digestive tract, the latter 
radiopharmaceutical is more suitable for visualization of tumor receptor ac-
cumulation in the upper abdominal region, where the small endocrine gastro-
entero-pancreatic target tumors are located. 
From this study, it can be concluded that the investigation of the handling of 
radiopharmaceuticals by the isolated rat liver perfusion is a rapid method to study 
kinetics of these substances in this organ. As the liver, besides the kidneys, is an 
important organ in the removal of many bioactive peptides from the body, such 
investigations may also have a predictable value for the in vivo metabolism. 
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Summary 
Various endocrine-related tumors contain large numbers of high-affinity 
somatostatin receptors. '"!-labeled ITyr']-octreotide (ITyr']-SMS 201-995, a 
synthetic derivative of somatostatin) was used to localize such tumors in vivo 
with a gamma camera. Positive scans were obtained for two meningiomas, 
two gastrinomas, and one carcinoid; negative scans were obtained for one 
insulinoma (in which unlabeled octreotide had no effect on insulin levels), 
one phaeocbromocytoma, one adrenal carcinoma ( octreotide had no effect on 
cortisol levels), and three medullary thyroid carcinomas (octreotide had no 
effect on calcitonin levels). Thus radioiodinated [Tyr']-octreotide can label 
somatostatin receptors in endocrine-related tumors in vivo and can therefore 
be used for tumor localization. 
INTRODUCTION 
Large numbers of binding sites with high affinity for somatostatin have been 
reported in tumors such as growth-hormone-producing pituitary adenomas (!), 
meningiomas (2), malignant breast tumors (3). astrocytomas and 
oligodendrogliomas (4), medulloblastomas (3), neuroblastomas (3), and oat cell 
carcinomas of the lung (5). As well as inhibiting the secretion of specific hormones 
by some of these tumors (6-9), somatostatin may inltibit tumor growth (9-12). 204-
090 (ITyr']-octreotide {ITyr']-SMS 201-995}. a synthetic derivative of somato-
statin) and somatostatin have a common active site. We have studied the in-vivo 
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binding of radioiodinated 204-090 to several endocrine-related tumors. Information 
on the labeling procedure, bioassay, pharmacology, and dosimetry in rats and man 
will be reported elsewhere. 
PATIENTS AND METHODS 
The somatostatin derivatives octreotide and 204-090 were prepared by Sandoz 
(Basel, Switzerland) (13,14). Radioiodination of octreotide was done with 
chloramine (13). 
Depending on the labeling procedure, the interval between injection and 
scintigraphy, and whether single photon emission computed tomography (SPECT) 
was required, the doses of '"1-204-090 ranged from 37 to 555 MBq, given as an 
intravenous bolus. Planar and SPECT images were obtained with a large field of 
view gamma-camera ('Counterbalance 3700', Siemens Gammasonics), equipped 
with a 190 keY parallel-hole collimator. Generally the field of view at the time of 
injection of '"1-204-090 covered the abdomen and some of the lung and heart area. 
From the time of injection digital images were recorded with a 'Gamma-ll' 
computer (Nuclear Diagnostics, Sweden) every 3 s for 2 min then every 60 s for 
28 min. In this 30 min period analogue images were also obtained regularly. 30 
min after injection, anterior and posterior whole-body static scintigraphy and, when 
indicated, SPECT were done. Static images, both analogue and digital, were 
obtained at about 0.5, 2, 4, 24, and sometimes 48 h after injection. ""'Tc-albumin 
microcolloid (56 MBq; Albu-Res, Solco, Switzerland) scintigraphy was used for 
subtraction of radioactivity in normal liver tissue. 
All patiens gave informed consent to participate. Clinical details are shown in 
the table. 
RESULTS 
After the injection of "'1-204-090 no side-effects were noted. As well as 
distribution of activity in the blood, radioactivity accumulated rapidly in the liver. 
About balf the activity was cleared from the blood within 2 min after injection. 
The table summarises our results. In all patients who showed significant inhibition 
of tumor hormone release in response to subcutaneous administration of 50 or 100 
p.g octreotide, scintigraphy revealed rapid accumulation of "'I-204-090 at tumor 
sites, which were verified by computerised tomographic (CT) scanning. Tumors 
that were seen on the 24 and 48 h scans were also visible on the 4 h whole-body 
scans. 
Both in patient I (gastrinoma) and 4 (carcinoid), metastases that had not been 
known about before the investigation were detected outside the abdomen. The 
primary tumor in the jejunum of patient 4 was also detected after the injection of 
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CLINICAL DETAILS AND RESPONSES OF PATIENTS 
Acute 
endocrine 
Patient Diagnosis response to Scintigraphy 
(sex/age [yr]) 50-100 f.L& with 
octreotide~ 1231-204-0901" 
l (F/46) Gastrinoma + + 
(MEN I syndrome): 
meningioma NA + 
2 (F/68) Meningioma NA + 
3 (M/37) Gastrinoma + + 
4 (M/75) Carcinoid + + 
5 (F/80) Insulinoma - -
6 (F/57) Phaeochromocytoma NT -
7 (M/49) Medullary thyroid carcinoma - -
8 (M/67 Medullary thyroid carcinoma -
-
9 (F/66) Medullary thyroid carcinoma - -
10 (M/44) Adrenal (cortex) carcinoma 
-
-
*+ = decrease and - = no decrease in level of specific tumor-marker {patients 1 and 3, 
serum gastrin; 4. uri.Mry 5-hydroxyind.ole acetic acid; 5, serum insulin; 7, 8, and 9, serum 
calcitonin; and 10, serum cortisol). 
1+ = correct localization of primary tumor and, if preseru. metastases, compared with CT 
scanning; - = no accumulation of label in tumor. 
NA = not applicable and NT = not tested. 
"'1-204-090. Fig I shows images from patient 4. Despite metastases in the liver, 
the initial images (not shown) of the liver obtained with '"l-204-090 revealed a 
diffuse pattern of radioactivity, which showed the capacity of these metastases to 
accumulate this radiopharmaceutical. Fig 2 shows localization of a gastrinoma 
(patient 3). Interestingly, two patients with meningioma (no 1 and 2) also showed 
accumulation of '"l-204-090 at the site of this tumor. An image from patient 2 is 
shown in fig 3; brain tissue was not labeled in any patient by this technique. The 
timecourse of the distribution of radioactivity in all these tumors was distinct from 
that in blood (fig I. centre, and 2). 
DISCUSSION 
Using 204-090 in an in-vitro assay with tumor homogenates and in receptor 
autoradiography, Reubi et al (2, 15) demonstrated high levels of somatostatin 
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Figure I 
Anterior abdominal images q{ patient 4 (carcinoid) qfler intravenous injection o{"'J-204-090. 
L~fl ~ subtraction image of"'J-204-090 and ""'Tc-microco/loid images at 20 min; I = heart, 2 =spleen, and 
3 = Jnimary tumor. Cemre = 48 h "'J-204-090 image. Note the resemblance of these two images; at 48 h, in 
addition to radioactivity in digestive tract and bladder, only primary tumor and metastases in liver and 
mesenterial lymphnodes are seen. Metastases in thorax (e.g .. lefl scapula, venebra, and rib)(right = posterior 
view qf thorax). neck, and supraclavicular region (not shown) were also found. 
Figure 2 
Anterior abdominal image of 
patient 3 at 30 min. 1 = primary 
site of gastrinoma. 2 = gallblad-
der. Note absence of spleen ac-
tivity, because of splenectomy. 
receptors in four of four gastrinomas, two of five insulinomas, and thirteen of 
thirteen meningiomas. A high proportion of carcinoids were also found to contain 
somatostatin receptors (J.C.R. and L.K. Kvols, unpublished). However, three 
phaeochromocytomas and two medullary thyroid carcinomas tested in vitro did not 
contain somatostatin receptors (3). Our in-vivo fmdings agree with these in-vitro 
results and with the acute endocrine response to intravenously administered 
octreotide. Tumors were not detected by our technique in three cases of medullary 
thyroid carcinoma, one phaeochromocytoma, and one insulinoma. Furthermore no 
acute endocrine response to octreotide was observed in these patients. Localization 
of the primary tumor and metastases with "'l-204-090 was possible in both cases 
of gastrinoma, in both cases of meningioma, and in one carcinoid case. The 
demonstration of previously unknown metastases in some of these patients shows 
the powerful discrimination of this technique. The detection also confirms in-vitro 
data which showed that metastases of somatostatin-receptor-positive primary 
tumors are themselves receptor-positive (3,15). The observed accumulation of 
radioactivity at the site of the tumor after intravenous injection was instantaneous 
and prolonged in contrast to activity in blood, which rapidly decreased. This 
excludes the possibility that the tumors were detected because of accumulation of 
blood in the tumor. 
The results of our study and in-vitro data (2-4, 15) snggest that tumors are 
labeled in vivo by binding of the radiopharmaceutical to membrane-bound recep-
tors (1-4). In addition to tumor localization, scintigraphy with "'1-204-090 may 
demonstrate in vivo somatostatin receptors in tumors if an acute endocrine response 
to octreotide carmot be measured (e.g., when a specific hormonal tumor-marker is 
not available). This detection will especially apply if these receptors are involved 
in tumor growth, because octreotide affects the growth of endocrine-related tumors 
(9-12). If somatostatin is directly antiproliferative (12), the presence or absence of 
somatostatin receptors on tumors ntight be expected to determine the response to 
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Figure 3 
uaeral image of head of patient 2 
at 3 h. Arrow = meningioma. 
therapy with somatostatin analogues. In view of this, the potential role of "'l-204-
090 scintigraphy and of beta-entitling radiolabeled analogues in radiotherapy needs 
further investigation. Whole-body scintigraphy with "'l-204-090 is feasible -
images can be interpreted several ntinutes after injection because of the rapid 
decrease in background radioactivity. 
Our study demonstrates tumor localization in patients by targeting receptor-rich 
tumors with relevant radioligands. The tecbnique may not be lintited to somatos-
tatin receptor-rich tumors, but may be extended to other receptor-containing tumors 
(i.e., receptors for epidermal growth factor). The method may be a powerful 
alternative to tumor labeling with monoclonal antibodies. 
We thank Dr J.W.F. Elte who contributed a patient to the study. Paula C. Schuijff and her staff 
for help with patients· management. Ina Loeve and Sjaak van Peski for technical assistance, and 
Joke M. Nijsse for secretarial help. 
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ABSTRACT. The ~ff<'CU\ ofoctr<;ootide in uWo Md in 1.1itro on 
hormone rdeaoe, in vioo J'""I]Tyr'-octr<.-otidc •cnnnin~. and m 
vitro ("'I]Tyr'-octreotid<' autoradiography W<•r<- eomP<J.r<><l in liw 
patients "'i'th endocrine pancreatic tumo,.,;. 
["'I]Tyr'-octrc<>tide >.ennninl(" localized the primary tumor 
and/or previou~ly unknown rnetnstaM"& in four of th~ five pa-
tiont..q. The pntient with a ne~tive >.Ciln had an in~ulinomn that 
did not r~•pond to octr..otide in c·ioo. No Tyr'·oetn'Otide-bindin~ 
~ires were ~ubo.equently found nt autoradiography of the tumor. 
whereao hO!Dilt<>htntin-14 r""eptors ~r<: p~nt at n hi~h den-
sity. In p.~rallel. culture ><tudioo with the cell~ prepared from this 
adenoma ~how...ct that insulin relcnoo wn" not aff<'<:ted byoctn-Q-
tidc, while b<.>th somatostatin-14 nnd -2Ssi""ificantly •uppn'!l......ct 
honnone relense. 
Culture atud.ie~ of the tumor c<-lh; from two r:<t~trinomn~ 
oho~d" dQ~;C-deyendcnt inhibition of gastrin release by octroo-
tidc. Octrc<>tide exert....:l direct: antiprolifermiw eff<·ct.~ in one of 
th<;-s(' gru;trinoman. which had be<::n ohown to be rapid.iy I(TOWin~ 
E NDOCRI:r--'E pancreatic tumors in man are often difficult to locillize, while metastases are in most 
cases already present at the time of their diagnosis (1, 
2). Most pre·v-iously used therapies are in the majority of 
patients of only temporary benefit (3--5). The clinical 
introduction of the somatostatin analog octreotide was 
reported to be especiillly $UCcessful in the control of the 
clinical signs and symptoms related to the hormonal 
hypersecretion of vasoactive intestinal polypeptide 
(VIP), [!"ilStrin, D.nd c:luca[!"on (6-14). The possible tumor 
p-owth inhibitory effects of octreotide in endocriM pan-
creiltic tumors seem to occur less frequently (15). 
Previously, we demonstrated the presence of larr:-e 
R~ceived~owmkr J";", l~S9. 
Addrc"' oll corNhPOndenC<> and t<>qUe't' for !"<'print.~ too S. W. J. 
Lambert.~. M.D .. D<'J)nrtrnont of M<'dicin<'. Univerr..ity HO«pit.~l Djjk-
zigt, 40 Doctor Molcwnt~r;>lcin. 301.:; GD Ron .. rdam. Th~ :-Jcth<"'rlnnd•. 
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in viw. Both pmtrinom& had specilic •omato~tntin receptors. 
no meaoured by in vitro ~ptor autoradio~phy. Somatostatin 
rolewe by the culrur...ct W!Dilto:\tntinom.n cdh. from one of the!\<.' 
patient,; waH suppr<:o.'<Cd by oct:I'("-Otide. 
In conduo;ion, 1} the ["'l]Tyi'-oct:r("-Otide "cnnnin1: procedure 
;~ vnlunbl.- in tho localization of primary endocrine pnncreatic 
turno,-,; as well their often dinicnlly not yet t("CO!(ni>:ed m<'tafi-
ta"'-"'; 2) the in vi!ro dc~on of !>O>na!.O:Itatin roc<'!) torn in tho"~ 
tumon\ that w~rc aho visuali~ed in uioo after inj~ction of ["'I] 
Tyr'-octrc<>tide indicateo that the ligand binding to the tumor 
in r;ivo indeed "-'P"'"'-'"t_, binding to spccilic ~omntostatin '""'-'P· 
tors; nnd 3) the pal'nUcl between the pre•ence of oomnto~tlltin 
r~C<'J)to,-,., on rumon; nnd in in vioo nnd in vitro effect.~ of 
oetNotidc on hormonal n-len.w from the•e tumon; indicn"te that 
o po,itivt• '""-" p!"<'d.ict.~ a gOOd ~uppN!!Sive effect of octr("-Otide 
on hormonal hype!"loCCTI'tion by theoe tumo!"». (J Clin Endocrinol 
M<'!Ob 71:566-574, 19110) 
numbers of hir;h affinity binding sites for the somato-
st..:ltin analog ['z''I]Tyr3-octreotide in 10 of 14 hormone-
producing endocrine pancreatic tumors (16). Thereafter, 
we showed in a preliminary study thnt these receptors 
cnn also be visualized in vivo in patients harboring these 
tumors by a new nuclear medical procedure involving the 
iv administration of [1::oi)Tyr'-octreotide (17). In the 
pre,;ent study we compared. in a group of 5 patients with 
endocrine pancreatic tumors, the preoperative reaction 
of circulating hormone levels to the iv administrution of 
a ;;ingle do;;e of octreotide, the in viuo detection of so· 
mato;;Ul.tin (analog} receptors after the injection of ['Z"J] 
Tyr'-octreotide. and the subsequent presence of these 
receptors on the tumor tissue inve;;tigo.ted in vitro. Fi-
nally. the po.rallel in vivo and in vitro investigo.tions were 
in o. few cases completed by studies on the effects of 
octreotide on hormone secretion by the cultured cells 
prepared from the!<e tumors. 
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Materials and Methods 
Cultu.ro: studies 
Sp.,;imellll of surgically removo:d tumor tis...~ue (two gn:;tri-
nomus, one parnthyroid adenoma, one insulinoma, and one 
somatostatinoma) were dispei'S('d into sing!<.' cell suspensions 
using a mixture of dispasc and collagenase, a.~ described previ-
ously (18). The cells were cultured in Minimum Et>Bential 
Medium supplemented with 10% fetal calf serum. oodium pyr-
uvate {1 =ol/L), nonessential amino acids. l-gluto.mi.ne (2 
=olfL), sodium bicarbonate (2.2 g/L), and nntibiotics. Medin 
nnd supplements were purchased from Flow (Irvine, Ayrshine. 
Scotland). The cells were cultured at a density of 1-1.5 x 10" 
cells/well. except for the somatostatinoma cells. which were 
seeded at 10• cells/wells. All incuhtltion.s (without or with drugs) 
were carried out in quadruplicate. At the end of th(' incubntion 
period th(' medio. were collected. Cell extracts were prepared by 
lysis of the cells in d,i,tilled water containing 0.1% BSA (19}. 
Media and cell extrncts were stored at -20 C until analysis. 
A=Y' 
The DNA content of the tumor cells was determined accord-
ing to the method described by Downs and Willinger (20} and 
bus been described previously in de-tail (21). 
Gostrin und insulin concentrations in the culture medin, cell 
e:rtracts, and sera were det('rmined by doubl(' antibody RLc.s. 
using kits purchu5ed from Cambridge Medical Diagnostics (Bil-
lerica, MA) and MedGenix Diap!Ostics (Brussels. Belgium). 
respectively. PTH concentrations were determined by n im-
munorndiometric ossay (IRMA) using a kit from Incsta.r Corp. 
(Stillwater, MN). Intra- nnd inter=y vo.riation.s were less 
than 8% for the gnstrin RIA. less than 8% and less than 6% 
for the insulin RIA, and less thnn 5% and less than 10% for 
the PTH IRMA, respectively. Gastrin, inBulin nnd PTH in the 
media and cell extrncts cliluted paralM to the respective stand-
ards supplied with kits. PRL wn:; determined by RIA as de-
scribed previously (22). Somatostatin concentrations were 
measured with standard RIA techniques with nn nntiserum 
supplied by Dr. R Guillemin (Salk Institute. La Jolln, CAl. 
The intraasaay variation wos 6%. Somatostatin in the medium 
of the cultured tumor cells diluted parallel to the standard. 
while OCtl:('Qtide up to a concentmtion of l ILM interfered less 
than 3% in the ossay. 
In vitro determination of somatostatin receptors 
Immediately after resection. a piece- of tissue for receptor 
autoradiographic analysis was cooled on ice nnd frozen at -70 
C. Th.,. storag"' time of the tumoro before autorad.iographic 
p!'Oeessing ranged from 1-3 months. Tumor M-mple diametero 
were between 5-15 mm. 
Somatostatin receptors were meosu:red by autoradiography 
on cryostat sections of the tumor tissue. a_~ do;oscribed previously 
in detail for various endocrine tumors (16, 23). Two iodinated 
BOmatostatin annlo{!S were used as rnd.ioliganoi~. the Tyi' analog 
of OCtreotide, code named 204-090. [H-o-Ph('·Cys-Tyr-o-Trp-
Lys-Thr-Cys-Thr(ol)] (24). as we-ll as the somntostatin-14 de-
rivative [Tyr]somatostatin-14 (25). Both lignnds were previ-
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ously shown to specifically label ~omato~tatin receptor~ (26). 
For nutoradiography the tumors were cut on a cryostat (Leit~ 
1720, Rockleigh, N.J) in 10-JJm section~. mounted on precleaned 
microocopc slidl'S. and ~tored at -20 C for at !cnst 3 days to 
improve adh""'ion of the ti:<>;u<:' to the slid ... s,.ction~ wer"' tht'n 
incubated for 2 hat ambient temp~·rature in 170 mM Tris-HCI 
buffer (pH 7.4) conroining 1% BSA. bncitracin (40 .,fUmLJ.and 
M~;Cb (5 mM) to inhibit endogenou;; protco_~es in the pre~ence 
of iodinated ligand (0.16 x 10• dpm/mL: -80 pM. Nonspecific 
binding was d('tennined by adding unlabeled somatostatin-14 
or 204-090 at a concentration of 1 JJM. Incubated sections wer(' 
wll$hed twiell for 5 min in cold incubation buffer containing 
0.25% BSA. Sections were washed in distilled wnter and dried 
quickly, apposed to "H LKB f'llms, and exposed for 1 week in 
x-ray cassettes. 
Select('(! tumors in which somatostatin re<:eptors Wt're visu-
alized with autoradiographical mc-thooi~ were aL«< characterized 
biochemically in a homo~;enato:- binding o_"''-'~Y in snturation and 
competition experin;-ents, as describ<:'dpreviou._~!y (25. 26). 
Jn uioo somatostatin receptor imaging 
Tyi'-octrcotide (204-090) was obtained from Sandoz {Ba_<;el, 
Switzerland). The preparation of ['"-'I]Tyr-octrcotide. th"' dose 
administered (37-555 MBq). and the technique of scintigraphy 
with i'-camem pictures as well as with single photon emi&qion 
computed tomogro.phy have bo:-c-n described previously (17). 
All patients have informed consent to po.rticipate in the 
study, which was approvOO by the ethical committee of our 
hospital. 
Results 
Patient I 
This 38-yr-old man patient underwent two stomach 
operations in recent years be<:ause of bleeding from sev-
eral duodenal ulcers, which could not be controlled by 
therapy with histamine~-receptor-blocking agents. Even-
tually. serum gastrin levels were found to be elevated 
(7200 and 8200 ng/L. respe-ctively). and at arteriogruphy 
a tumor with a diumeter of 2.5 em was found in the 
corpus of the pancreas. Fifty micrograms of octreotide 
suppres.sed gastrin levels by 70% from 1-8 h after 
administration. 
An [lZli]Tyi'-octreotide scan was carried out (Fig. 1). 
Two minutes after injection of the isotope-coupled so-
mutostatin analog a normal liver was visualized, while 
there was still some radioactivity in the hea.--t. In the 
center of the abdomen under the left lobe of the liver a 
somatostatin receptor-positive tumor muss was seen. 
which be<:ame more cleo.r in the subsequent pictures. 
After 30 und 90 min the gnllbladder and bile duct con-
tained high amounts of r.ldioactivity. Throughout the 
scanning period it became clear that the positive picture 
in the region of the pancreas consisted of three more or 
less independent tumor deposits. 
At subsequent laparotomy two tumors were found in 
568 LAMBERTS ET AL. JCE.«M•H.,.., 
Voi7J•I<o'J 
Flc.l. [""I]Tyr"-octrcotid~ "=in pa-
tient 1 with a ga.strinoma.. "l'·Cam<:l'a pic-
ture~ oftb~ nbdomcn werc taken 2, S. 10. 
15, 30, and 90 min after the iv injection 
of lS mCi ["'"I]Tyr'-octrootide. Note th<> 
normal liver, and the fillinJ: of the gall-
bladder and the bile duct.~ after 30 and 
90 min. ln the center of all pictu~ two 
gastrin-oecreting tumorn are visible in 
the pnncreW>. "" well ru. a [:I.IStrinoma-
contWning lymph node in th<> 1'\.'troperi· 
toneum. 
the corpus of the pancreas (4 X 4 and 5 x 6 em in 
diameter) as well ns a tumor-containing lymph node. All 
tumor tissue stained immunohistochemically strongly 
positive with antigastrin. Autoradiographic studies with 
['21oi]Tyi'-octreotide revealed that both the two pan-
crentic tumors and the lymph node metastm,;is contained 
large numbers of somatostatin analog-binding sites, 
which were diffusely distributed over the tumor tissue. 
Biochemical analysis showed the presence of high affm-
ity binding sites for Tyi'-o~reotide, with a ~ of 0.16 
nM and a binding cupacity of 683 fmol/mg protein (Fig. 
2}. Similar results were obtained in the metastatic tumor 
tissue (data not shown). 
From the primary tumors in the pancreas 3.6 g tissue 
were dispersed; this resulted in a totul of 800 x lOr, viable 
tumor cells, which were seeded in the culture wells at a 
density of 1.5 x 10~ cells/welL During a period of2 weeks 
the control cells continued to secrete large amounts of 
gastrin. Both 0.1 and 10 nM octreotide effectively con-
trolled gastrin release by the cultured tumor cells; from 
day 8 on, gastrin secretion was completely blocked by 
the drut;. 
The possibility of a direct antimitotic effect of octreo-
tide on these cultured tumor cells was evaluated und 
compared with that exerted by two cytostatic drugs (Ta-
ble 1). Octreotide (10 nM). vincristin (10 nM), and adri-
amycin (10 nM) suppressed hormone release, the intra-
cellular gastrin content, rmd the DNA content of these 
tumor cells. In Fig. 3 the close correlntion between the 
gastrin content and the DNA content of those tumor 
cells exposed to octreotide and the cytostatic drugs is 
shown (P < 0.01). 
0.2 0.4 0.6 0.8 
[oM] 
~ 5 
~ ' 
r 0 
0 
I 0 
~ 0 
200 400 600 800 
S (fmolstmg Prot) 
FIC. 2. Binding of !ml]Tyr'-octreotide (204·090) to th<> membran5 of 
the primary I("W!trinoma of patient 1. Top, Saturation curve U!<ing a 
~Llstrinoma m..mbr<~.ne p!'<'parntion incubated for 60 min with incn:w;-
in~ eon,.,tratioM of ['"IJTyr'-octrcotidc. Specific binding minu~ 
bindin~:; per-i,ting in lh<> presence of 100 nM Tyi'-oct!'<'Otide (nonspe-
cific) is shown. Point,' n:n: th<> avera!:<' of triplicate tubca. Bortom, 
Scatchard plot from tht" data shown in th~ top fii:U~ (K., 0.16 nM; 
binding ""Pacity, 6S3 fmol/mll: prot<>in). 8/F, Bound to f""" ratio. 
Patient 2 
This 48-yr-old woman has multiple endocrine adeno· 
matosis type I. In the past she hod Cushing's syndrome 
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TAnLIS: 1. The e!!...:ts of O<;tr~tlde, vlneriatin, and adriamyein on I:Mtrin r..!,.,.•e o.nd on the 1:'\Strin and DNA content~ of the cultured tumor e<>lls 
o! two patient>; with malignant gru,trinomn 
ca~trin 
DNA 
M..dium Cont<>nt Total ni:/well 
{;<,<:/well-96 hJ (;<~) (;<~) 
Pmientl 
Control 1.33 = 0.04 0.611 = 0.11 2.02 = 0.06 527 = 67 
Octreotide (10 nM) 0.21 = 0.04" 0.34 ± 0.01" 0.5.5 = o.o;;· 29S: 36" 
Vineriatin (10 nM) 0.34 = 0.06" 0 . .27 = 0.03" 0.61 = 0.06" 361 = 7• 
Adriamycin (10 nM) 0.43 = 0.03" 0.49::!: 0.05" 0.92::!: 0.04." 344 = 26" 
Pntient2 
Control 37.0 = 2.5 6.5::!: 0.3 43.5 z Li 169:; = 17 
Octreotidc (10 nM) 8.1 = 1.5" 13.1 :0.2" 21.2::!: 0.9• 1332 = 135 
Vincrllitin (10 nM) 32.0 ± 4.0 3.7 = 0.4" 35.7 :t 3.3 1677 :t 14 
Adriamycin {10 nM) 21.3-;!:: 0.7" 4.8 ... 0.1" 26.1 ... 0.5" 1661 ... G3 
Th<." tumor cells had kt-n preineubat<>d for% h. Thereafte!', th<> effw:ts of the dru)!S w~re inv,.,;til:)lted for another 96 h (mean ± S£M; n = 4 
wc&/group}. 
• P < 0.01 !Is. control. 
• P < 0.05 ~·s. control. 
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Ftc. 3. The relation b<otwoon the &lllltrin content and th<> DNA content 
of the cultured tumor cell~ Pl'<'J>'ll'o><i from tht> primo.ry l:llStrinomn. of 
pati<mt 1 after a 96-h ..xposuno to octreotide (10 nM), vincriatin (10 
nM), and ndriamycin (10 nM; r = 0.84; P< 0.01). 
caused by a unilateral adrenal adenoma, primary hyper-
parathyroidism which was unresolved despite the re-
moval of two parathyroid adenomas {serum calcium at 
present. 3.2 m.mol/L), a glucagonoma in the tail of the 
pancreas {removed), and subsequently, a gastrinomn in 
the corpus of the p<:~ncreas {removed). In addition, she 
had a microprolactinoma. In the past 5 yr her serum 
gastrin levels had slowly increased to 70.000 ng/1. Com-
puted tomogrnphic {CT) scanning of the abdomen and 
repeated ultrnsound examinations did not reveal the 
localization of a metnstasis of the gastrin-secreting tu-
mor. Fifty micrograms of octreotide suppressed gnst::in 
levels for more than 14 h to a low level of 6400 ng/L. 
The increased circulating concentrations of PTH and 
PRL were not affected by octreotide. 
An [1:.-JI]T)'il-octreotide scan {Fig. 4) 2 min after injec-
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tion of the isotope coupled to the somatosta.tin analog -
showed a somatostatin receptor-positive tumor in the 
middle of the abdomen. Subsequently. the liver and 
gnllbladder sta.rted to absorb radioactivity (Fig. 4). The 
pituitary microadenoma and the parathyroid udenoma{s) 
could not be visualized {datu not shown). Reexamination 
of the CT scan and ultrn...wunds showed one single en-
larged lymph node in the hilus of the liver with a diameter 
of 6 em. which was subsequently removed. Pathological 
examinntion showed in the lymph node a metastasis of 
an endocrine pancreatic tumor resembling the primary 
tumor, which had been removed in the past. Immunohis-
tochemistry showed positive staining with antigastrin. 
The tumor-containing lymph node was shown in in citro 
nutoradior;rnphy to contain larg-e numbers of somato-
statin analog-binding sites which were homogeneously 
distributed over the tumor tissue. Competiti.on experi-
ments with membranes prepnred from this tumor showed 
that increasing concentrntions of 204-090 and soma.to-
stntin-28 displaced [12l>I]Tyil-octreotide. while the bio-
logically inactive derivntive somntostatin-28 (1-12) was 
unnble to displace the rad.iolignnd. 
From 8.5 g tumor tissue 250 x 10" tumor cells were 
prepared, which were cultured at a density of 1.5 x lOL 
cell/well. In Table 2, short and long term effects of 
octreotide on hormone release, intracel!ulnr hormone 
content, and DNA content of the tumor cells nre shown. 
In the 4- and 24-h incubations 10 nM octreotide inhibited 
gastrin release by 55% nnd 76%, respectively (Table 2). 
Octreotide (1 ><M) mo..ximally suppressed gnstrin release 
after 8 days by 83%. The intracellular hormone content 
at the end of a 24-h incubation had increased from 
20.3 ± 3.1 >tg/well {control) to 40.2 ± 2.6 to 56.3 ± 3.4 
.,.gjwdl after octreotide at different concentrations. After 
an 8-day exposure to octrcotide the intracellular gastrin 
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F1c:. 4. Th~ [""I]Tyr'-oc:uootide scan in 
pnti~nt 2 with a metw;tasiz\'d li'!St:ri· 
noma. "f·Camcxn picture~ of the abdo-
m<m taken 2. 5. 10. 15. 20. Md 25 min 
after isotope administrntion show a nor-
mal liver and n slowly increa,;ing umount 
of radiooctivity in the ~!bladder. At 2 
min 11 gastrinom~~-contninins;: lymph 
node is vh<ible in the middle of the ab-
domen. 
TAlll.E 2. The dfoctof O<:tn'<>tide on s;:astrin relea.;e and on the gll.l<trin and DNA contents of the cultured tumor oelis of the malignant g8$trinomn 
ofpatient2 
GllEtrin (I'IUwell) DNA after 
4 h {medlum) 24 h (m<><lium) S days {medium) Content 
Sdays (ng/ 
Tow! 
-n> 
Control 1S.3:t 0..3 72.0± 3.6 134.9 ± S-9 6.0 = 0.7 140.9 = 7.8 1146 ±52 
Octrt'Otide (0.1 nM) 9.6 = 0.3• (52) 20.9 ± 1.0" (29) 54.1 :t 4.1" (40) 16.5 = 1..2" 70.6 = 3.6" 1050 ± 3S 
Octreotide (10 nM) 8.2 = 0.4" (45) 17.2:!::0.5"(24) 3S.8 :t 3.1" (29) 17.3 :t 0.7" S6.1: 4.1" 937 :!::" 36 
Octrrotide (1 pM) 7.4- 0.2" (40) 14.5- o.s·~ (20J 23.4. ± 2.6 .... (17) 17.9- 0.9" 41.3- 3.0 .... 964 ... so 
The tumor ~dlo had not been prein~ubatcd. The effects of octreotide wei\' meru<ured for 4 and 24 h and for 8 days (mean :!::" SEM; n - 4 wells/ 
gTOUp). Pe«:entnges are s;:ivcn in parenth<.>S<:&. 
• P < 0.01 ""·controL 
• P < 0.01 u•. octreotide (0.1 nM). 
content was also significantly higher than that in the 
control cells, while the DNA content of the cells had not 
changed (Table 2). In this case there was no significant 
correlution between the intracellular gastrin content and 
the DNA content of the tumor cells. In Tnble 1 the 
effects of octreotide. vincristin. and adriamycin are com-
pared. Octreotide suppressed hormone release more ef-
fectively than both cytostatic drugs. However. octreotide-
mediated inhibition of gastrin release was accompanied 
by an increase in the intracellular hormone content. 
which contrasts with the effects of vincristin and adria-
mycin. 
Thereafter, patient 2 underwent a reexploration of the 
neck in order to remove the remaining parathyroid nde-
noma(s). One adenoma (3 g) was found and removed. 
Postoperatively, serum CD.lcium concentrations normal-
ized (2.38 nmol/L). No somatostatin receptors could be 
detected on this adenoma in the in uitro autoradiogrnphy. 
Dispersion of 0.9 b of the adenoma yielded n single cell 
suspension of 13 x lOG adenoma cells. The cells were 
plated at 10~ cells/well. Basa.l PTH release by these cells 
amounted to 49.1 ± 1.3 ng/well-24 hand was not affected 
by 1 nM. 10 nM. und 1 ~M octreotide (data not shown). 
Patient 2 currently has sli~;htly elevated gastrin levels 
(460 ng/L) and is free of complaints. 
Patient 3 
This 36-yr-old womun developed psychintric symp-
toms over the past 6 months which occurred in ntt.acks. 
She lost consciousness frequently and became aggressive 
afterward. During one incident a serum glucose level of 
1.6 mmol/L was detected with an inappropriately ele-
vated plasma insulin concentration of 136 pmol/L. 
A tumor with a diameter of 2 em was detected in the 
head of the pancreas at D..rt.eriography. The administra-
tion of 50 ~g octreotide. sc, suppressed fasting glucose 
levels from 2. 7 to 2.4 mmo!JL, without ultering circulat-
ing insulin levels, which varied between 129-180 pmolj 
L. However. serum GH levels were suppressed for 2 h 
from 5.6 J.JrJL to less than 1 J.Jb!L- The patient did not 
experience side-effects after the administration of oc-
treotide. An ['Z"li]Tyi'-octreotide scan did not reveal 
evidence for the presence of a somatostatin receptor-
positive tumor in the region of the pancreas or elsewhere 
(dnta not shown). At lap:::rotomy a 2-cm. adenoma was 
removed from the pancreas. Postoperatively this patient 
was well and did not experience hypoglycemic attacks in 
the follow-up period of 8 months. 
Pathological examinntion revealed an endocrine pan-
creatic tumor which stained only with insulin in the 
immunohistochemical examination. In uitro autorndios-
raphy showed that the tumor had a low density of so-
matosw.tin analog [ 1 ~''I]Tyr"-octreotide-binding sites. 
Only pnrt of the tumor sample showed n low density of 
Tyr"-octreotide receptors. whereas the major part was 
devoid of them. Interestingly however, a very high den-
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sity of [l~I]Tyr11 -somatostatin-14-binding sites was 
found homogeneously distributed over the whole tumor 
sample in an adjacent section. From 0.8 g udenoma tissue 
13.5 x 10" dispersed tumor cells were prepared. These 
were plated at a density of 5 x 10• cells/well. In addition, 
0.8 g surrounding normal pancreatic tissue were dis-
per~d. This resulted in a total of 1 x 10~ cells, which 
were also plated at a density of 5 x 104 cells/welL The 
effects of octreotide, somatostatin-14, and somatostatin-
28 on basal hormone release by the cultured insulinoma 
cells showed that octreotide did not suppress, while both 
10 and 500 nM somatostatin-14 and -28 effectively sup-
pressed tumorous insulin release effectively in a similar 
fnshion by about 50%. Interestingly, insulin release from 
the cells prepared from the normal surrounding po.n-
creutic tissue was effectively suppressed by octreotide as 
well as by somatostatin-14 and -28. 
Patiem4 
This 46-yr-old woman was referred to us 5 yr ago 
because of an infiltrating carcinoma of the pancrens. At 
laparotomy a 12 X 14-cm infiltrating tumor was found 
in the head of the pancreas, with several local metastases 
in lymph nodes. The surgeon (H.A.B.) was struck by the 
strange texture of the tumor. and pathological examina-
tion during operation of a tumor-containing lymph node 
was suggestive of apudoma. Therefore, a 'Whipple pro-
cedure was carried out, removing the complete pnncreas 
and leaving several deposits of tumor infiltration in the 
surrounding tissue in situ. After 5 yr the patient is well 
and virtually without complaints. Retrospectively, she 
was known to have mild type II diabetes mellitus, which 
was well controlled with a sugar-free diet, and periods of 
loose stools. while asymptomatic gall stones were 
present. 
Part of the tumor was dispersed and a total of 900 x 
lOa tumor cells were plated at 106 cells/well. The tumor 
cells secreted 18 :::!::: 2 ng somatostatin/well· 24 h: 5 mM 
dibutyryl c.'\.i.\1P stimulated hormone release to 33 ± 2 
ng (P < O.Olvs. control). while 3 mM calcium stimulated 
hormone release to 27 ± 2 ng (P < 0.05 vs. control). Low 
concentrations of 1 and 10 nM octreotide did not sup-
press, but 100 n.M octreotide effectively suppressed so-
matostatin release by these tumor cells by iS% (P< 0.01 
vs. control; Table 3). 
It was decided to ask the patient to undergo a soma-
tostatin analog scun 5 yr after operation. This scan 
revealed the presence of somatostatin receptor-positive 
tumor tissue in the liver hilus. the peritoneum. a lymph 
node on the left side of the neck, and tv.'O ribs. Because 
the patient is asymptomatic. it was decided not to treat 
her at present. 
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T"su: 3. SomatOKtntin ""!~"""by th~ cultun:d tumor cdl~ pn-par..d 
!rom th<· ~ndocrin~ pancroutic tumor of !><'ti<•nt 4 
Control 
Oetreotide (1 nMJ 
Oetrootide (10 nM) 
Oetrootide (100 nMJ 
Somuto,tutin 
(nJUwdl-24 hJ 
17.9 = 0.7 
1~.8 ± OA 
H.7:0.3 
3.l .... OA" 
Incubation time w1111 24 h. Values nre the mean ± SEM; four wdh; 
P<"r group. Th<- •tud.i<':l w.-n: carried OUt on dny 4 of eultur~. 
• P < 0.01 vs. control. 
Patient 5 
This 64-yr-old man underwent laparotomy 5 yr ago. 
At operation a carcinoma (12 x 17 em} was found in the 
heud of the pancreas which infiltrated into the surround-
ing tissue. It was decided that this tumor was inoperable. 
Pathological examination of a biopsy showed an undif-
ferentiated curcinoma. No specific ·treatment seemed 
available for the patient, and only palliative therapy 
directed to alleviate pain was given. Over the next 5 yr, 
however, no obvious deterioration of the clinical condi-
tion occurred, althou~;h the pain in the abdomen was 
often excruciating requiring opiate drugs. 
Because of the discrepancy between the actual clinical 
course and what had been expected. this patient under-
went an [ 12~I]Tyr1-octreotide scan. Immediately after 
injection of the isotope lab-eled to the somatostatin ana-
log a tumor was visualized in the region of the bend of 
the pancreas. In Fig. SA, the picture after 25 min is 
shown: both the liver and gnllbladder can be clearly seen, 
as well as the spleen nnd. in the center, the tumor. The 
tumor remained visible 48 h after isotope ad.ministrution. 
In Fig. SB it is seen that a somatostatin receptor-positive 
tumor is also present on the left side of the neck. A 
needle biopsy in this just palpable, slightly enlarged 
lymph node in the neck revealed an undifferentiated 
carcinoma which was histologically similar to that found 
5 yr previously. Funher examinations proved that both 
tumor deposits were in fact apudomas (chromogranin 
positive and Grimelius positive}. but immunohisto-
chemistry was negative for 6 endocrine pancreatic hor-
mones. Funher clinical examination of the patient did 
also not reveal signs of symptoms of hypersecretion of 
hormones. This putient wus treated thereafter with oc-
treotide (three doses of 100 !J.g/day, sc). This resulted in 
a considerable decrease in pain, enabling a decrease in 
the use of opiate drugs. After 6 months of therapy, 
reevaluation of tumor size by CT scanning did not reveal 
a change in the size of the pnncreatic tumor. 
Discussion 
With the exception of insulinomas. most endocrine 
pancreatic tumors are malignant and have already 
metastasized at the time of diagnosi,;; ( 1. ZJ. SutJ;ery is 
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FJc. 5. A. the ["'I]Tyr"1-octieotide "can 
in patient G, 25 min alter ~wtcp!: admin· 
i5trntion. The normal liver. the gallbfad-
d<>T, the bilc dueu;, and a normal spl<.'t'n 
are visible "" well as a som~to><tatin r<>· 
eeptor·posi.tive tumor ln the region of 
the he11d of the J>11IlCrca~ B, ..,.Cnmcrn 
picture of the head of the Ml.me pati-ent 
90 min after i•otope admini•tration. 
:-Jote the som:.>.to~tatin reccptor-positiw 
lymph node on the ldt side of the neek. 
generally considered to be the prim::..ry treatment, but 
debulking of the tumor is often the only option when 
metastases are discovered during operation (2). P::..lliative 
treatment with cytostntic drugs and/or interferon and 
hepatic arterial embolization have been shown to be of 
temporary benefit in varying numbers of patients (3-5). 
Octreotide effectively controls the clinical syndromes 
related to hypersecretion of hormones by these tumors; 
invalidatinr; diarrhea, dehydration and hypokalemia, 
peptic ulceration, life-threateninr; attacks of hypoglyce-
mia, and necrolytic skin lesions were reported to improve 
during chronic therapy with 100-600 J.l.f; octreotide daily 
in most patients (6-15). In parallel. we previously showed 
that 10 of 14 hormone-producinr; endocrine pancrentic 
tumors contained large numbers of high affinity binding 
sites for the somatostatin analog e"~I]Tyr3-octreotide 
(16). In the present study we extended in both gastri-
noma patients the concept of a close relation between 
the inhibitory effects of octreotide on hormone secretion 
by this type of tumor in oioo nnd the presence of high 
numbers of high affinity somatostntin analog-bindinr; 
sites on the tumor tissue in vitro. In the insulinoma 
patient, however. no suppressive effect of octreotide on 
tumorous insulin release was noted, while serum glucose 
levels even slightly decreased further in response to the 
drug. In parallel, several in vitro investigations under-
lined the virtual absence of somatostatin analog- recep-
tors on this tumor and the insensitivity of the cultured 
tumor cells to the analog-. 
The in vitro studies carried out with the cultured cells 
prepared from the two patients harboring a gastrinoma 
and the patient with the somatostntinoma might aid in 
understnnding the mechanism of action of octreotide on 
endocrine poncreatic tumors. Octreotide directly inhib-
ited hormone release by the cultured gostrinomo cells in 
a do:;e- nnd time-dependent fashion. In a 24-h incubation 
the maximal inhibitor::.: concentrn.tions of the dru:: ran::ed 
toO.l-10 nM. Apart from an inhibitory effect on hormone 
secretion, the total amount of gastrin (as reflected by the 
amount of hormone releused plus the intercellulru: con-
tent) was suppressed by the exposure to octreotide. It is 
interesting to note that somatostatin release by the tu-
mo:: cells prepared from the tumor of patient 4 was also 
inhibited during incubation with octreotide, albeit at a 
higher concentration of 100 nM. This suggests that in 
this particular tumor basal hormone release was il.lready 
under the influence of an autocrine-mediated inhibitory 
control of somatostatin, requiring a higher exogenous 
concentration of somatostatin analog to further suppress 
hormone release. 
Somatostatin nnalogs hnve been shown to suppress 
tumor growth in some patients with endocrine pancreatic 
tumors. Maton (15) recently summarized the literature 
concerning the possible effects on tumor size of chronic 
octreotide therapy in 46 patients with malignant endo-
crine pancreatic tumors. These pntients received between 
200-1500 J.l.g octreotide/day for over 2 months; the size 
of the metastases increased during therapy in 20 (44 %), 
remained unchanged in 18 (39%). and decreased in 8 
(17%) patients. Reduction of tumor size was noted in 3 
patients with gastrinoma, 3 with a VIPoma, and 1 with 
a GH-releasing hormone-producing tumor. Our study 
shows a antiproliferotive effect of octreotide on the cui· 
tured cells prepared from the tumor of patient 1. The 
mechanism of action of octreotidc on hormone relea.<;e 
and hormone synthesis by these tumor cells seemed to 
differ from that of the cytostatic compounds vincristin 
and adriamycin, in that octreotide more potently inhib-
ited hormone releuse. The absence of an antiproliferative 
effect of octreotide and the two cytostatic drugs on the 
cultured tumor cells of patient 2 might reflect the slow 
~;towth of this tumor; one tumor-containing lymph node 
wus found 7 yr after removal of the primary tumor. 
Probably, the cells of this tumor did not grow in culture, 
also explaining the absence of an effect of vincristin and 
udriamycin. The clinical hi:;;tory of patient I suggested 
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rapid tumor growth in the period preceding the operation. 
Our studies might, therefore, explain in part the often 
rather unconvincing observations of tumor growth inhib-
itory effects of octreotide in patients with met<l!>tatic 
endocrine pancreatic tumors. Most of these tumors are 
{very) slow P"Owing cancers, and possible tumor growth 
inhibitory effects of octreotidc in this category of patients 
might only be detected during extensive long term pro-
spective placebo-controlled trials. 
A new aspect of our present study is the application of 
the technique of in uiuo imaging of somatostatin recep-
tor-positive tumors {li). In this technique [':::tl]-labeled 
Tyi'-octreotide, a somutostatin analog similar to octreo-
tide in its biological actions, is injected iv. It is an easy. 
relatively cheap, and harmless technique. which in four 
of the five patients with endocrine pancreutic tumors 
investigated visualized both the primury and. in three 
cases (patients 1. 4, and 5). previously unknown meta:>· 
tases. There was a close relationship between the in Vitro 
detection of somatostatin receptors in the tumors using 
autoradiography and the -y-camera pictures obtained 
after injection of [':::tl]Tyi'-octreotide. This indicates, 
therefore. that the ligand binding to the tumor in uiuo 
indeed represents binding to specific somatostatin recep-
tors. Furthermore, the close correlation between the 
presence of somatostatin receptors on tumors and the in 
uivo or in vitro 'effects of octreotide on hormonnl release 
from these tumors clearly indicates that these receptors 
are functional. This indeed points to a high specificity of 
this new technique of tumor imaging. It is presently not 
known how sensitive this technique is in the detection 
of very smull endocrine pancreatic tumors. Nevertheless, 
we already know that curcinoids can be visualized even 
when less than 1 em in diameter. Our data showing that 
metastases of these tumors often retain a similar number 
and affinity of somatostatin receptors as the primary 
tumors are of importance with regard to both the future 
role of the in uiuo imug:ing technique and therapy with 
octreotide. In the scanning procedure a small amount of 
Tyi'-octreotide (<10 ,ug) is injected iv. Therefore, this 
scanning might ben safe alternative to in ~·iuo octreotide 
administration in the selection of insulinoma patients 
for chronic treatment with the drug. 
There is a wide variation in the clinical presentation 
of endocrine pancreatic tumors in man. Most tumors 
present with signs and symptoms related to the hormonal 
hypersecretion from these tumors, but less frequently 
symptomatology is related to the tumor mass itself (2). 
In these latter cases the often undifferentiated tumors 
do not secrete considerable amounts of biologically active 
hormones, or the clinicul syndrome is rather inconspic-
uous (1-3, 27). The five patients described in our study 
seem to represent this spectrum of clinical presentation 
well. as patients 1-3 presented with signs and symptoms 
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related to hypersecretion of go.strin and/or insulin, while 
in patients 4 and 5 the tumors had been detected only 
by signs and symptoms related to the local infiltration 
of tumor in the surrounding tissue. Interestingly, the 
clinical symptomatology of patient 4 with a somatosta-
tinoma (mild diabetes mellitus. gallstones, and loose 
stools) bud not been recognized before the operution, 
while the actuul diagnosis in patient 5 was made only 5 
yr after the operation. In this category of patients espe-
cially the use of the [':::ti]Tyr''-octreotide scan might be 
successfuL We previously showed that exocrine adeno-
carcinomas of the pancreas do not contain somatostatin 
receptors (28). In none of three patients with ductal 
adenocarcinomas of the pancreas were the tumor or its 
metastases visualized with the somatostatin analog scan 
(data not shown). The use of this visualization method 
of somatostatin receptor-positive tumors might gain a 
place in the differential diagnosis of ductal adenocurci-
nomas and undifferentiated endocrine pancreatic can-
cers, especially among the smull group of long term 
survivors with the former diagnosis. 
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SOMATOSTATIN~RECEPTOR IMAGING IN THE LOCALIZATION OF ENDOCRINE TUMORS 
S.WJ. LAMBERTS. \1\:.H. BAKKER,J.-C. REUB!, AND E.P. KRENNlNG 
Abstract Background and Methods. A number of dif-
ferent tumors have receptors for somatostatin. We eval-
uated the efficacy of scanning with 1231-labeled Tyr3-
octreotide, a somatostatin analogue, for tumor localization 
in 42 ·patients with carcinoid tumors, pancreatic endo-
crine tumors, or paragangliomas. We then evaluated 
the response to octreotide therapy in some of these 
patients. 
Results. Primary tumors or metastases, often pre. 
viously unrecognized, were visualized in 12 of 13 patients 
with carci:lold tumors and in 7 of 9 patients with pancreatic 
endocrine tumors. The endocrine symptoms of these pa-
T ARGE numbers of high-::Jfinity som:ltostatin bind-
L ing sites have been found on most pancreatic en-
docrine tumors and carcinoid rumors. 1-" In the major-
ity of ·patients with such tumors, long-term therapy 
with octreotide successfully controls clinical symp-
toms, .apparently through the somatostatin receptor-
mediated inhibition of hormone rdease.~7 
YVe recentlv described the visualization of such tu-
mors in vivo ;fter the intravenous :J.dministration of a 
somatostatin analogue bbded with iodine-123.3 In 
this study we describe the results of this scanning pro-
cedure in 42 p;"J.tients with known endocrine tumors. 
METiiODS 
Patients 
We >tudied 13 p.niem' ""ith metd.,tdtie c..rcinoid di~ease (9 men 
and .J. ""omen: medn -"~e, 61 Y~"-"' [ran'-'"• 2'1 to 78]). All13 patients 
had histologic..lly confirmed metastatic cardnoid disease. In seven 
patients the prim:u-y c.;u·cinoid tu.mor, which W3.5 in the gut in all 
seven, had been removed. The re.ults of the scannin!-": procedure in 
one of th~e patients have been deseribed elsev.·here." In addition, 
we studied nine patients with panereatie endocrine tumors (four 
men and five women; mean age, 62 years [range, 'IS to 81]). In 
ail nine patients the diaf:11osls W:l.'l histologically confirmed after 
the removal or the primary tumor; in seven of them preoperative 
hormonal examinations suggested the presenee of the tumor. In 
both the patients witl1 metastdtic careinoid di>ease and those with 
p;lncreatic endocrine tumors, the spread of the disease had been in-
vestigated by CT scanning of the ;obdomcn and uhr:l.'l<>nography. In 
five of the patient:> the results of >cannin~; ,.,•ith 'ZJJ-Iabeled 
Tyr1-octreotide have been de>cribed ebewhere."1' Twenty patients 
with pat<l.ganr:liom"" (10 men and 10 women; mean age, 51 years 
[r'"'nf:c, 16 to 83]) were also studied. In all of them the presence of 
<l.t least one p;~ragangliom;~. '''"-' Sll>~t~d, bec::tuse <lf earlier arte-
riogr4phy. All the pati~ot> g;,vc informed consent to participate in 
the study, whieh wa~ approved by the ethics committee of our 
hO>.pital. 
Materials 
11te ,om."HO>.tatin :.nalrn;uc:. octreotide (Sando:.tatin. SMS 201-
995) and Tyr''-octreodde (204-090) were obtained from Sandoz (Ba-
From the Dcranmcnt' of Modocone (S.W.J.L.. E.P.K.J .,d Nud.,.,. M"docone 
(W.H.e., E.P.K.J. £ru,mu' Un•ve"''Y· R<>nordom. the Netherland•; and S..ndoz 
Re...,~reh ln"nute. Scm. Swi~'crl~nd (L·C.R.). Addr"'-' ropnnt O"eG"""~' to Dr. 
Umbert' at the DcP"f!ment of Mcd•c•ne. L:nm:n.ny H"'pnlll DijkzoJ:t. 40 
Molcwuterplom. 3015 GD Ron<:r(!am. the Notherlllll<h. 
Supported by f:l'l"" from the Dutch Cancer Foundoltion .,d a >pc<:olll grant 
from the Untvet"hlt}" H"'piul D•jkzij!t. R~nc:rdam 
tients responded well to therapy with octreotide. Among 
20 patients with paragangliomas, 8 of whom had more 
than one tumor. 10 temporal (tympanic or jugular). 9 carot-
id, and 10 vagal tumors could be visualized. One small 
tympanic tumor and one small carotid tumor were not seen 
or. the scan. 
Conclusions. The 123!-labeled Tyr-3-octreotide scan· 
ning technique is a rapid and safe procedure for the visual-
ization of some tumors with somatostatin receptors. A 
posltlve scan may predict the ability of octreotide therapy 
to control symptoms of hormonal hypersecretion. (N Eng! 
J Med 1990; 323:1246-9.) 
sel, Swio:erland). The Tyrl-oareotide was. Jabded with 12li with 
use of chloramine-T. 10 As a final prepMatory step the radiopharma-
ceutical <l.gent was p=ed throuf:h a low prot,in-binding 0.22-.,.m 
Millex-GV filter (Millipore. Milford. M;r.ss..) in order to sterili~e it. 
Depending on the results of the 14beling proczdure, the interval 
betv>·een injection and scintigraphy. and whether sinr:le-photon· 
emission CT (SPECT} was abo performed, the doses of IZIJ.J...bded 
Ty,.3-oetreotide ranged from 37 to 555 MBq, given a.s a bolus intra· 
venous injeetion." There were no side effects of the <l.dministration 
of l:i:IJ-Iabeled Ty,.3-octreotide. 
Scanning 
Planar and SPECT images were obta.ined with " 14rge-fidd-of· 
,·iew gamma camera (Counterbalance 3700, Siemens G<l.mma!lon-
ic.'. Erlangen, Germany) equipped with a 190-KcV par<l.lld-hole 
co!lim<l.tor. Generally, the field of view when the T~-octreotide 
W:l.!o injected covered the <l.bdomen and some of the thorax. Suning 
at the time of the injection, digital images were recorded with " 
Gamma-Il computer (Nuclear Diagnostics, Upps.al4, Sweden) ev· 
ery 3 seconds for 2 minutes, then every 60 seconds for28 minutes. In 
this 30·minute period <l.na.logue images were alw obtained regular· 
ly. Thin:y minutes afterthe injection, the patients underwent =teri-
or <l.lld posterior whole-body static scintigraphy =d, if indicated. 
SPECT. Static imag.:s, both <l.lla.logue and digital. wen: obtdined 
about 30 minut~ <l.lld 2, -4, 24, =d sometimes 48 hours aSter injec· 
tion. Subtraction scintigraphy with albumin microeoll<lid labeled 
with technetium-99m (56 MBq; Albu-Res. Solco, Birsfelden. Swit· 
zerl<l.lld) wa.s performed in normal liver tissue. 
We used a simple yes-or-no system to define the tumors as visual-
ized during this scanning procedure, but always at a time when the 
surrounding organs were vinually devoid of radioactivity. Depend· 
ing on the type and location of the tumor we chose different stand-
ard times and techniques of visualization. The bes.t time for obtain-
ing optimal gamma-camera piCtures, as well as SPECT scans, is 
discussed below. 
lill;ULn 
Patients w[th Carcinoid Tumors 
Among the patients with metasta.tic carcinoid dis-
ease, I 0 had undergone surgery :md in 7 the primary 
carcinoid tumor iud been removed. In the six whose 
primary carcinoid tumors had not been removed, the 
tumor was visualized; in all six the primary tumor was 
located in the small intestine. In II of the 13 patients 
liver metastases were detected; in 1 patient only peri-
toneal metastases were visualized, and in I no uptake 
of l:::lJ-labeled Tyil-octreotide was seen. The best 
gamma-camera. pictures showing the metastases were 
obtained within 2 minutes after the injection of the 
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isotope (when normal Ever tissue had not yet been 
ful!y visualized) or after 2+ to 48 hours (when the 
normal liver, gallbbddcr, and bile ducts no longer 
contained appreciable amounts of radioactivity). The 
JZJI-labelcd Tvil-octreotidc liver scan and the 'l?rnTc-
labded colloid scan of one of these patients arc shown 
in Figures lA and I B. The tumor tissue visualized in 
the Tyil-octreotide scan was localized mainly in the 
right lobe of the liver (Fig. !.-\), whereas the ""mTc-
labeled colloid was localized mainlv in the left lobe 
(Fig. !B). The two scans show a grea.tly enlarged liver. 
Extrahepatic metastases (Fig. IC} were found in 
lymph nodes on the left side of the neck in seven 
patients, and in bone (ribs, vertebrae, skull, or pelvis) 
in eight: in five there was evidence of peritoneal or 
intraabdominal metast:J.ses (or both). None of the 
13 patients were known on the basis of symptoms, 
physical examination, or other imaging studies to 
have such extensive disease. In particular, the lymph 
nodes containing tumor in the left side of the neck 
had been detected on physical examination in only 
two of the patients who had abnormal scans in this 
region, but they were palpated in three other patients 
after the results of the Tvil-octreotide scan were 
known. In the first four pati~nts studied, the presence 
of carcinoid-tumor tissue in the lymph nodes in 
the neck, liver, or both and in the peritoneum was 
confirmed by needle biopsy. The one patient with 
no abnormalitY on the Tvr'-octreotide scan had ex-
tensive carcin~id tumor i'u the liver, abdomen, and 
thora..x. 
All 13 patients were subsequently treated with oc-
treotide, given subcutaneously in divided doses vary-
ing from 150 to 600 (J.g per day. In 10 of the 1 I pa-
tients who had episodes of flushing, the number per 
A B 
day decreased by 50 percent or more: in 8 of the 9 who 
had diarrhea, it decreased by 50 percent or more: :1.nd 
in all4 with abdominal or bone pain (or both) thC' p<~.in 
virtually disappeared. After three days of octreotide 
therapy, urinary excretion of 5-hydro:-:yindoleacetic 
acid decreased by 22 to 85 percent (mean, 36) in the 
six patients in whom it w:ts measured. The patient 
whose carcinoid tumor was not visualized with 1 ! 1 J-
labeled Tyil-octreotide had no decrease in flushing 
episodes and diarrhea during two weeks of therapy 
with octreotide in doses of up to 1500 (J.g per day. 
Patients with Pancreatic Endocrine Tumors 
In seven patients with pancreatic endocrine tumors, 
the primary tumors were visualized after the injection 
of 11li-labeled Tyr'-octreotide. Three patients had 
gastrinomas, two insulinomas, one a somatostatino-
ma, and one an undifferentiated endocrine pancreatic 
tumor. The size of the primary tumors in these pa-
tients ranged from 2 to 14 em in diameter. Metastases 
were visualized in four of the seven patients. In none 
of these four patients had the metastases (in lymph 
nodes in the neck in two, bone in one, and liver in two) 
been detected earlier. In five patients a single subcuta-
neous dose of 50 (J.g of octreotide substantially de-
creased the secretion of hormone bv the tumor from 
two to six hours after administrati~n. In the patient 
with an undifferentiated endocrine pancreatic tumor 
in whom no hormonal hypersecretion was detected, 
long-term therapy with octreotidc (300 !J.g a day for 
six months) resulted in a decrease in upper abdominal 
pain, but no change in tumor size as evaluated by 
CT scanning. In four of the patients with positi\·e 
scans, in vitro autoradiography confirmed the pres-
ence of large numbers of high-affinity I~JI-labeled 
c 
Figure 1. Primary Tumor and Metastases in a Patient with Metastatic Carcinoid Disease. 
Panel A shows a gamma-camera picture of the liver 24 hours after the administration of 123i-labeled Tr-octreottde. Note the tumor 
deposJts positive for somatosta~n receptors, mainly in the right lobe of the liver. Panel B shows a '1'l"'Tc-labeled colloid scan of the liver in 
the same patient 20 minutes after injection. Most of the lett lobe appears Intact, whereas the liver tissue contaming tumor Is not 
visualized. Note the enlargement of the liver in both scans. Panel C shows carcinoid metastases m a supraclavicular lymph node on the 
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lett side {SC), in the retromedlastlnum {AM), and in the pleura {P) 30 minutes atter the admiOIStration of 
ml-labeled Tyr-3-octreotlde (anterior view) (x2). 
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Tyr:!-octreotide binding sites. In two p~tients the tu· 
mors were not visu~lized ~fter the administr::uion of 
Tyi!-octreotide. Both patients had o.n insulinomo.. and 
neither tumor bound any ~~~1-labded Tyi!-octreotide 
in vitro. 
Patients with P:.rogangliomas 
In all 20 patients with par~g~ngliomas. the tumors 
were visualized after the administration of 1 ~31-labeled 
Tyi!-octreotide. Ten of the II temporal tumors (tym-
panic or jugular). 9 of the 10 carotid tumors, and all 
10 vagal tumors were visualized (Fig. 2). Two tumors 
were not visualized in these 20 patients: one patient 
had a small (Jess than 5 mm) tympanic-nerve para-
ganglioma. and another patient h~d a small (3 mm) 
carotid tumor. Eight patients h~d more than one tu-
mor deposit. The smallest tumors visu~lized were 
about I em in diameter. The specificity of our findings 
was confirmed by path~logic.J.l examination of the tu-
mors in 15 patients and by arteriography. CT, or both 
·"in the other 5. 
DISCUSSION 
Octrt'otide is currently used to treat patients with 
mct~st:.ttic c:.~rcinoid and pancreatic endocrine tu-
mors.""' hs ~dministr~tion results in a rem:.trb.ble im-
pro\"emcnt in the clinical c-ondition of most p:.ttients, 
mainly through the suppression of hormonal hyperse-
cretion. \\"e have previously found that most such tu· 
mors, especially those in patients with a good response 
to octreotide therapy, contain large numbers of oc-
treotide receptors. 1"4 The rdatiYe affinity of the so-
Figure 2. Gamma-Camera Picture Four Hours after the Adminis-
tration of mi-Labeled Tyr'-Octreotide In a Patient with Multiple 
Paragangliomas. Showing Bilateral Carotid Paragangliomas and 
One Vagal Paraganglioma (Antcr1or V1ew). 
matostatin receptors on most human tumors for natu-
ral somatostatin-14, its precursor somatostatin-28, 
and Tvil-octreotide v~ries: in most instances the affin-
ity for,Tyfl-octreotide is slightly higher than that for 
somatostatin-14 or somatostatin-28. 1•3 
In 12 of 13 patients with metastatic carcinoid dis· 
ease and in 7 of 9 patients with pancreatic endocrine 
tumors, the in vivo i=ging procedure using 1231-la-
beled T yi!-octrcotide provided information concern-
ing the localization of the primary tumors, the second-
ary spread of the disease, or both. Virtu~lly all the 
patients had previously undetected metastases. The 
identification of tumor tissue in lymph nodes on the 
left side of the neck in seven patients with carcinoid 
tumors and two with endocrine pancreatic tumors un-
derlines the value of a thorough examination in such 
patients. In one patient with carcinoid disease in 
whom the scan was negative, long-term octreotide 
therapy had no beneficial clinical effect, suggesting 
that the patient's tumor had no receptors. Similarly, 
no receptors could be detected on the insulinoma tis· 
sue o~ the two patients in whom the in vivo scan was 
negauve. 
The 1231-la.beled Tyil-octreotide imaging technique 
was also used successfully in the localization of para· 
gangliomas. Such tumors are often difficult to localize, 
and in most patients arteriography is necessary to con-
firm the diagnosis. 11 ·12 Of considerable importance 
was the localization of multiple paragangliomas in 
eight patients. 
VVe found that tumors in the abdomen were well 
visualized within 30 minutes after the administration 
of the isotope, before the surrounding background ac· 
tivity in the liver, biliary tract, and gastrointestinal 
tract was so considerable that it became difficult to 
distinguish between tumor and physiologic uptake. 
Additional scans were possible 24 hours later, when 
the organs again contained little radioactivity. SPECT 
proved to be of great value in localizing the site of 
Tyi!-octreotide uptake in tumors, especially when the 
tumo!"S were located close to sites with physiologic 
uptake of r:.tdio:.tctivity. Tumors positive for somato-
statin receptors in the chest, neck. and skull, however, 
can be readily visualized at any time 30 to 240 min· 
utes after the administration of the isotope because 
the background level of radioacti-..1ty is vel)' low by 
that time. 
We did not correlate the degree of radionuclide up-
take in these tumors with the extent of the biochemical 
response or the clinical responsiveness to short-term 
or long-term octreotide. Uptake of 1231-labelcd Tyil-
octreotide was found, however, in all tumors with 
a clinical or biochemical response to a single dose 
of octreotide or to long-term administration. Thus, 
1 ~'1-labeled Tyil-octreotide imaging may be useful in 
predicting responsiveness to octreotide therapy. 
We conclude that 1:r.ll-labeled Tyi!-octreotide imag-
ing is a quick and safe way to identify tumors that have 
somatostatin receptors, and tumors as small as I em in 
diameter (e.g., paragangliomas) can be detected. We 
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found this technique to be v::du;;r.ble in locating not 
only primary but also secondary deposits of these tu-
mors. which mo.y be very difficult to loco.lize with cur-
rent diagnostic techniques. Although these results are 
encouraging. the sensitivity and specificity of this 
scanning procedure in the localizo.tion of such tumors 
must be confirmed by studies of larger numbers of 
patients. 
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Treatment With Sandostatin and In Vivo Localization of Tumors 
With Radiolabeled Somatostatin Analogs 
Steven W.J. Lamben:s, Willem H. Bakker, Jean-Claude Reubi, and Erik P. Krenning 
The presenee of high numbe.-s of somatostatin receptors seems to be the basis for the successful eontrol by Sl.lndosta'tin"' of 
hormonal hypersecre-tion by mos:t growth hormone-secreting pituitary adenomas. endocrine pancreatic tumors. and careinoids. 
In this report,. we present preliminary data on in vivo somatostatin receptor imaging with a ':oH;oupled soma~ostatin analog {204-
090) in patients with these types of tumors. 
~ 1990 by W.B. Saunders Ccmlpany. 
SOMATOSTATIN is a regulatory hormone or tissue fuctor that plays an inhibitory role in the normal regulation 
of several organ systems., including the central ner.<ous system. 
the hypothalamus and the pituit::uy gland. the gastrointestinal 
tr:!ct, and the e::<:ocrine and endocrine pancreas. 1"3 Recently, 
Sando"statin became available for routine clinical use: it is a 
somatostatin analog that Ius sever::l.! cha.r.lcteristics different 
from native somatostatin: (I) it inhibits growth hormone 
(GH) preferentially over insulin; (2) it has a longer half-life 
in the circubtion, causing a prolonged inhibitory effect in 
Urget organs of somatostatin; (3) it is active after subcuu-
neous administrntion: and (4) administrntion ofSandostatin 
is not followed by rebound hypersecretion of hormones (see 
ref 4). 
Somatostatin receptors remain present on a variety of tu-
mor.> that arise in tissues that also contain these receptors in 
the normal state. High numbers. of somatostatin receptors 
have been found on GH-secreting pituitary tumors. and on 
most metastatic endocrine pancreatic tumors and carei-
noids.~7 Sandostatin treatment normalizes clinical symp-
tomatology in mos. acromegalic patients. while GH hyperse-
cretion and elevated circulating insulin·like growth factor type 
1 (IGF-1) levels are well controlled.~ Hormonal hypersecre-
tion from endocrine pancreatic tumors and carcinoids is also 
suppressed during Sandosutin therapy in mos. patients."·'0 
This results in rapid improvement in the quality oflife. while 
preliminary evidence of control of tumor growth Ius been · 
presented (see ref 4). 
It was remarkable that in vitro autoradiographic studies 
ofth= tumors vinually always revealed very high densities 
of somatostatin binding sites. which comr.lSted relatively 
sharply to those found on the surrounding -normal- tissue.•·' 
The presence of higher numbers of somatostatin r=Ptors 
on many ofth= tumors was also reflected by the observ.ltion 
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that one single subcuuneous administrntion of 50 to 100 JJ.g 
Sandastatin suppressed tumorous hormone secretion (ie. in 
acromegalic or gasuinoma patients) much longer than normal 
hormone secretion.8 
Th= considerations led us to explore whether it might be 
possible to detect somatostatin receptor positive tumor.> in 
vivo by the administration of a radioactive iodine-labeled 
analog.' 1 204-090 is a Sandostatin analog with tyrosine in 
position 3, substituting for phenylalanine. The biological ac-
tivities of Sandostatin and 204-090 are similar. 1:c:Jl-bound 
204-090 (37-555 mBq) was injected intravenously (IV) in 
p.:ltients who were suspected to have somatosutin-receptor 
positive tumors. and planar or emission computed tomog-
raphy {ECT) images were made with a g.amma camera. After 
the bolus injection of radioiodinated 204-090. rapid accu-
mulation ofradiroctivity was seen in the liver. Approximately 
50% of the activity was cleared from the bloodpool within 2 
minutes after IV injection. Localization of the primary tumors 
and their (previously often unknown) metastases with radio-
iodinated 204-090 was possible in five of six endocrine p;ln-
creatic tumors (the sixth patient had a 204-090 receptor-neg-
ative insulinoma) and in 12 of 12 patients with metastatic 
carcinoid disease. The detection of metastases in lymph nodes. 
bone, .and liver points to'-"':lrd the powerful discriminating 
ability of this technique. It also confirms previous in vitro 
observations that showed that metastases ofsommosutin re-
ceptor-positive tumors remain rceeptor-positive.e The ob-
served accumulation ofr.tdionuclide at the site of the tumor 
after IV injection appears to be instanuncous and prolonged. 
in contraSt to the bloodpool activity, which rapidly decreases. 
In Figs lA-D, the dynamics of this in vivo somatostatin 
receptor imaging technique in one of our patients with a 
metastatic carcinoid can be clearly seen. In Fig JA, both the 
heart {top) and the Jlver are visualized 2 minutes after isotope 
administration, while a dense metastasis is visible in the lower 
margin of the liver. After 30 minutes (Fig 18). radioactivity 
has disappeared from the heart, while more somatosutin re-
ceptor-positive metastases are visible now throughout the 
liver. In addition. the spleen is visualized. Note that the huge 
metastasis in the right upper part of the liver is not homo-
geneous: this is caused by central necrosis within this metas-
tasis. In Fig JC. the liver of this patient is just visible after 
21 hours., while the som::ttostatin receptor-positive carcinoid 
Mer:;l)()hsm. Vol39. No 9, Suppl2 (5<:>P1ember). 1990: pp 152-155 
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Fig 1. The dynamics of somatostatin r~eptor imaging in a P<>ti<mt with m<.'tasta'tic carcinoid syndrome. Gamma-camera pict,.res. (A) 
2 minllte ... (B) 30 min,.tes. (C) 21 ho"'""· and (0) 40 ho"'rs after ':'1-204·090 administration. 
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mt:tastascs remain positive even up till 40 houn after ad-
ministr.ltion of the t:JJ-::!04-090 (Fig I D). Whole-body scan-
ning of this carcinoid patic:nt also revealed a somatostatin 
rec:eptor-positive metastasis in a lymph node: on the left side 
of the neck (Fig 2). 
Apart from endocrine pancreatic tumor:s and c:~rcinoids. 
we extended our studies on the usc of the som:~wstatin re-
ceptor imaging technique :~I so to other tumors of the :~mine 
precursor uptake and decarboxybtion (APUD)-ccll system: 
in 18 of 1 S patients with p:lr.lgangliomas_ the tumor could 
be visualized. In four of these patients previously unknown 
multiple tumor loc:J.Iiz:ltions were dc:tected. All three small-
cell lung cancers. :l.S well as one neuroblastoma.. but only one 
of four pheochromocytomas and one of five medullary thy-
roid carcinomas could be visualized. So. virtually all APUD 
cell tumors are somatostatin receptor-positive. However, in 
those tumors. which arc known in general to synthesize and/ 
or=ete somatosutin, the tumors can often not be visualized 
in vivo, probably because of descnsitiw.tion of the somato-
statin receptors on these tumors. 
The in vivo receptor imaging technique on also be applied 
to patients with pituiury tumors. In all three acromegalic 
patients. in two patients with thyrOtropin (TSH) secreting 
pituitary tumors. as well as in three patients with "non func-
tioning" pituitary tumors. the application of this technique 
successfully visualized the somatostatin receptor-positive tu-
mors. Figure 3 shows an ex.ample of a suprasellarly extending 
GH-secreting pituitary tumor 24 hours after isotope :~dmin­
istr:ltion. 
Fig 2. A somatostatin recepter•!)()Sitive lymph node in the left 
part o1 the neck,. 30 minute-s aft•H "'"1-204-090 <~dministration in 
a patient with memstatic car<:inoid syndrome. 
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Fig 3. The 24-l>our ""'1-204-090 scan in " patient with a su-
prasellar GH·sec:retlng pituit'lry adenom'l. 
Most well-differentiated human brain tumors. like menin-
giomas and low-grade JStrocytomas_ contain somatostatin 
receptors. while undifferentiated br.:~in tumors m:.Unly contain 
epidermal grov.rth f:~ctor (EGF) receptors.. 1 ~" 14 All five menin-
giomas and three low-grade astrocytomas investigated so far 
could be visualized with the ml-204-090 im:~ging technique. 
In conclusion. we have described in this report the prelim-
inary results of the use of a new imaging technique with 1 ~1 
coupled to a somatosutln analog. This method for the first 
time opens the possibility ofloc:aliw.tion of primary somato-
statin receptor-positive tumors and their metastases. Prelim-
in;uy data have been obtained th:!t a hormone-secreting tu-
mor th:~t can be visualized by this method will also respond 
to ther.:~py with Sa.ndosutin. with a suppression of hormone 
release. Theoretically, this somatostatin receptor im:~ging 
technique represents a new approo.ch that might be extended 
to other receptor-containing tumors. Therefore. it can be 
considered as a new, powerful alternative to tumor loc:aliza-
tion performed with monoclonal :~ntibody technology. Many 
of these tumors show still consider::tble :~ccumulation ofra-
dioo.ctivity :It the tumor site :lfter 24 to 48 hours. This occurs 
despite the half-life of J:JI of approximately 13 hours.. In 
principle. this opens the possibility that radiotherapy of these 
somatosutin receptor-positive tumors with {3-emitting t:.ldio-
nuclides labeled to somatosutin analogs will be feasible in 
the future. 
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SUMMARY AND CONCLUSION 
In this thesis the development and application are described of two radiophar-
maceuticals, which act on the basis of specific binding that exists between the 
peptide hormone somatostatin and its receptor. 
Chapter 1 starts with a brief historic review of the research on radionuclides 
and corresponding kinds of radiation. The introduction of the "tracer" -concept in 
botany by Hevesy in 1923 bas actually marked the start of what we at present call 
in vivo nuclear medicine diagnostics. In 1926 followed the first in vivo application 
in man: the measurement of blood flow by means of the naturally occurring 
radium-C. In the next decennia a large number of discoveries has been made in the 
field of nuclear physics. By means of nuclear reactors and cyclotrons artificial 
radionuclides were produced. A number of them were rapidly applied in in vivo 
nuclear medicine. Radioactive iodine ("'!) was long the most important tracer for 
human in vivo applications. Later, this radionuclide was replaced by the much 
shorter living technetium (""Tc), which gamma energy also appeared to be much 
more favourable for imaging. Finally, in the historic review the first in vivo 
applications of radionuclides to tumor diagnostics are described. 
The second part of the chapter describes the general biochemical principles of 
scintigraphic imaging. Various types of radiopharmaceuticals are mentioned, such 
as radionuclides in ionic form or as element, coupled to particles and aerosols, and 
as part of dissolved compounds. The last group is divided in non-specifically acting 
(i.e. with inert behaviour) and specifically acting (e.g., with particular metabolic 
properties) radiopharmaceuticals. Finally, radiopharmaceuticals are introduced 
which actions are based on binding to receptors on tumor cells. Therefore, these 
tumors can be imaged scintigraphically. 
In the last part of the chapter the peptide hormone somatostatin is introduced. 
Somatostatin inhibits the function of various, mostly endocrine glands. Also, in 
many endocrine-active tumors which contain large numbers of somatostatin 
receptors, hormone production is inhibited by somatostatin. Somatostatin itself 
however, is not suitable for therapy, because it is rapidly degraded in vivo. The 8 
amino acids-containing somatostatin-analogue octreotide is more stable in vivo than 
somatostatin itself (with 14 amino acids) because of its smaller cyclic structure 
along with two D-amino acids. Octreotide is now frequently used in the treatment 
of patients with hormone-producing tumors. Because of the receptor-mediated 
131 
action of octreotide it is concluded that radiolabeled somatostatin analogues are 
potentially suitable to visualize somatostatin receptor-positive tumors by means of 
the gamma camera. 
In Chapter 2 is described that octreotide derivatives bind specifically to 
somatostatin receptors. Already in 1985 [Tyr']-octreotide has been successfully 
applied in vitro to detect somatostatin receptors in tumors. For this purpose, 
[Tyr']-octreotide is labeled with radioactive iodine ('"!). The research described in 
this chapter was done in order to investigate whether radiolabeled [Tyr']-octreotide 
would be suitable as radiopharmaceutical for in vivo detection and visualization of 
somatostatin receptor-positive tumors, that are otherwise difficult to trace. [Tyr']-
octreotide was labeled with '"! by the chloramine-T method. HPLC-investigations 
showed that predominantly monoiodo-[Tyr']-octreotide (with strong somatostatin 
receptor-binding properties) is formed. Diiodo-[Tyr']-octreotide (with diminished 
somatostatin receptor-binding properties) is formed in a much smaller amount. In 
addition, it was demonstrated that ['"1-Tyr']-octreotide, [Tyr']-octreotide, and 
somatostatin itself inhibited the secretion of growth hormone by rat pituitary cells 
in a similar way. In vivo experiments were performed with "'!-labeled [Tyr']-
octreotide, which is suitable for scintigraphic imaging in contrast to ["'!-Tyr']-
octreotide. The compound was athninistered intravenously to control rats and rats 
having somatostatin receptor-positive pancreatic tumors. The radiopharmaceutical 
is rapidly cleared from the circulation by the liver. This results in a rapidly 
decreasing background radioactivity in favour of the detection of somatostatin 
receptor-positive processes, already very shortly after administration. Above the 
somatostatin receptor-positive tumors an increasing radioactivity was measured, 
allowing their scintigraphic imaging. The specificity of this detection was 
demonstrated by the observation that in rats in which the somatostatin receptors 
were previously blocked with a large excess of octreotide, only decreasing blood 
background could be measured above the tumors. It was concluded that 
radiolabeled [Tyr']-octreotide is a promising radiopharmaceutical for diaguosis in 
humans, because various human tumors possess large numbers of receptors with 
high affmity for somatostatin. 
Chapter 3 deals with the first human applications of ["'1-Tyr'J-octreotide. The 
metabolism of this somatostatin-analogue in humans has been investigated. Similar 
to the rat ['"!-Tyr']-octreotide was cleared very rapidly from the blood circulation 
mainly by the liver (nearly 85 % of the dose within 10 minutes), and the 
radionuclide became visible directly afterwards in the gallbladder and subsequently 
in the intestines. Three hours after injection still 70 % of radioactivity in the 
circulation consisted of intact ['"I-Tyr']-octreotide. The radioactivity in the urine 
showed a similar pattern. Later. an increasing amount of free iodide was found, 
pointing to degradation of the radiopharmaceutical in vivo. On the basis of the 
radioactivity in blood and excreta and of gamma camera measurements of the liver 
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and the gallbladder as a function of time the radiation dose of the most important 
organs was calculated. Thus, an effective dose equivalent (0.021 mSv/MBq) was 
detennined, similar to that of other "'1-radiopharmaceuticals. At the end of the 
chapter the tumor-seeking properties of ['"1-Tyr']-octreotide are described followed 
by some examples of successful sciotigraphy of somatostatin receptor-positive 
tumors. 
Chapter 4 starts with an enumeration of important disadvantages of ['"I-Tyr']-
octreotide: (a) the limited availability of the pure radionuclide, (b) the time-con-
sumiog labeling and purification procedure, (c) the physical half-life of '"! (13.2 
hours), which is so short that sciotigraphy later than 24 hOUl"S after administration 
is difficult, and (d) the ioterferiog background radiation io the upper abdomioal 
area, where somatostatin receptor-positive tumors often are located. Because of 
these disadvantages a DTPA-conjugated somatostatin analogue, i.e. [DTPA-D-
Phe']-octreotide, was developed which can be labeled with radioactive iodium 
('"In, t, = 2.8 days) io a simple one-step procedure. The labeling appeared to be 
performed with retention of the somatostatio-like properties. ["'ln-DTPA-D-Phe']-
octreotide bound specifically to somatostatin receptors io rat braio cortex 
membranes, although not as strongly as the iodinated compound. Besides, the 
specific somatostatio-like biologic effect was demonstrated by a dose-dependent 
iohibition of growth hormone production by rat pituitary cells. It was noted, that 
this iodium-labeled somatostatin analogue is very suitable for a simple "kit"-
preparation. 
Chapter 5 describes the first io vivo application of ["'ln-DTPA-D-Phe']-
octreotide io rats. The biodistribution of the radiopharmaceutical after iotravenous 
iojection was investigated io control rats and io rats with somatostatin receptor-
positive pancreatic tumors. Similar to ["'1-Tyr']-octreotide, the iodium-labeled 
compound was rapidly cleared from the blood circulation. But io contrast to the 
predominant hepatic clearance of ['"1-Tyr']-octreotide, ["'ln-DTPA-D-Phe']-
octreotide is largely cleared by the kidneys. The majority of the administered dose 
was excreted iota the urioe io the form of the iotact radiolabeled peptide, without 
significant degradation. Specific accumulation was demonstrated by ex vivo 
autoradiography io the anterior pituitary gland which contaios somatostatin 
receptors. In the adrenals of rats io which the somatostatin receptors were not 
previously blocked with excess octreotide, considerably more radioactivity was 
measured than io those of blocked animals, which is io agreement with the 
presence of somatostatin receptors io this organ. The same held for the radioac-
tivity measured in the tumors. The tumors were clearly detected with the gamma 
camera io the untreated rats but not io those treated with excess octreotide. Sioce 
["'ln-DTPA-D-Phe']-octreotide has a longer residence io the blood circulation as 
compared to ['"1-Tyr']-octreotide, the exposure of the tumor to the radiophar-
maceutical is longer, although this results io higher background on the day of 
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mJection. However, 24 hours after administration of ['"ln-DTPA-D-Phe']-
octreotide more radionuclide is cleared from the body as compared to ["'1-Tyr']-
octreotide, with a consequently lower background. Furthermore, the interference in 
the upper abdomen as seen with ["'!-Tyr']-octreotide is not present after ad-
ministration of ["'ln-DTPA-D-Phe']-octreotide. Finally, the imaging of tumors 24 
hours and later will be favoured by the longer physical half-life of "'ln. ln 
conclusion ["'ln-DTPA-D-Phe']-octreotide was named a promising radiophar-
maceutical for routine imaging of somatostatin receptor-positive tumors. 
The scintigraphic application of ['"ln-DTPA-D-Phe']-octreotide in man is 
introduced in Chapter 6. As in the animal model, the radiopharmaceutical was 
rapidly cleared from the blood and predominantly excreted via the kidneys. HPLC-
investigations of urine demonstrated that ['"ln-DTPA-D-Phe']-octreotide was 
excreted mainly in the intact form. Intestinal excretion amounted to only a few 
percent of the administered radionuclide. Based on the radioactivity-time courses in 
blood, excreta, kidneys, spleen and liver the radiation doses of the most important 
organs were determined. The calculated effective dose equivalent is 0. 08 
mSv/MBq, which is similar to other "'In-labeled radiopharmaceuticals. Scin-
tigraphy by means of ['"ln-DTPA-D-Phe']-octreotide was best performed 24 hours 
after adntinistration of the radiopharmaceutical, when circulating background has 
considerably decreased. The sensitivity of the detection of somatostatin receptor-
positive tumors appeared to be similar to that of ["'!-Tyr']-octreotide, with the 
exception of the upper part of the abdomen, where somatostatin receptor-positive 
tumors are frequently localized and where ['"ln-DTPA-D-Phe']-octreotide shows 
much less background radiation. 
Because the liver is an important organ in the degradation of many bioactive 
peptides, the hepatic metabolism of both radiolabeled somatostatin analogues was 
investigated. Chapter 7 describes the use of the isolated rat liver perfusion system, 
in which the circulating medium as well as the excreted bile were radiochemically 
analyzed. Similat to in vivo studies, radioiodinated [Tyr']-octreotide appeared to be 
rapidly cleared from the circulating medium. Radioactivity was rapidly excreted 
into the bile as intact ['"1-Tyr']-octreotide. ln contrast to ['"1-Tyr']-octreotide, 
["'ln-DTPA-D-Phe']-octreotide was hardly cleared by the liver: the amount of 
radioactivity in the medium remained almost constant during the study, whereas 
little radioactivity was found in the bile. These results show, that whereas f"'l-
Tyr']-octreotide is rapidly cleared by the liver and is excreted in intact form into 
the bile, ["'ln-DTPA-D-Phe']-octreotide is hardly handled by the liver. The results 
of the liver perfusion studies are in full agreement with the human and rat fm-
dings. The isolated rat liver perfusion system appears to be a convenient method 
for the study of the hepatic metabolism of potential radiopharmaceuticals. The 
results obtained with this system may be used to predict the in vivo metabolism of 
such compounds, although additional information about renal clearance is required. 
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The frrst more extensive clinical results of scintigraphy with radiolabeled 
somatostatin derivatives are described in the Appendix-papers. Appendix I deals 
with the first application of ["'1-Tyr']-octreotide to the localization of various 
endocrine somato-statin receptor-positive tumors. In Appendix II the agreement 
between in vitro study of the presence of somatostatin receptors, octreotide 
therapy, and in vivo scintigraphy, is described. It was concluded, that positive 
scintigraphy with ["'!-Tyr']-octreotide predicts an effective suppression by 
octreotide of hormone hypersecretion by these tumors. This conclusion was also 
drawn from the studies described in Appendices ll1 & IV, in which patients with 
hormone-producing carcinoid tumors, endocrine pancreatic tumors, or pituitary 
adenomas, and patients with paragangliomas were investigated scintigraphically 
using ['"!-Tyr']-octreotide. 
CONCLUSION 
During the past 10 years favourable results are obtained with specifically acting 
radiopharmaceuticals. It is remarkable, that this is especially the case with small 
molecules. The successful positron emission tomography (PET) of the brain, using 
small positron-emitting compounds, is well known. Unfortunately, application of 
PET -radiopharmaceuticals is limited for economic reasons, and mainly useful for 
diagnosis of brain and heart pathology. A broader indication field exists for 
radiolabeled monoclonal antibodies and their fragments: various tumors and 
infections may be traced because of the specific binding to antigens present on 
these processes. However, monoclonal antibody scintigraphy is frequently hindered 
by (a) slow clearance from the circulation, (b) minor accumulation in processes, 
and (c) high non-specific binding to various (non-target) tissues. Compared to the 
antibodies and their fragments (> 70 kD), much smaller compounds ( < 2 kD) 
have two advantages: (1) the much more rapid clearance results in a low back-
ground, which favours scintigraphic imaging and, (2) diffusion into the extravas-
cular space occurs more easily. The radioiodinated MIBG which is used for 
imaging pheochromocytoma and neuroblastoma, has gained importance in this 
group of low-molecular weight radiopharmaceuticals. 
As small native bioactive peptides have been used in characterization of 
pathology in vitro already for a long period of time, it was decided to use 
derivatives of such compounds in vivo in order to image tumors on the basis of 
binding to native peptide receptors. Ocrreotide is an octapeptide, which has a 
bioactive site like that of the 14 amino acids-containing native peptide hormone 
somatostatin, a peptide with hormone release-inhibiting properties. Because of its 
larger stability as compared to the native peptide, octreotide is frequently used for 
therapy in patients with hormone-producing tumors. The action of octreotide is a 
receptor-mediated process. Like octreotide, ['"!-Tyr']-octreotide was known to 
bind in vitro to somatostatin receptors, present on cells of various tumors. In the 
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described studies, ["'l-Tyr']-octreotide appeared to accumulate in vivo also in 
somatostatin receptor-positive tumor tissue after intravenous injection. By conse-
quence, these tumors were imaged with the gamma camera. However~ major draw-
backs such as the strong background interference in the upper abdomen (where 
somatostatin receptor-positive tumors often are located) and the cumbersome 
preparation procedure led us to a second octreotide derivative with somatostatin 
receptor-binding properties: [DTPA-D-Phe']-octreotide. This peptide was 
radiolabeled with '"ln in a simple one-step procedure without the need for further 
purification. In vitro indium-labeled [DTPA-D-Phe']-octreotide, like iodinated 
[Tyr']-octreotide, showed somatostatin receptor-binding properties and somatos-
tatin-like hormone release inhibition. However, in vivo the indium-labeled 
somatostatin analogue showed a metabolic behaviour, completely different from 
1"'1-Tyr']-octreotide: in contrast to the hepatobiliary clearance and consequent 
intestinal degradation of [1231-Tyr']-octreotide, ['"ln-DTPA-D-Phe']-octreotide was 
cleared from the circulation by the kidneys without distinct degradation. The very 
fast disappearance of ['"!-Tyr']-octreotide from the blood circulation was con-
sidered as an advantage for tumor scintigraphy because of the low background 
already shortly after administration (Chapter 2), while the much slower disap-
pearance of ["'ln-DTPA-D-Phe']-octreotide was also regarded as a benefit (Cha-
pter 5) because of a longer exposure to the tumor. This is understandable, con-
sidering that the advantage of ['"!-Tyr']-octreotide only holds for the first hours 
after administration while the benefit of ["'ln-DTPA-D-Phe']-octreotide holds for 
24 hours and later due to its much better excretion without degradation. Despite its 
somewhat lower receptor-binding properties ["'ln-DTPA-D-Phe']-octreotide turned 
out to be a better alternative for ["'!-Tyr']-octreotide for imaging of somatostatin 
receptor-positive tumors, becanse of its more suitable metabolism. the longer half-
life of the radionuclide, and its ready availability. 
lt has been demonstrated with ["'1-Tyr']-octreotide and ["'ln-DTPA-D-Phe']-
octreotide that it is possible to image somatostatin receptor-positive tumors (which 
are often difficult to localize with other techniques) with derivatives of a native 
peptide hormone by scintigraphy. Besides, if such tumor is endocrine-active, i.e. 
hormone-producing, a positive scintigraphy can predict efficient therapy with 
octreotide. Furthermore, it is likely that also radiotherapy with similar compounds, 
labeled with suitable, e.g., &·-emitting radionuclides, will be possible. Concerning 
the number of bioactive native peptides known, the two described radiophar-
maceuticals will probably be followed by other small radiolabeled peptides for 
specific tumor targeting in the near future. 
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SAMENVATTING EN CONCLUSIE 
In dit proefschrift worden de ontwikkeling en de toepassing beschreven van 
twee radiofannaca, waarvan de werking berust op de specifieke binding die bestaat 
tussen het peptidehormoon somatostaline en zijn receptor. 
Hoojdstuk I begin! met een kort historisch overzicht van het wetenschappelijk 
onderzoek op het gebied van de radionucliden en de bijbehorende stralingsoorten. 
De introductie van het "tracer"-concept in de plantkunde door Hevesy in 1923 is 
feitelijk het startsein geweest voor wat we tegenwoordig de nucleair geneeskundige 
in vivo diagnostiek noemen. AI snel daarna (in 1926) volgde de eerste in vivo 
toepassing van een radionuclide bij de mens: de meting van de snelheid van de 
bloedsomloop met behulp van het in de natuur voorkomende radium-C. In de 
daarop volgende decennia werd een groot aantal ontdekkingen gedaan op het 
gebied van de kernfysica. Met behulp van kemreactoren en cyclotrons werden 
kunstrnatige radionucliden geproduceerd, waarvan er een aantal snel hun toepassing 
vonden in de in vivo nucleaire geneeskunde. Nadat radioactief jodium ("'!) 
aanvankelijk lange tijd de belangrijkste tracer was voor in vivo applicaties bij de 
mens, werd dit radionuclide van de eerste plaats verdrongen door het vee! korter 
levende technetium (""'Tc), waarvan de gammastralingsenergie bovendien vee! 
gunstiger bleek voor de beeldvormende diagnostiek. Het historisch overzicht 
vermeldt tenslotte de eerste in vivo toepassingen van radionuc!iden op het gebied 
van de tumordiagnostiek. 
Het tweede gedeelte van het hoofdstuk beschrijft de algemene biochemische 
grondbeginselen, waarop scintigrafische beeldvorming berust. Aan de orde komen 
de verschillende typen radiofannaca (met voorbeelden), zoals radionuc!iden in 
ionvorm of als element, gekoppeld aan deelljes en aerosolen en als onderdeel van 
opgeloste verbindingen. In de laatstgenoemde categorie wordt onderscheid gemaakt 
tussen niet-specifiek (d. w.z. met een inert gedrag) en specifiek werkende radiofar-
maca (d.w.z. met bijzondere metabole eigenschappen). Tenslotte word! in dit 
gedeelte het accent gelegd op radiofarmaca, waarvan de werking berust op binding 
aan receptoren, die op tumoren aanwezig zijn. Als gevolg hiervan kunnen deze 
tumoren scintigrafisch in beeld gebracht worden. 
In het laatste dee! van het hoofdstuk wordt het peptidehormoon somatostaline 
ge!ntroduceerd. Somatostatine heeft een remmende werking op de functie van 
verschillende, meestal endocriene klieren. V eel endocrien actieve tumoren worden, 
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omdat zij grote aantallen receptoren voor somatostatine bevatten. in hun hor-
moonproductie geremd door somatostatine. Somatostatine zelf is echter niet ge-
schikt voor tberapie. omdat het in vivo snel wordt afgebroken. Het 8 aminozuren 
bevattende somatostatine-analogon ocrreotide heeft een biologisch actieve kern. die 
lijkt op die van somatostatine (met 14 aminozuren). en een grotere stabiliteit in 
vivo vanwege zijn kleinere cyclische structuur waarin zich bovendien twee D-
aminozuren bevinden. Yanwege deze eigenschappen wordt octreotide nu frequent 
gebruikt bij de behandeling van patienten met hormoon-producerende tumoren. 
Omdat de tberapeutische werking van octreotide berust op de aanwezigheid van 
receptoren voor somatostatine. wordt geconcludeerd dat radioactief gemerkte 
somatostatine-analoga potentieel geschikt zijn om somatostatinereceptor-positieve 
tumoren met behulp van de gammacamera zichtbaar te maken. 
In Hoofdstuk 2 wordt beschreven dat octreotidederivaten. die een met somato-
statine vergelijkbare biologisch actieve structuur hebben. specifiek binden aan de 
sornatostatinereceptoren. AI sedert 1985 wordt de van octreotide afgeleide verbin-
ding [Tyr']-octreotide met succes toegepast om in vitro het bestaan van receptoren 
voor somatostatine in tumoren aan te tonen. Daanoe wordt dit peptide met 
radioactief jodium ('"I) gemerkt. Het in dit hoofdstuk beschreven onderzoek had 
als doe! na te gaan of radioactief gemerkt [Tyr']-octreotide geschikt zou zijn als 
radiofannacon voor het in vivo detecteren en zichtbaar maken van somato-
statinereceptor-positieve tumoren. die vaak anderszins moeilijk zijn op te sporen. 
[Tyr']-octreotide werd gemerkt met '"I met behulp van de chloramine-T methode. 
HPLC-onderzoek wees uit dat hoofdzakelijk monojodo-['"l-Tyr']-octreotide (met 
sterke somatostatinereceptor-bindende eigenschappen) wordt gevormd. Van di-jodo-
['"1-Tyr']-octreotide (met minder sterke somatostatinereceptor-bindende eigenschap-
pen) wordt vee! minder gevormd. Bovendien werd aangetoond. dat ["'!-Tyr']-
octreotide de secretie van groeihormoon door rattehypofysecellen in gelijke mate 
afremt als bet ongemerkte [Tyr']-octreotide en somatostatine zelf. In vivo ex-
perimenten werden uitgevoerd met het voor scintigrafie geschikte "'! gebonden aan 
[Tyr']-octreotide. De verbinding werd intraveneus toegediend aan controleratten en 
ratten. die somatostatinereceptor-positieve pancreastumoren hadden. Het radiofar-
macon wordt snel door de lever geklaard. waardoor de achtergrondactiviteit 
navenant daalt ten gunste van de vroegtijdige detectie van somatostatinereceptor-
positieve processen. al zeer kort na de toediening. Ter plaatse van de somato-
statinereceptor-positieve tumoren werd een stijgend activiteitsverloop gemeten. 
waardoor de tumoren scintigrafisch in beeld konden worden gebracht. De 
specificiteit van deze detectie werd aangetoond door de waarneming. dat in ratten 
waarin de somatostatinereceptoren tevoren door een grote overmaat octreotide 
geblokkeerd waren. ter plaatse van de tumor slechts een dalende bloedachtergrond 
werd gemeten. Geconcludeerd werd dat radioactief gelabeld [Tyr']-octreotide een 
veelbelovend radiofarmacon voor de mens zou kunnen zijn, gezien het feit dat 
verschillende humane tumoren grote aantallen receptoren met een hoge affiniteit 
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voor somatostatine bezitten. 
Hoojdstuk 3 behandelt de eerste humane toepassingen van ['"1-Tyr']-octreotide. 
Het onderzoek naar het humane metabolisme van <lit somatostatine-analogon wordt 
beschreven. Evenals bij de rat werd ["'1-Tyr']-octreotide zeer snel uit de bloedbaan 
geklaard door de lever (bijna 85 % van de dosis binnen 10 minuten), terwijl direct 
daarna het radionuclide zichtbaar werd in de galblaas en daarna in de darmen. Drie 
uur na injectie bestond nog 70 % van de nog aanwezige radioactiviteit in de cir-
culatie uit intact [ '"1-Tyr']-octreotide. De radioactiviteit in de urine vertoonde 
hetzelfde beeld. Later na injectie werd in toenemende mate vrij jo<lide gevonden, 
hetgeen wijst op afbraak van bet radiofarmacon in vivo. Op basis van het ac-
tiviteitsverloop in bloed en excreta en van gammacamerametingen van de lever en 
de galblaas als functie van de tijd werden de stralingsdoses van de belangrijkste 
organen bepaald. Zo werd een effectief dosisequivalent (0,021 mSv/MBq) 
berekend, vergelijkbaar met dat van andere "'1-radiofarmaca. Tenslotte worden de 
tnmorzoekende eigenschappen van ["'I-Tyr']-octreotide beschreven aan de hand 
van enige voorbeelden van succesvolle scintigrafie van somatostatinereceptor-
positieve tumoren. 
Hoojdstuk 4 begint met een opsomming van gebleken belangrijke nadelen van 
['"!-Tyr']-octreotide: (a) de beperkte beschikbaarheid van het voor labeling vereiste 
ultrazuivere radionuclide, (b) de tijdrovende labelings- en zuiveringsprocedure, (c) 
de korte fysische halfwaardetijd van "'I (13,2 uur), die scintigrafisch onderzoek na 
meer dan 24 uur bemoeilijkt en (d) de storende achtergrondstraling ten gevolge van 
de lever-gal klaring in het bovenste dee! van de buik, waar somatostatinereceptor-
positieve tnmoren zicb vaak bevinden. Voor het ondervangen van de genoemde 
nadelen werd een DTPA-geconjugeerd somatostatine-analogon, t.w. [DTPA-D-
Phe']-octreotide. ontwikkeld, dat op een eenvoudige een-staps manier met radioac-
tief indium ('"In, t,. = 2,8 dagen) gemerkt kan worden. De labeling bleek te 
kunnen worden uitgevoerd met behoud van de eigenschappen van somatostatine. 
['"ln-DTPA-D-Phe']-octreotide bond specifiek aan somatostatinereceptoren in 
rattehersencortexmembranen, hoewel niet zo sterk als de gejodeerde verbinding. 
Bovendien werd het specifieke, op dat van somatostatine gelijkende, biologisch 
effect aangetoond door een dosis-afhankelijke remming van de groeihormoonsyn-
these in rattehypofysecellen. Opgemerkt wordt dat ['"ln-DTPA-D-Phe']-octreotide 
zeer geschikt is voor een eenvoudige "kit" -bereiding. 
Hoofdstuk 5 beschrijft de eerste in vivo toepassing van ["'ln-DTPA-D-Phe']-
octreotide in ratten. De biodistributie van het radiofarmacon na intraveneuze 
injectie werd onderzocht in normale ratten en in ratten met somatostatinereceptor-
positieve pancreastumoren. Evenals ['"1-Tyr']-octreotide werd ['"ln-DTPA-D-
Phe']-octreotide snel uit de bloedcirculatie geklaard, in <lit geval niet door de lever, 
maar door de nieren. Het overgrote dee! van de toegediende dosis werd in de vorm 
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van intact ['"ln-DTPA-D-Phe']-octreotide in de urine uitgescheiden, zonder 
noemenswaardige afbraak. Specifieke stapeling werd met behulp van ex vivo 
autoradiografie aangetoond in de hypofysevoorkwab, waarin zich somato-
statinereceptoren bevinden. In de bijnieren van ratten, waarvan de somato-
statinereceptoren niet vooraf geblokkeerd waren met octreotide werd een aan-
merkelijk hogere radioactiviteit gemeten dan in die van geblokkeerde dieren, 
hetgeen in overeenstemming is met de aanwezigheid van somatostatinereceptoren in 
dit orgaan. Hetzelfde gold voor de in de tumoren gemeten radioactiviteit. Met de 
gammacamera bleek het mogelijk ter plaatse van de ongeblokkeerde tumoren een 
in de tijd toenemende radioactiviteit te meten, terwijl de tumoren ook scintigrafisch 
in beeld konden worden gebracht. Omdat ['"In-DTPA-D-Phe']-octreotide Ianger 
dan ["'l-Tyr']-octreotide in de bloedcirculatie blijft, is de blootstelling van de 
tumor aan bet radiofarmacon groter, hoewel daardoor de achtergrondstraling op de 
dag van injectie hoger is. Echter, 24 uur na toediening van ["'ln-DTPA-D-Phe']-
octreotide is meer radionuclide geklaard nit het lichaam vergeleken met ["'l-Tyr']-
octreotide, met als gevolg een lagere achtergrondstraling. Verder is de - bij ["'1-
Tyr']-octreotide gebruikelijke - storende achtergrondstraling in de bovenbuik bij 
f"'ln-DTPA-D-Phe']-octreotide niet aanwezig. Tenslotte zal het zichtbaar maken 
van tumoren na 24 uur en later door de langere fysische balfwaardetijd sterk 
worden begunstigd. In de conclusie wordt ['"ln-DTPA-D-Phe']-octreotide een veel-
belovend radiofarmacon voor routine scintigrafie van somatostatinereceptor-
positieve tumoren genoemd. 
De scintigrafische toepassing van ['"ln-DTPA-D-Phe']-octreotide bij de mens 
wordt in Hoojdstuk 6 gelntroduceerd. Evenals in bet diermodel werd het radiofar-
macon snel geklaard nit de bloedcirculatie en hoofdzakelijk via de nieren uitge-
scheiden. HPLC-onderzoek van urine wees uit, dat ['"In-DTPA-D-Phe']-octreotide 
hoofdzakelijk in intacte vorm wordt uitgescheiden. Via de darmen werden slechts 
enkele procenten van bet toegediende radionuclide uitgescheiden. Op basis van het 
activiteitsverloop in bloed en excreta en van gammacamerametingen van de nieren, 
milt en lever als functie van de tijd werden de stralingsdoses van de belangrijkste 
organen bepaald. Het effectieve dosis equivalent werd berekend op 0,08 
mSv/MBq, vergelijkbaar met waarden gevonden voor andere "'ln-radiofarmaca. 
Scintigrafie met behulp van ["'ln-DTPA-D-Phe']-octreotide bleek het beste te 
kmmen worden uitgevoerd 24 uur na toediening van het radiofarmacon, wanneer 
de circulerende achtergrond belangrijk is afgenomen. Scintigrafie van het bovenste 
gedeelte van de buik, waar somatostatinereceptor-positieve tumoren frequent 
voorkomen bleek met ["'ln-DTPA-D-Phe']-octreotide beter mogelijk omdat dit 
radiofarmacon daar juist minder hinderlijke achtergrondstraling geeft. Overigens 
bleek de gevoeligheid waarmee somatostatinereceptor-positieve tumoren elders in 
bet licbaam konden worden aangetoond vergelijkbaar met die van ["'1-Tyr']-
octreotide. 
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Omdat de lever een belangrijk orgaan is voor de atbraak van vee! biologisch 
actieve peptiden. werd het metabolisme van beide in de vorige hoofdstnkken 
beschreven radioactief gemerkte somatostatine analoga in dit orgaan onderzocht. In 
dit, in Hoofdstuk 7 beschreven, onderzoek werd gebruik gemaakt van een gei-
soleerd ratteleverperfusiesysteem, waarin zowel het circulerende medium als de 
uitgescheiden gal radiochemisch werden onderzocht. ['"1-Tyr']-octreotide bleek 
snel uit het circulerende medium geklaard te worden, evenals in vivo het ["'1-
Tyr']-octreotide uit de bloedbaan. Bovendien werd de radioactiviteit snel in de gal 
uitgescheiden, terwijl HPLC-onderzoek uitwees, dat het intact ['"I-Tyr']-octreotide 
betrof. In tegenstelling tot ['"1-Tyr']-octreotide werd ["'In-DTPA-D-Phe']-
octreotide vrijwel niet door de lever geklaard: de radioactiviteit in het medium 
bleef nagenoeg gelijk tijdens het onderzoek, terwijl weinig radioactiviteit in de gal 
werd aangetroffen. Deze resultaten tonen aan, dat, terwijl ['"!-Tyr']-octreotide snel 
wordt geklaard door de lever en intact word! uitgescheiden in de gal, ["'ln-DTPA-
D-Phe']-octreotide nauwelijks in de lever word! verwerkt. De resultaten van de 
leverperfusiemetingen stemmen volledig overeen met de in vivo bevindingen bij de 
rat en bij de mens. Het geisoleerde ratteleverperfusiesysteem blijkt een geschikte 
methode te zijn om het levermetabolisme van potentiele radiofarmaca te onder-
zoeken. De resultaten die met dit systeem verkregen worden, zouden kunnen 
worden gebruikt om het in vivo metabolisme van zulke verbindingen te voorspel-
len. hoewel aanvullende informatie over nierklaring vereist is. 
In de Appendix -anikelen worden de eerste uitgebreidere klinische resultaten van 
scintigrafie met radioactief gelabelde somatostatine analoga beschreven. Appendix I 
behandelt de eerste toepassing van ['"1-Tyr']-octreotide bij de lokalisatie van 
verschillende endocriene somatostatinereceptor-positieve tumoren. ln Appendix II 
wordt de gevonden overeenkomst tussen in vitro onderzoek (naar de aanwezigheid 
van somatostatinereceptoren), octreotidetherapie en in vivo scintigrafie beschreven. 
Geconcludeerd wordt dat positieve scintigrafie met behulp van ["'!-Tyr']-octreotide 
een effectieve onderdrukking (door octreotide) van de verhoogde hormoonsecretie 
in deze tumoren voorspelt. Deze gevolgrrekking wordt ook gemaakt uit het in 
Appendices Ill & IV beschreven onderzoek, waarin patienten met hormoon-
producerende carcinoid tumoren, endocriene pancreas tumoren of hypofyse 
adenomen en patienten met paragangliomen met ['"1-Tyr']-octreotide scintigrafisch 
onderzocht zijn. 
CONCLUSIE 
Gedurende de afgelopen 10 jaar zijn gunstige resultaten verkregen met specifiek 
werkende radiofarmaca. Het valt op. dat dit meer het geval is naarmate de 
molecuulgrootte afneemt. Bekend is de succesvolle positron emissie 
tomografie(PET)-scintigrafie van de hersenen met behulp van kleine positron-
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emitterende verbindingen. Helaas kunnen deze PET-radiofannaca hoofdzakelijk om 
economische redenen nog maar beperkt worden gebruikt, terwijl bovendien de 
toepassing vrijwel aileen tot de hersenen en het hart beperkt blijft. Een ruimer in-
dicatiegebied leek te zijn gevonden voor de toepassing van radioactief gemerkte 
monoclonale antilichamen en fragmenten daarvan: allerlei tumoren en ontstekingen 
zouden ermee kunnen worden opgespoord door specifieke binding aan antigenen, 
die op deze processen voorkomen. Vaak bleek echter scintigrafie met monoclonale 
antilichamen in belangrijke mate gehinderd te worden door (a) trage klaring uit de 
bloedcirculatie, (b) geringe stapeling in de ziekteprocessen en (c) hoge aspecifieke 
stapeling in allerlei weefsels. Vergeleken met de grote antilichamen c.q. fragmen-
ten daarvan ( > 70 kD) hebben vee! klein ere verbindingen ( < 2 kD) twee voor-
delen, die het in beeld brengen van ziekteprocessen gunstig be!nvloeden: (!) door 
een vee! snellere klaring ontstaat a! snel een !age achtergrondsttaling en (2) zij dif-
ftmderen beter naar de extravasculaire ruimte. Onder meer het M!BG (voor het in 
beeld brengen van het feochromocytoom en het neuroblastoom) heeft in deze groep 
van laag-moleculaire radiofarmaca een vaste plaats gevonden. 
Omdat kleine natuurlijke biologisch actieve peptiden a! lang gebruikt werden bij 
het in vitro karakteriseren van ziekten, werd besloten derivaten van zulke verbin-
dingen in vivo te gebruiken om tumoren zichtbaar te maken op basis van binding 
aan natuurlijke peptidereceptoren. Octreotide is een octapeptide met een biologisch 
actieve kern vergelijkbaar met die van het 14 aminozuren bevattende natuurlijke 
peptidehormoon somatostarine, een peptide met remmende eigenschappen op hor-
moonproductie. Vanwege zijn grotere stabiliteit vergeleken met het natuurlijke 
peptide, wordt octreotide vaak gebruikt voor tberapie bij patienten met hormoon-
producerende tumoren. De werking van octreotide verloopt via receptoren. Evenals 
octreotide bindt ['"!-Tyr'J-octreotide in vitro aan somatostatinereceptoren op cellen 
van verschillende tumoren. in het beschreven onderzoek bleek !"'l-Tyr']-octreotide 
in vivo ook in somatostatinereceptor-positief tumorweefsel te stapelen na 
intraveneuze toediening. Daardoor werden deze tumoren met de gammacamera in 
beeld gebracht. Belangrijke nadelen, zoals de sterke achtergrondstoring in bet 
bovenste dee! van de buik (waar somatostatinereceptor-positieve tumoren zich vaak 
bevinden) en de omslachtige bereidingsprocedure, brachten ons op een tweede 
octreotide derivaat met somatostatinereceptor-bindende eigenscbappen: [DTPA-D-
Phe'J-octreotide. Dit peptide werd radioactief gelabeld met "'In door middel van 
een eenvoudige eenstaps-procedure, waarna verdere zuivering niet noodzakelijk 
bleek. In vitro vertoonde indium-gelabeld [DTPA-D-Phe']-octreotide (evenals 
gejodeerd [Tyr'J-octreotide) somatostatinereceptor-bindende en hormoonproductie-
remmende eigenschappen. In vivo gedraagt ["'ln-DTPA-D-Phe']-octreotide zich 
echter geheel anders dan ["'!-Tyr'J-octreotide: in tegenstelling tot de lever-gal 
klaring en daarop volgende afbraak in de darmen, wordt ["'ln-DTPA-D-Phe']-
octreotide door de nieren uit de bloedcirculatie geklaard zonder duidelijke afbraak. 
De zeer snelle verdwijning van ["'1-Tyr'J-octreotide uit de bloedcirculatie werd als 
voordeel voor tumorscintigrafie beschouwd vanwege de lage achtergrond al kort na 
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toediening (Hoofdstuk 2), terwijl de vee! tragere verdwijning van ["'ln-DTPA-D-
Phe']-octreotide eveneens een voordeel werd genoemd (Hoofdstuk 5) vanwege de 
langere blootstelling aan de tumor, Dit kan echter gemakkelijk worden ingezien, 
als in aanmerking genomen word!, dat het voordeel van ["'!-Tyr']-octreotide aileen 
geldt gedurende de eerste uren na toediening, terwijl het voordeel van ["'ln-DTPA-
D-Phe']-octreotide geldt voor 24 uur en later vanwege de veel betere excretie 
zonder afbraak, Zo bleek ondanks wat lag ere receptor -bindende eigenschappen 
["'ln-DTPA-D-Phe']-octreotide een beter alternatief te zijn voor ["'I-Tyr']-
octreotide voor de scintigrafie van somatostatinereceptor-positieve tumoren, juist 
vanwege het geschiktere metabolisme, de langere halfwaardetijd van het 
radionuclide en de gemakkelijke beschikbaarheid, 
Met behulp van twee in dit proefschrift beschreven peptiden, ["'I-Tyr']-
octreotide en ["'ln-DTPA-D-Phe']-octreotide, is nu aangetoond dat het mogelijk is 
somatostatinereceptor-positieve tumoren scintigrafisch in beeld te brengen met 
derivaten van een natuurlijk peptidehormoon (lokalisatie met andere technieken is 
vaak moeilijk), Bovendien, als zo'n tumor endocrien-actief (d,w,Z, hormoon-
producerend) is, kan positieve scintigrafie eflectieve therapie met octreotide 
voorspellen, Verder lijkt het waarschijnlijk, dat ook radiotherapie met ver-
gelijkbare verbindingen, geJabeid met geschikte, b,V, fi·-eJDitterende radionucliden, 
mogelijk zal zijn. Gezien het aantal bekende biologisch actieve natuurlijke pep-
tiden, zullen de twee in dit proefschrift beschreven radiofarmaca waarschijnlijk 
door andere kleine radioactief gelabelde peptiden voor specifieke tumorbinding 
gevolgd worden in de nabije toekomst. 
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NAWOORD 
Velen hebben bijgedragen aan bet gereed komen van dit proefschrift. Aan hen 
allen ben ik vee! dank verschuldigd. 
In de eerste plaats dank ik mijn ouders, die mij na enige omzwervingen in een 
ander - mijn vader bekend - vakgebied voor een tweede maal in staat stelden, een 
universitaire studie aan te vangen en deze af te ronden. 
Joan, MaJjolein en Maarten hebben mij de laatste tijd meestal aileen via de 
huistelefoon gesproken en dan ging het over de fouragering of andere 
huishoudelijke zaken. Door de veelheid van (door Joan gestimuleerde) activiteiten 
in ons gezin is dat overigens niet a! te zeer opgevallen. Het valt gelukkig te 
verwachten, dat bet beschreven communicatiepatroon nu enige verandering zal 
ondergaan. 
T oen Eric Krenning in 1983 J org Henne mann opvolgde als Hoofd van de 
afdeling Nucleaire Geneeskunde van het Academisch Ziekenhuis Rotterdam 
Dijkzigt wisten we dat we met hem een medicus met een (van huis uit ontwikkeld) 
gevoel voor techniek binnenhaalden. De aanwezigheid van een arts met technisch 
inzicht is immers essentieel voor de Nucleaire Geneeskunde. Eric bleek daarnaast 
een klinicus te zijn, die dankzij zijn werk in de afdeling lnwendige Geneeskunde 
Ill vee! ervaring met het laboratoriumresearch had opgedaan. Hij legde in ons 
ziekenhuis de basis voor de brug tussen het laboratorium onderzoek en de in-vivo 
nucleaire geneeskunde, een essentiele voorwaarde, waaraan voldaan moet worden 
voor snelle en doeltreffende vernieuwingen. In-vitro biologisch werkzame stoffen 
moesten naar zijn vaste overmiging ook in-vivo bij de mens kunnen worden 
toegepast. Voor zijn voortdurende stimulans (wei eens lastig .. ) en niet aflatend en-
thousiasme ben ik hem bnitengewoon erkentelijk. 
ln de periode, dat de beschreven artikelen en dit proefschrift zelf tot stand 
kwamen, heeft Theo Visser vele malen zijn waardevolle redactionele bijdragen 
geleverd. Met plezier denk ik terug aan de opbouwende sfeer van de gesprekken. 
die ik met hem voerde bij de samenstelling van de manuscripten mede namens aile 
andere auteurs. Vooral zijn compacte, duidelijke en zuivere weergave van het 
gescbreven woord, was voor ons allen van onschatbare waarde. 
Wout Breeman dank ik voor zijn belangrijke bijdragen aan het onderzoek. Zijn 
opgeruimde karakter, hulpvaardigheid, pragmatische aanpak, diplomatie en veelzij-
digheid, zijn van grote waarde geweest. lk stel het op hoge prijs, dat Wout bij de 
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promo!ie als paranimf wil optreden. 
Steven Lamberts en Jean-Claude Reubi zijn reeds lange tijd werkzaam in het 
gebied van de endocriene tumoren. Jean-Claude legde ongeveer I 0 jaar geleden a! 
de basis voor het in dit proefschrift beschreven onderzoek door bet aantonen van 
de binding van bet somatostatine analogon ['"!-Tyr']-octreotide aan membranen 
van dit soon tumoren. Steven en Jean-Claude brachten mij de noodzakelijke kennis 
op dit gebied bij. 
Rainer Alben, Leo Hofland, Jan-Will em Koper en Christian Bruns hebben 
vooral belangrijk ondersteunend onderzoek verricbt in de fase, die voorafging aan 
de humane toepassing van de twee beschreven nieuwe radiofarmaca. Zij voerden 
nauwgezet de synthese van het DTPA-octreo!ide (RA), de proeven met betrekking 
tot de biologische respons (LH) en de in-vitro bindingsproeven (JWK & CB) nit. 
Peter Kooij verrichtte de !ijdrovende berekeningen, die vereist zijn voor de 
schatting van de stralingsdoses, die patienten oplopen nadat aan hen de beschreven 
nieuwe radiofarmaca zijn toegediend. 
Halverwege het onderzoek kwam Marion de Jong bij onze afdeling. Haar 
ervaring met Ieverperfusiemetingen in het schildklierlaboratorium kwam voor ons 
zeer goed van pas bij dit basale onderzoek, waarmee de onderling verschillende 
(lever)metabolismen van de twee radioac!ief gelabelde peptiden werd bevestigd. 
Haar hulpvaardige instelling en vooral haar optreden als klankbord zullen mij bij 
blijven. 
Boddy Setyono-Han zorgde steeds zeer nauwgezet voor bet in vivo mmormodel, 
waaraan we de beide radiofarmaca met succes getoetst hebben. 
lk dank ook Marcel van der Pluijm, die samen met de stageaires van bet Van 't 
Hoff lnstitout zorgvuldig de kwaliteit van de nieuwe radiofarmaca bewaakte onder 
meer met behuJp van meer dan 1000 HPLC-runs! 
De !eden van ons in vivo team (onder Ieiding van Ina Loeve) wil ik zeker niet 
onvermeld Iaten: zij hebben tussen het gewone werk door en vaak buiten de 
normale werkuren de gammacamerarnetingen uitgevoerd. 
Pallia van Sintrnaartensdijk-Schnijff en haar staf in de afdeling Endocrinologie 
ben ik zeer erkentelijk voor hun al!ijd bereidwillig gegeven verp!eegkundige steun. 
De medewerkers van het Audio Visueel Centrum dank ik voor de zorgvuldige 
uitvoering van het fotowerk. 
Tot slot dank ik zeker oak aile anderen, die - op welke manier dan ook - mede 
de nitvoering van het "SMS"-onderzoek in onze afdeling mogelijk maakten. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd op 23 oktober 1944 te 's-Gravenhage 
geboren. Het eindexamen gymnasium Jl werd in 1963 behaald aan het Tweede 
Vrijzinnig Christelijk Lyceum te 's-Gravenhage. Na in 1963 een korte periode aan 
de Technische Hogeschool Delft als student elektrotechniek ingeschreven te zijn 
geweest, volgde hij in de periode 1964/1965 het eerste jaar elektrotechniek aan de 
Hogere Technische School Wegastraat te 's-Gravenhage. In 1965 werd een begin 
gemaakt met de studie in de scheikunde aan de Rijksuniversiteit te Leiden. Het 
kandidaatsexamen (hoofdvak: scheikunde en bijvakken: wisktmde, namurktmde en 
biologie) werd in mei 1969 behaald. In mei 1972 werd het doctoraal exam en 
scheikunde afgelegd met hoofdvak organiscl!e chemie (radiochemie) en bijvakken 
neutronen-activeringsanalyse en fysisch-chemische scheidingsmethoden. Aanslui-
tend volgde een dienstverband als doctoraal-assistent in de afdeling Rontgen- en 
Electronendiffractie van de Rijksnniversiteit te Leiden. In januari 1974 werd hij 
aangesteld als radiochemicus in de afdeling Nucleaire Geneesktmde van het 
Academisch Ziekenhuis Rotterdam Dijkzigt. In februari 1976 werd het "C"-
diploma Desktmdigheid Stralenbescherming behaald aan het J .A. Cohen lnstimut, 
lnteruniversitair lnstimut voor Radiopathologie en Stralenbescherming, te Leiden. 
Op I november 1978 volgde de benoeming tot waamemend hoofd van de afdeling 
Nucleaire Geneesktmde. Op 20 april 1985 werd hij als chemicus voor nucleaire 
geneesktmde ingeschreven in het A-register van de Nederlandse Vereniging voor 
Nucleaire Geneesktmde. 
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